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Receptor tyrosine kinase like orphan receptor 1 (ROR1) is an onco-embryonic 
antigen present on a range of solid and haematological malignancies, including 
chronic lymphocytic leukaemia. Additionally, limited, low level expression on 
normal tissues makes it an attractive therapeutic target. Chimeric antigen receptor 
T cells and Bispecific T Cell Engagers have emerged as exciting immunotherapeutic 
approaches, utilising the inherent cytotoxic potential of autologous T cells to yield 
demonstrable benefit for patients. We therefore aimed to generate novel ROR1 
CAR T cells and BiTEs.  
Following a rat ROR1 immunisation programme, we screened over 150 single 
cell hybridoma clones to isolate 13 novel antibodies of which 10 bound in a single 
chain variable fragment format. Iterative optimisation led to two lead candidates 
that imparted superior cytotoxicity and cytokine secretion. To minimise 
immunogenicity we screened 50 humanised ROR1 scFv variants and selected a final 
humanised candidate, hF(1x1), which maintained effector function, specificity and 
demonstrated broad applicability against a panel of cell lines representing various 
tumour subtypes.  
Focusing specifically on haematological cell lines and CLL, our humanised CAR 
demonstrates superior cytotoxicity compared to previously reported ROR1 
constructs. However, low ROR1 antigen density limits efficacy in B cell malignancies, 
compared to CD19 CAR T cells and strategies to overcome this are in development. 
Our ROR1 BiTE mediates cytotoxicity at low concentrations (ng/ml) and 
effector to target ratios against cell lines, but in untreated and relapsed CLL 
patients, inherent T cell dysfunction limits efficacy. This can be overcome with the 
BTK inhibitor Ibrutinib, with T cells isolated from patients on treatment, showing 
markedly improved cytotoxicity against autologous CLL cells.  
 This work has laid the preclinical foundations for translation of these novel 
agents into clinical trials for a range of tumours including CLL and many of which 
have high unmet therapeutic need.  
  




ABC  Antigen binding capacity 
ALL  Acute lymphoblastic leukaemia 
ASCT  Allogeneic Stem Cell Transplant 
BCR  B cell receptor 
BCRi  B cell receptor inhibitors 
BiTE  Bispecific T Cell Engager 
BTK  Bruton’s tyrosine kinase 
CAR  Chimeric Antigen Receptor 
CDR  Complementary determining regions 
CEA  Carcinoembryonic antigen 
CFSE  Carboxyfluorescein succinimidyl ester 
CLL  Chronic lymphocytic leukaemia 
CRS  Cytokine release syndrome 
DART  Dual affinity retargeting antibodies 
DLBCL  Diffuse large B cell lymphoma 
ELISA  Enzyme linked immunosorbent assay 
EMA  European Medicine Agency 
EpCAM Epithelial cell adhesion molecule 
FACS  Fluorescent activated cell sorting 
Fab  Fragment antigen-binding 
Fc  Fragment crystallisable region 
FCR  Fludarabine, Cyclophosphamide, Rituximab 
FCS  Foetal calf serum 
FMD2A Foot and mouth disease virus 2A peptide 
GD2  Disialoganglioside 
GMP  Good manufacturing practice 
GvHD  Graft versus host disease 
GvL  Graft versus leukaemia/lymphoma 
IFN  Interferon  
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IHC  Immunohistochemistry 
IL-2  Interleukin 2 
ip  Intraperitoneally 
iv  Intravenous   
kDa  kilo Daltons 
MCL  Mantle cell lymphoma 
MFI  Mean fluorescent intensity 
MHC  Major histocompatibility complex 
MRD  Minimal residual disease 
mRNA  Messenger RNA 
NHL  Non-Hodgkin’s lymphoma 
NK  Natural killer (cells) 
PCP  Planar cell polarity 
PDX  Patient derived xenograft 
PGK  Phosphoglycerate kinase 
PI3K  Phosphoinositide 3-kinase 
RACE  Rapid amplification of cDNA ends 
ROR1  Receptor tyrosine kinase like orphan receptor 1 
ROR2  Receptor tyrosine kinase like orphan receptor 2 
SBT  Sleeping beauty transposons 
scFv  Single chain variable fragment 
SPR  Surface plasmon resonance 
TAA  Tumour associated antigen 
TCR  T cell receptor 
TE  Transduction efficiency 
Treg  Regulatory T cell 
tEGFR  Truncated epidermal growth factor receptor 
WT1  Wilms tumour 1 
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The immune system is intricately related to cancer, playing a vital role in 
tumour biology, progression and outcomes. Attempts to utilise it therapeutically 
have faced many hurdles and much debate, but decades of continued research to 
understand the immunological complexities of cancer, combined with advances in 
gene therapy has resulted in treatments that demonstrate real promise for 
patients. 
 
William Coley,  a surgeon in the 1890’s, utilised Coley’s toxin, a mixture of 
inactivated bacterial species, to trigger immune responses against sarcoma (Coley, 
1891). Despite low response rates of 10%, it represented one of the earliest 
attempts to harness the immune system to target cancer. Following on, Paul Ehrlich 
in 1909, likened developing neoplasms with invading micro-organisms, to which 
effective immunity could be mounted (Rhoads, 1954) and these early interventions 
laid the foundations for immunotherapy.  
Initial enthusiasm was muted as tumour cells were thought to be akin to 
normal tissue and therefore protected by immune tolerance (Burnet and Fenner, 
1949, Billingham et al., 1953). This view was challenged, with the realisation that 
immunocompetent animals treated with chemical carcinogens or tumour cells were 
protected against subsequent re-challenge and led to the theory of constant 
immune surveillance (Burnet, 1957, Thomas, 1982). Although paradigm shifting, 
this was later found to be an overly simplistic approach as the immune system is 
not solely a passive bystander but plays a pivotal role in tumour evolution. Initial 
preferential targeting of dominant epitopes, selects for cancer cells better able to 
evade it, whilst also allowing evolution of cellular strategies to limit tumour antigen 
expression, such as downregulation of MHC. This immune editing of tumours 
results in enhanced growth and metastatic potential (Shankaran et al., 2001). 
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Strategies to utilise the potential of the immune system have made significant 
progress since Coley’s toxin. Although both the innate and adaptive arms are 
required for effective anti-tumour immunity,  T cells are the primary focus 
given their terminal effector status, cytotoxic potential, ability to orchestrate 
potent immune responses and potential for long lived immunological memory.  In 
keeping with this, T cells are vital for the graft versus leukaemia/lymphoma effect 
seen with allogeneic bone marrow transplantation (ASCT) and subsequent donor 
lymphocyte infusions. They mediate the responses to IL-2 therapy and efficacy with 
PD-1, PDL-1 or CTLA-4 checkpoint inhibition (Rosenberg et al., 1985b, Jenq and van 
den Brink, 2010, Hodi et al., 2010). Therapeutic responses are dependent on the 
mobilisation of endogenous polyclonal T cells, whilst more targeted approaches 
include isolation, expansion and re-infusion of T cells with known specificity for a 
tumour antigen or through cancer vaccines, which aim to stimulate and expand 
existing anti-tumour T cells (Rosenberg et al., 1985a, Romero et al., 2016).  
A further approach is through genetic engineering of T cells to impart novel 
specificity. This can be via a new T Cell Receptor (TCR) or artificial chimeric antigen 
receptor (CAR). A critical limitation of this approach is selection of an appropriate 
tumour associated antigen (TAA), which should be specific for tumour cells,  absent 
on normal tissues and be stably expressed at a sufficient density to allow for robust 
immune responses, to minimising antigen escape.  
In this regard receptor tyrosine kinase like orphan receptor 1 represents an 
attractive TAA. It is expressed during embryonic and foetal development but is 
downregulated by birth and absent from critical organs in adulthood. This 
differential expression, dependent on developmental stage, is one example of a 
TAA class.  Others include antigens expressed at higher levels on malignant versus 
normal tissues (such as Wilms tumour 1); those expressed in immune privileged site 
but also on tumours (such as cancer testis antigens) and TAA resulting from 
infection with oncogenic viruses (such as human papillomavirus). Another group, 
and also the largest, are neo-antigens which arise due to the extensive somatic 
mutation that occurs in the context of cancer cells but are highly patient specific 
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and cannot be easily targeted with a single novel receptor (Martincorena and 
Campbell, 2015).  
 
  Receptor Tyrosine Kinase Like Orphan Receptor 1 
 
Receptor tyrosine kinase like orphan receptor 1 (ROR1) and the closely related 
ROR2, were first identified in 1992, using degenerative primers to screen the SH-
SY5Y neuroblastoma cell line for putative tyrosine kinase receptors (Masiakowski 
and Carroll, 1992). They are both type 1 single pass transmembrane receptors, 
located on chromosome 1p31-p32 (Reddy et al., 1997) and 9q22 (Oldridge et al., 




FIGURE 1.1 TOPOGRAPHICAL REPRESENTATION OF ROR1 AND ROR2. 
The extracellular domain of ROR1 contains an Immunoglobulin, Frizzles and Kringle Domain. 
Intracellularly resides a tyrosine kinase domain with a proline rich motif separated by 
serine/threonine repeats. Adapted from Masiakowski and Carroll, 1982. 
 
An N-terminal Immunoglobulin domain is linked with a Frizzled, cysteine rich 
domain, followed by the membrane proximal Kringle domain. The intracellular 
portion contains a tyrosine kinase like domain, along with a proline rich sequence, 
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the latter flanked by serine threonine repeats. The expected molecular weight is 
104 kDa but actual migration is as a 130 kDa protein due to extensive glycosylation, 
which has a role in signalling (Kaucka et al., 2011). A truncated transcript lacking the 
extracellular and transmembrane domains has been identified in foetal and adult 
central nervous tissue, lymphoma and leukaemia cell lines and a subset of solid 
malignancies, although the precise role for this variant is undefined (Reddy et al., 
1996).  
The tyrosine kinase domain was initially thought to be capable of auto-
phosphorylation, but when introduced into negative cell lines in a purified system, 
showed no intrinsic kinase activity and this is due to substitutions of key canonical 
residues (Masiakowski and Carroll, 1992). ROR1 is therefore better considered a 
pseudokinase, with phosphorylation dependent on cell line specific partner 
signalling molecules, which are cell type dependent. In chronic lymphocytic 
leukaemia there is some evidence of constitutive phosphorylation (Gentile et al., 
2011, Bainbridge et al., 2014).  
 
The ROR1 family is closely related to the muscle specific tyrosine kinase 
(MuSK) and tropomyosin receptor kinase (Trk) family and shares many structural 
features, with the exception of the Kringle domain, which is not seen within any 
other receptor in the tyrosine kinase family.  
There is strong evolutionary conservation with a single homolog in 
Caenorhabditis elegans (CAM-1), which directs migrating cells, orients cell division 
and controls axon development (Forrester et al., 1999). In Drosophila 
melanogaster, Dnrk and Dror, the homologs of ROR1 and ROR2 respectively, are 
expressed solely within developing neural tissue (Wilson et al., 1993, Oishi et al., 
1997). Homologs have also been detected in Aplysia californica (McKay et al., 
2001), Xenopus laevis (Hikasa et al., 2002) and Torpedo californica (Jennings et al., 
1993). Expression is seen in neuronal tissue in all cases, where they are postulated 
to be involved in neurite extension and synapse formation based on in vitro studies 
(Paganoni and Ferreira, 2005, Paganoni et al., 2010). This led to the synonym of 
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Neurotrophic Tyrosine Kinase Receptor-Related 1, but this term is no longer widely 
used.  
 
Analysis of ROR1 in developing murine embryos by in situ hybridisation 
demonstrate expression in developing brains as would be expected given the 
above, but also in limbs, especially at the buds. This is in keeping with ROR1 having 
a role in limb development in other species (Rodriguez-Niedenfuhr et al., 2004). 
Within the body, ROR1 is expressed in developing lung buds, the aortic arch, heart 
ventricles, major blood vessels and within areas of the urogenital and 
gastrointestinal tract (Al-Shawi et al., 2001, Matsuda et al., 2001).  
 
In the first report of ROR1 knockout mice, survival was reported to be less 
than 24 hours secondary to pulmonary dysfunction and there were no reported 
gross skeletal morphological abnormalities (Nomi et al., 2001). In contrast ROR2 
knockout animals exhibited dwarfism, shortened limbs and tails along with facial 
abnormalities, ventricular septal defects and respiratory dysfunction (Takeuchi et 
al., 2000). Mutations in human ROR2 have been identified that account for Robinow 
and Brachdactyly type 2 syndromes, resulting in similar phenotypic abnormalities; 
primarily shortened digits and long bones (Schwabe et al., 2000, van Bokhoven et 
al., 2000). In contrast, no human phenotype or disease has been mapped to 
mutations within ROR1, suggesting embryonic lethality if absent or mutated.   
Re-examination of ROR1 knockout animals by an independent group reported 
two main differences from the earlier study despite mice being generated through 
the same mechanism. Firstly, mice survived for more 24 hours, although still died 
within a few days of birth despite. Secondly, a more focused skeletal examination 
revealed subtle defects such as fusion of the sternum, moderately shortening of the 
long bones, cleft in the basosphenoid bone, abnormal development of the C2 
vertebral body, kidney defects and enlarged seminal vesicles, which is in keeping 
with the expression seen in developing murine tissues (Lyashenko et al., 2010).  
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Combined ROR1 and ROR2 knockouts have a more pronounced phenotype 
with enhanced sternal defects, dysplasia of the symphyses of bones and complete 
transposition of the arteries (Nomi et al., 2001). 
 
 ROR1 & Malignancies 
 
ROR1 expression is associated with a range of haematological and solid 
malignancies making it an attractive therapeutic target. The disease where it is best 
characterised and most uniformly expressed is chronic lymphocytic leukaemia 
which I will discuss in greater detail, followed by an examination of its expression 
within normal human tissues.  
 
1.2.1 Chronic Lymphocytic Leukaemia (CLL) 
 
CLL is the commonest leukaemia in the western world and is a B cell 
lymphoproliferative disorder characterised by the accumulation of CD5+CD19+ cells 
in the peripheral blood and secondary lymphoid tissues with resultant peripheral 
blood lymphocytosis, bone marrow failure, lymphadenopathy, hepatosplenomegaly 
with or without B symptoms. Associated immune defects result in increased 
infections, in part, due to hypogammaglobulinaemia but with suboptimal T cell 
responses also playing a role. 
Lymphocytosis, the hallmark of CLL, was initially thought to be due to increased 
cell survival due to a lack of proliferation seen in vitro and as 99.5% of peripheral 
blood CLL cells were in the G0 or G1 phase of the cell cycle (Andreeff et al., 1980). 
Heavy water labelling experiments however, show CLL to have a high proliferative 
capacity, with 109 new leukaemic cells generated per day (Messmer et al., 2005), 
whilst other studies demonstrated markedly reduced telomeres, suggesting 
multiple cycles of replication (Hultdin et al., 2003). This proliferation occurs within 
the tumour microenvironment, which plays a pivotal role in the pathogenesis of 
CLL, as leukaemic cells receive survival and proliferation signals in pseudofollicles 
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(Herndon et al., 2017). Here they are brought into contact with a range of 
supporting cells including stromal nurse cells providing favourable cellular 
interactions and a conducive cytokine milieu (Burger et al., 2000). Signalling 
through the B cell receptor (BCR) is key to this process and combined with other 
cell-cell interactions, leads to a cascade of downstream pro-survival and 
proliferation signals (Herishanu et al., 2013).  
The diagnostic criteria of CLL as defined by the International Working Group on 
CLL (iwCLL) is the presence of greater than 5x109/litre of B lymphocytes in the 
peripheral blood (with less than 55% pro-lymphocytes), with flow cytometry 
demonstrating B cell lineage and clonality. CLL shows aberrant expression of the T 
cell marker CD5 along with the usual B-cell marker CD19, whilst CD20 and surface 
immunoglobulin levels are lower than on normal B-cells (Hallek et al., 2008).   
CLL has a variable clinical course with some patients living with quiescent 
disease for a number of years, whilst others have a rapidly progressive form of 
disease requiring urgent therapy. This phenotype is governed by a complex 
interplay of cytogenetic, molecular and biological aberrations within the leukaemic 
cells at a clonal and sub-clonal level. The sum of these interactions dictates the 
biology of the disease, the need and response to treatment as well as long term 
outcomes. Indeed sub-clones vary over time and with treatment. Massive parallel 
sequencing has delineated driver mutations and documented clonal evolution 
patterns (Landau et al., 2015, Landau et al., 2013).  
A range of prognostic qualifiers have been developed, beginning with clinical 
staging systems that assess disease burden and bone marrow failure (Rai et al., 
1975, Binet et al., 1981). Despite their age and simplicity, they remain valid tools to 
stratify patients. More modern approaches assess expression of cell surface and 
intracellular proteins such as ZAP-70, CD38 and CD49d and of the three CD49d is 
the most discriminatory (Bulian et al., 2014). Additional prognostic information can 
be obtained from assessing the molecular signature of the CLL such as the mutation 
status of the immunoglobulin V gene heavy chain locus, which defines the cell of 
origin in relation to prior antigen experience (Hamblin et al., 1999, Damle et al., 
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1999). This can not only used for prognostication purposes, but has predictive 
power with regards to response rates to FCR chemotherapy (Thompson et al., 
2016).   
The advent of high throughout sequencing has revealed a plethora of molecular 
aberrations that can be used as prognostic markers including mutations affecting 
the TP53, NOTCH1, SF3B1 and BIRC3 genes, although these are not routinely 
assessed for in clinical practice (Wang et al., 2011a, Rossi et al., 2012).  
At diagnosis, cytogenetic abnormalities occur in 80% of patients and include 
deletion 13q, deletion 11q and trisomy 12. The key abnormality, and some would 
argue the most important, is deletion of 17p which encodes the p53 tumour 
suppressor gene. This is associated with poor risk disease, failure to respond to 
standard chemotherapy and decreased overall survival (Dohner et al., 2000).  
Some patients never require treatment, living with their disease for a number of 
years, whilst others have a rapidly progressive form requiring prompt therapy. 
Consensus guidelines developed to guide treatment decisions; Table 1.1 (Hallek et 
al., 2008).  
 
Treatment Indications  
 
Progressive marrow failure with development of anaemia and/or thrombocytopaenia 
Massive (>6cm below costal margin) or progressive symptomatic splenomegaly  
Lymph nodes >10cm or progressive lymphadenopathy 
Lymphocyte doubling time < 6 months (if starting lymphocyte count >30,000/l) 
Autoimmune anaemia or thrombocytopaenia poorly responsive to standard therapy 
Constitutional symptoms 
- Unintentional weight loss >10% over prior 6 months 
- ECOG Performance Score 2 or more 
- Fevers >38 for 2 weeks without evidence of infection 
- Night sweats > 1 month 
TABLE 1.1 IWCLL CRITERIA FOR COMMENCING THERAPY 
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Treatment for CLL has undergone a revolution with the advent of small 
molecule inhibitors disrupting BCR signalling, which is vital for CLL survival. They 
include Ibrutinib; which inhibits Bruton’s Tyrosine Kinase (BTK) and Idelalisib; a 
Phosphoinositide 3-Kinase (PI3K) delta inhibitor. In addition CLL cells have elevated 
levels of the anti-apoptotic protein BCL2 and Venetoclax, a BH3 mimetic targets this 
to lead to CLL cell death. These agents have revolutionised the treatment of 
relapsed/refractory, newly diagnosed and most excitingly 17p deleted patients with 
significant response rates, which can be maintained for a number of years (Byrd et 
al., 2013, Byrd et al., 2014, Furman et al., 2014, Roberts et al., 2016).  
Prior to the development of these agents the gold standard is the combination 
of fludarabine, cyclophosphamide and rituximab (FCR) for patients biologically fit 
enough to receive intensive treatment, termed “go-go” patients (Keating et al., 
2005). Additionally, FCR chemotherapy has the advantage of being delivered over 
approximately 6 months with no need for ongoing treatment. CLL primarily affects 
the elderly and therefore not all patients would be suitable for FCR. For “slow go” 
patients, the combination of an anti-CD20 monoclonal antibody such as Rituximab 
or Obinutuzumab with chlorambucil would be recommended (Goede et al., 2014). 
For those in between, dose reduced FCR or Rituximab-Bendamustine are other 
possible options depending on pre-exiting comorbidities and performance status 
(Eichhorst et al., 2016, Foon et al., 2009). However with the advent of novel agents 
the boundary between “go-go” and “slow-go” patients has been disrupted due to 
toxicity profiles that are favourable irrespective of age (Burger et al., 2015b), 
although these are not completely benign and can have dose limiting toxicities and 
result in fatalities.  
Ibrutinib has been licensed as first line therapy in the Unites States & Europe 
based on the findings of the RESONATE-2 study which showed superiority over 
chlorambucil and although these were striking, it did not randomise between 
comparable arms (Burger et al., 2015b). In the United Kingdom Ibrutinib is 
authorised in the front line setting for patients with 17p deletion/TP53 mutation or 
for salvage after failure of at least 1 previous line of therapy. The multi-centre 
phase III National Cancer Research Institute (NCRI) FLAIR trial is assessing Ibrutinib-
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Rituximab against FCR to compare equivalent 1st line regimens for fit non-17p 
deleted patients. The trial has been expanded to include Ibrutinib-Venetoclax and 
Ibrutinib monotherapy arms.  
 
One of the major outcomes measures identified with FCR is the attainment of 
minimal residual disease (MRD), defined as less than 1 CLL cell per 10,000 
leucocytes as this is associated with enhanced progression free and overall survival 
(Kwok et al., 2016). B cell receptor inhibitors (BCRi) by contrast, lead to an initial 
lymphocytosis, representing translocation of CLL cells from the bone marrow and 
lymph nodes into the peripheral blood. Unlike traditional chemotherapy which 
results in rapid tumour de-bulking, the lymphocytosis seen with BCRi can persist for 
a significant period of time but is not associated with inferior outcomes, with 
responses improving with time (Woyach et al., 2014). Attainment of MRD negativity 
is rare with BCRi monotherapy and multiple combination regimens are under 
investigation to improve this such as with Ibrutinib and Venetoclax, as well as trials 
looking to stop treatment in those who achieve MRD negativity. 
These novel agents are not curative in themselves, with patients required to 
take continuous treatment, some of which can be associated with dose limiting 
toxicities requiring cessation. Although patients can be bridged from one novel 
agent to the next with good responses (Mato et al., 2015), refractory disease still 
occurs, necessitating novel therapeutic strategies for these high risk patients with 
unmet need.  
In addition, approximately 5% of patients develop a high grade transformation, 
termed Richter transformation, which is usually a diffuse large B cell (DLBCL) 
subtype but can rarely transform to a Hodgkin’s phenotype. The high grade 
component is clonally related to the underlying CLL in the majority of cases. 
Prognosis, is significantly lower than for de novo DLBCL, with the primary treatment 
objective to consolidate responses with ASCT if fitness allows (Jain and Keating, 
2016).  
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1.2.2 ROR1 and CLL 
 
ROR1 was found to be overexpressed in CLL based on gene expression profiling 
in two separate studies (Rosenwald et al., 2001, Klein et al., 2001) and confirmed at 
the mRNA and protein level by a number of groups as demonstrated in Table 1.2. 
The largest study, analysing over 1500 cases demonstrated expression in 95% of CLL 
patients, with expression being incorporated into flow cytometry diagnostic panels 
in some specialised centres (Cui et al., 2016).  
ROR1 became a protein of interest in CLL for entirely different reasons following 
immunotherapy approaches by two different groups. The first investigated infusion 
of autologous CLL cells transduced to express CD154, as a means of decreasing the 
immune suppressive nature of CLL and allowing upregulation of costimulatory 
molecules to promote T cell responses. In this study 3 of the 6 patients developed 
antibodies against ROR1 and based on this finding, this group went on to develop 
their own antibody against ROR1, which bound to CLL cells but not normal CD5+ B 
cells (Fukuda et al., 2008).  
The second group used Lenalidomide, an immunomodulatory agent that 
mediates its anti-leukaemic effect through direct cytotoxicity, modulation of the 
tumour microenvironment and correction of functional defects in immune cells 
(Maffei et al., 2016). They demonstrated upregulation of CD154 on CLL cells with 
subsequent production of anti-ROR1 antibodies (Lapalombella et al., 2010). CD154 
upregulation however is not a prerequisite for immune responses as patients can 
have naturally occurring reactive antibodies and T cells against ROR1 (Hojjat-
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Paper Number of CLL 
Samples Positive 
ROR1 Assessment Correlation with prognostic 
markers 
    
(Baskar et al., 2008) 107/107 mRNA Expression No correlation with ZAP70 
 32/32 Flow Cytometry No correlation with IgVH 
mutational status 
    
 






 18/18 Western Blotting & 
Flow Cytometry 




    
(Fukuda et al., 2008) 69/69 Flow Cytometry No correlation with ZAP70 
    
 






 14/14 Flow Cytometry 
 
 
    
(Li et al., 2010) 7/7 Western Blotting  
    
 






Flow Cytometry  
 
 
    
(Shabani et al., 2011) 79/84 mRNA No correlation with IgVH 
mutational status or indolent vs 
progressive samples 
    
 






No correlation between 
untreated and treated or with 
CD38 and ZAP70 
 
    
(Daneshmanesh et al., 2013) 24/24 Flow Cytometry % ROR1+ cells increased in 7 
patients from Non-Progressive 
to Progressive Disease 
    
 















    
 
(Cui et al., 2016) 
 




ROR1High had lower treatment 
free survival and overall survival 
ROR1 levels to not change with 
time or treatment 
 
 
TABLE 1.2 SUMMARY OF ROR1 EXPRESSION DATA IN CLL. 
 
 
Although expressed in the majority of CLL patients, there is no evidence to link 
it to negative prognostic markers such as ZAP70, CD38, Immunoglobulin Heavy 
Chain mutational status. Furthermore there is no evidence that it varies from 
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diagnosis through to treatment. A small study in 20 patients suggested that the 
proportion of ROR1 positive CLL cells was higher in those with progressive disease 
compared with non-progressive cases (Daneshmanesh et al., 2012). A more recent 
study has shown higher levels of ROR1 corresponding to a shorter treatment free 
survival, with ROR1High cases showing enhanced activation of Akt signalling pathway 
(Cui et al., 2016).This is in keeping with murine studies; when ROR1 was under the 
control of the IgH promoter to limit expression to the B cell lineage, mice developed 
a CD5+ lymphoproliferative disorder that could be transmitted to syngeneic 
animals. The T cell leukaemia 1 (TCL1) transgenic mouse, is frequently used as a 
mouse model for CLL (Hamblin, 2010) and ROR1xTCL1 mice developed more 
aggressive disease and potentiation of the Akt signalling pathway (Widhopf et al., 
2014). 
 
1.2.2.1 Wnt5a and ROR1 
 
Wnt signalling occurs through two distinct pathways; the canonical pathway, in 
which signalling stabilises beta-catenin and leads to a range of outputs including cell 
fate determination, cell renewal and proliferation (Sethi and Vidal-Puig, 2010). In 
contrast, the non-canonical, planar cell polarity (PCP) pathway is beta-catenin 
independent and involved in cellular asymmetry and guided cell migration (Witze et 
al., 2008).  
Wnt5a was hypothesised to be the main ligand for ROR1 based on the presence 
of the cysteine rich domain within the Frizzled portion of the receptor (Saldanha et 
al., 1998) and there has been an accumulation of evidence supporting a pleiotropic 
role. CLL cells cultured in the presence of Wnt5a demonstrate enhanced survival 
(Fukuda et al., 2008) and Wnt5a induces a heterodimer of ROR1 and ROR2 which 
upregulates CLL motility through activation of Rac1 and RhoA, via the 14-3-3z 
adaptor protein (Yu et al., 2016, Yu et al., 2017, Sato et al., 2010). In addition, 
Wnt5a induces ROR1 to complex with haematopoietic-lineage-cell-specific protein 
1 (HS1), further enhancing migration of CLL cells (Hasan et al., 2017). There is also 
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evidence that Wnt5a is produced in an autocrine manner by leukaemic cell with 
higher Wnt5a levels associated with un-mutated IgVH samples and earlier time to 
treatment (Janovska et al., 2016). 
 
1.2.3 ROR1 in other haematological malignancies 
 
ROR1 has been reported in 6-45% of unselected B-ALL patients (Shabani et al., 
2007, Shabani et al., 2008, Dave et al., 2012), but is expressed in cases with the 
t(1;19) translocation. Here, expression is independent of the resulting E2A-PBX1 
chimeric transcription factor but due to maturation arrest at an intermediate to late 
stage of B cell development comparable to normal bone marrow B-cell precursors 
termed haematogones. These cells are CD45dim, CD10+ and CD19+ but also express 
low levels of ROR1 (Broome et al., 2011, Dave et al., 2012). Within the context of 
t(1;19) ALL, ROR1 and the pre B cell receptor co-operate to enhance survival such 
that when pre-BCR signalling is inhibited with dasatinib, there is a reciprocal 
increase in ROR1 expression mediating enhanced survival (Bicocca et al., 2012). 
Other reported lymphoid malignancies expressing ROR1 include Hairy Cell 
Leukaemia, Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma, Diffuse Large 
B Cell Lymphoma and Follicular Lymphoma, although ROR1 levels appear to be 
lower and with greater variation. Large validation exercises have not been 
undertaken, thus limiting a true picture to emerge (Hudecek et al., 2010, Barna et 
al., 2011, Daneshmanesh et al., 2013, Hogfeldt et al., 2013). 
ROR1 has also been claimed to be expressed on acute myeloid leukaemia, 
chronic myeloid leukaemia and multiple myeloma, but this has been reported by 
single groups, has not been corroborated by others and relied solely on mRNA 
expression levels with no demonstrated protein expression (Shabani et al., 2011, 
Daneshmanesh et al., 2013). 
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1.2.4 ROR1 in solid malignancies 
 
The 4A5 anti-ROR1 antibody developed by Tom Kipps in San Diego 
demonstrated ROR1 expression in a range of solid and haematological 
malignancies, specifically: 78/144 (54%) ovarian cancers, 63/110 (57%) colon 
cancers, 49/64 (77%) lung cancers, 52/58 (90%) lymphomas, 49/55 (89%) skin 
cancers, 38/48 (83%) pancreatic cancers, 35/48 (73%) testicular cancers, 17/40 
(43%) bladder cancers, 28/29 (96%) uterine cancers, 19/21 (90%) prostate cancers, 
and 10/12 (83%) adrenal cancers (Zhang et al., 2012b).  
An assessment by Stanley Riddell’s group using the 6D4 antibody, specifically 
selected and optimised for IHC demonstrated 50% of ovarian cancers to be ROR1 
positive (of which 90% of endometreoid adenocarcinomas were positive), 57% of 
triple negative breast cancers, 42% of lung cancers and 15% of pancreatic cancers, 
which is considerably lower than the Kipps group.  
 Within the lung cancer cohort they assessed expression in draining lymph 
nodes and found only 60% of ROR1 positive primary disease specimens had ROR1 
positive metastatic disease (Balakrishnan et al., 2017).  Discrepancy between these 
two studies include the use of differing ROR1 antibody clones, differing IHC 
protocols and the use of tissue microarrays to assess expression, which can be 
variable in terms of quality and preparation (Voduc et al., 2008). The Seattle group 
did use the 4A5 clone as a comparator antibody but claimed it to be suboptimal for 
IHC analysis. 
 
In addition to these two large studies, other groups have demonstrated 
expression in a range of malignancies, for example 13/16 renal cell cancer samples 
showed ROR1 expression at the mRNA level (Rabbani et al., 2010). In breast cancer, 
expression is seen in 22.4-72.3% of specimens, depending on the study protocol. 
There is, however, association with higher grade disease, triple negative hormonal 
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receptor status and metastatic potential secondary to enhanced epithelial-
mesenchymal transition and cancer cell survival (Cui et al., 2013b, Chien et al., 
2016, Zhang et al., 2012a). Expression has been demonstrated in melanoma cell 
lines where a dynamic and reciprocal relationship with ROR2 has been reported 
(Hojjat-Farsangi et al., 2013a, O'Connell et al., 2013, Fernandez et al., 2016).  
In ovarian cancer, other groups report 50-55% of cases are ROR1 positive and 
expression was again associated with lower progression free survival and overall 
survival (Zhang et al., 2014a, Zhang et al., 2014b). In this setting and unlike 
melanoma, ROR1 and ROR2 appear to cooperate to bring about a more invasive 
phenotype and associate with enhanced epithelial-mesenchymal transition; a pre-
requisite for metastases (Henry et al., 2015, Henry et al., 2016, Henry et al., 2017).  
In lung cancer, there is an association with advanced disease and negative 
prognostic markers (Yamaguchi et al., 2012, Karachaliou et al., 2014, Liu et al., 
2015b, Zheng et al., 2016). Finally neuroblastoma, sarcoma (Potratz et al., 2016, 
Huang et al., 2015, Elmacken et al., 2015), gastric adenocarcinoma (Chang et al., 
2015, Tao et al., 2015) and colorectal carcinoma (Zhou et al., 2017) have also been 
shown to express ROR1 in variable subsets of tumour samples, but further 
characterisation of these tumour subtypes is required.  
A key finding which highlights the potential of targeting ROR1, is the reported 
expression on ovarian cancer and glioblastoma stem cells (Zhang et al., 2014b, Jung 
et al., 2016). These cells are typically more resistant to therapy and form a niche 
from which relapses occur. Being able to target these cancer initiating cells via 
ROR1 to enhance anti-tumour responses is an appealing attribute and may lead to 
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1.2.5 ROR1 Expression in healthy normal tissue 
 
No matter how many cancer subtypes express a TAA, its utility depends on 
normal tissue expression being absent or low. Initial mRNA data for ROR1 
demonstrated low level expression on adipocytes, which was subsequently 
confirmed by flow cytometry but levels were lower compared to CLL cells (Hudecek 
et al., 2010). ROR1 is also expressed on haematogones in normal marrow, as 
discussed above. Depletion of these cells does not affect overall bone marrow 
constitution (Tom Kipps, iwCLL, New York, USA, 2017).  
This restricted tissue expression was initially corroborated in a good 
laboratory practice compliant, tissue cross reactivity IHC study, with no staining  
seen on normal postpartum tissue using Cirmtuzumab, a high affinity ROR1 
antibody. In view of concerns of ROR1 expression on adipocytes, the pancreas and 
adipose tissue were subjected to detailed scrutiny (Choi et al., 2015a).  
These findings were challenged by Balakrishnan et al. who with their ROR1 
antibody demonstrated convincing evidence of ROR1 expression in the parathyroid, 
areas of the gastrointestinal tract, including the stomach and pancreatic islet cells, 
using both IHC and western blotting (Balakrishnan et al., 2017). Expression on 
normal tissues has been further confirmed within the Human Protein Atlas datasets 
(Uhlén et al., 2015) and has realigned our expectations with regards to potential 
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The origins of cellular therapy arise from transplantation studies undertaken 
in the 1950s in which bone marrow derived from foetuses and cadavers were 
infused into recipients after removal of bone fragments and fat (Thomas et al., 
1957). Although it was largely unsuccessful, it was before full knowledge of 
histocompatibility was elucidated and therefore unsurprising. Even when successful 
engraftment was achieved, patients often developed fatal graft versus host disease 
(GvHD). With greater understanding of the basic science that underpinned 
histocompatibility and better conditioning and immunosuppressive regimens, 
allogeneic transplantation became more widely used and now is a standard 
treatment for haematological malignancies.   
The potential to generate graft versus leukaemia (GvL) effect was discerned 
from murine studies (Barnes et al., 1956) but later became apparent in the human 
setting (Weiden et al., 1979, Weiden et al., 1981). Although many groups had 
moved to T cell deplete infusions to limit GvHD, this was also associated with a 
higher risk of disease relapse, confirming T cells’ central role in disease control 
(Marmont et al., 1991). Donor lymphocyte infusions following ASCT, are used a 
mechanism to control disease relapses through recognition of leukaemia associated 
antigens or minor histocompatibility mismatches triggering further GvL (Mackinnon 
et al., 1995). 
 
1.3.2 Allogeneic Stem Cell Transplantation for CLL 
 
ASCT was previously recommended for patients if they achieved no 
response to intensive therapy, relapsed early after fludarabine containing regimens 
or had 17p deleted disease. Even in fit patients, myeloablative regimens were 
associated with significant transplant related complications and mortality and were 
superseded by reduced intensity conditioning protocols which provided reasonable 
Page | 37 
 
overall progression free survival of 50-60% at 2 years with the possibility of 
achieving further responses with DLI. Despite this, the majority of patients relapse 
with CLL (Kharfan-Dabaja et al., 2007, Richardson et al., 2013). 
With the advent of small molecule inhibitors, the number of allografts being 
undertaken has substantially decreased and the timing has been deferred until 
patients have i) failed two lines of conventional therapy and respond to BCR 
inhibition, ii) have failed front line and BCR inhibition therapy but respond to 
Venetoclax or iii) have progressive disease or a poor response to Venetoclax 
(Kharfan-Dabaja et al., 2016). The precise regimen to enable the last cohort of 
patients to achieve a disease state suitable for transplantation remains challenging.  
An alternative to ASCT is autologous transplantation, which utilises high 
dose therapy with stem cell rescue. This has been assessed in CLL but no clear 
benefit was demonstrated (Reljic et al., 2015). In addition treatment with 
Xcellerated T cells, which are autologous T cells ex vivo stimulated and expanded 
with CD3/CD28 beads before re-infusion into patients, showed no long term benefit 
(Castro et al., 2004).   
 
1.3.3 TCR Engineered Cells 
 
The native TCR recognises short protein fragments presented in the groove 
of the major histocompatibility complex. Recognition between a T cell and its 
cognate MHC:peptide complex leads to activation, proliferation and effector 
function. Maximal function is dependent on T cells receiving a co-stimulatory signal 
2, to provide a positive feedback loop and prevent anergy.  
TCR specificity can be redirected by insertion of alternate TCR  and  
chains to provide novel T cell specificity against TAA presented by the appropriate 
MHC. This was first demonstrated with the isolation of the  and  chains from one 
clone of cytotoxic T cells and transferred to another (Dembic et al., 1986). Proof of 
concept with this approach has been investigated against a number of antigens in 
haematological and solid malignancies (Morris and Stauss, 2016) and a recent trial 
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against NY-ESO-1 demonstrated a 58% overall response rate (Robbins et al., 2015). 
One of the advantages is that TCR gene therapy is the ability to target intracellular 
proteins such as Wilms tumour 1 and p53 as well as surface antigens processed by 
the proteasome and expressed in the context of MHC presentation. Furthermore 
signalling through the TCR is exquisitely sensitive with 10-100 MHC-peptide 
complexes able to trigger T cell activation (Valitutti et al., 1995).  
Difficulties of TCR gene therapy include the need for correct pairing of alpha 
and beta chains within T cells, with aberrant cross pairing resulting in potential 
altered T cell specificity. T cell responses are also dependent on presentation of the 
peptide fragment on the correct HLA context with the most common being HLA-
A*0201 which is present in 40% of the Caucasian population. Despite this, 
strategies to maximise TCR expression, mute endogenous TCR and enhance 
signalling have been developed, enhancing the prospect and applicability of TCR 
engineered T cells (Morris and Stauss, 2016).   
 
1.3.4 Chimeric Antigen Receptor T-Cells 
 
A chimeric antigen receptor (CAR) is composed of an antigen recognition 
domain fused to intracellular signalling domains which, when introduced and 
expressed on the surface of T cells allows for MHC independent T cell activation and 
target cell cytotoxicity. This is important as MHC downregulation is an important 
evasion mechanism utilised by tumours (Hicklin et al., 1999). 
The initial concept of CARs arose when the  and  chains of the TCR were 
substituted for the heavy and light chain variable regions of antibodies thereby 
imparting MHC independent antigen recognition (Gross et al., 1989, Goverman et 
al., 1990). Subsequently the two separate chains were cloned into a single chain 
variable fragment (scFv) in which the variable regions are linked with a flexible 
linker sequence, thus maintaining antigen recognition but allowing simpler 
molecular cloning and transduction (Eshhar et al., 1993). 
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The antigen recognition scFv, is linked to an extracellular spacer domain, which 
mediates the distance and flexibility between the CAR on the T cell surface and 
target cell. This distance can be modified unlike the TCR and peptide-MHC 
interaction. This distance is critical for effective CAR T cell functioning by allowing 
appropriate cytotoxic synapse formation, granule secretion and exclusion of 
inhibitory phosphatases (Hudecek et al., 2013).  
The spacer is linked to a transmembrane domain and is linked to intracellular 
signalling domains, which were initially composed solely of the CD3 chain. 
Although these 1st generation CAR T-cells were able to recognise and kill target 
cells, long term proliferation was limited (Savoldo et al., 2011).  
 
 
FIGURE 1.2 2ND GENERATION CAR SCHEMATIC 
The scFv forms the membrane distal antigen recognition domain and is separated from the T cell 
membrane by a suitable spacer region. Intracellularly there is a costimulatory domain which is 
usually CD28 or 41BB intracellular region linked to the CD3 intracellular domain. 
 
Physiological signalling requires both TCR (signal 1) and co-stimulation (signal 2) 
to achieve full T cell activation (Mueller et al., 1989). In CAR format this was 
reproduced with 2nd generation signalling domains comprising CD3 and CD28 or 
CD3 and 41BB fusion proteins, which demonstrate enhanced cytokine secretion, 
proliferation and most importantly, persistence compared to CD3 alone (Maher et 
al., 2002, Imai et al., 2004). 2nd generation signalling domains remain the most 
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widely used constructs in clinical trials and the use of CD28 vs 41BB varies by 
institution and setting. In vitro and in vivo models however, suggest less exhausted 
T cells with a 41BB-CD3z intracellular chain, whilst CD28 based CAR T cells impart 
stronger initial cytotoxicity (Long et al., 2015, Cherkassky et al., 2016). 
3rd generation signalling domains combine multiple co-stimulatory modules 
including CD28, 41BB and OX40 with CD3 and although these show advantages in 
pre-clinical settings, clear superiority in clinical trials have yet to be demonstrated 
(Till et al., 2012, Pule et al., 2005).  
Fourth generation CAR T cells are those which in addition to the CAR release 
soluble pro-inflammatory mediators such as IL-12 (Koneru et al., 2015) or disrupt 
the tissue micro-environment with release of heparanase, with the aim of 
promoting tumour infiltration and immune responses, especially against solid 
malignancies (Caruana et al., 2015).  These are just two examples in which CAR T 
cells can be engineered to enhance their effector function above and beyond the 
receptor only. Others include manipulation of T cell checkpoints such as secretion 
of PDL-1 by CAR T cells or expression of a dominant negative PD- 1 receptor to 
mitigate against exhaustion (Suarez et al., 2016, Cherkassky et al., 2016). 
 
 
1.3.4.1 CAR T cell Generation 
 
CAR T cell generation is a multistep process, requiring isolation of peripheral 
blood lymphocytes from patients via leukapheresis, before ex vivo expansion, 
stimulation and engineering.  Once produced, modified cells are cryopreserved until 
patients have received conditioning chemotherapy, usually with fludarabine and 
cyclophosphamide, to allow for efficient engraftment (Brentjens et al., 2011).  
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1.3.4.1.1 Electroporation  
 
mRNA electroporation is a relatively quick and cost effective method to 
transfect large number of primary cells. Small scale electroporation occurs in 
cuvettes in which T cells and mRNA encoding the CAR are mixed in a suitable 
conducive buffer and a set pattern and amplitude of electrical pulses applied. This 
leads to the formation of pores within the cell membrane, allowing mRNA entry 
with subsequent transcription and expression. Higher throughput large scale good 
manufacturing practice (GMP) compliant electroporation occurs in a continuous 
flow loops, with cells and mRNA passing through a current for a fixed regulated 
time. This approach has been assessed with mesothelin specific CAR T cells where 
proof of concept was demonstrated following infusion in 2 patients, one with 
malignant pleural mesothelioma and the second with pancreatic cancer. A small 
and transient response was obtained in one patient (Beatty et al., 2014). However, 
CAR expression is temporary, resulting in significant expenditure and processing for 
limited efficacy. The rationale however, is that when targeting antigens for the first 
time, especially those expressed to some degree on normal tissues, transient CAR 
expression mitigates against significant toxicity due to the short half-life of mRNA 
and inherently limits CAR expression.  
 
1.3.4.1.2 Sleeping Beauty Transposons (SBT) 
 
SBT is a non-viral electroporation based method which unlike mRNA leads to 
permanent somatic insertion of the transgene on interest. It relies on insertion of 2 
DNA plasmids into cells: the first comprises the transposon, which encodes the CAR 
sequence sandwiched between inverted repeats and directly repeated DNA 
sequence motifs and the second is the transposase, which recognises these motifs 
and translocates the CAR sequence into the host genome (Ivics et al., 1997, Singh et 
al., 2008). As this technique utilises DNA plasmids there is a considerable cost 
advantage compared to viral vector based methods, but due to the inherent toxicity 
of the electroporation process it necessitates significant ex vivo T cell manipulation 
and processing, including culture on artificial antigen presenting cells, to allow 
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recovery and expansion. Therefore despite its initial promise, there has been 
limited uptake and clinical responses (Kebriaei et al., 2016). 
 
1.3.4.1.3 Viral Transduction 
 
Retroviral and lentiviral vectors form the major method by which T cells are 
engineered. Retroviruses are double stranded RNA viruses that are able to infect 
dividing cells, following which viral reverse transcriptase generates a DNA template 
which is inserted into the host genome. The viral genome can be replaced with a 
transgene of interest (in this case a CAR sequence) to allow permanent modification 
and expression. Lentiviruses, a subclass of retroviruses, differ in their ability to 
infect non-dividing cells and have a number of additional genes that regulate viral 
gene expression and assembly (Mann et al., 1983, Naldini et al., 1996).  
Viral vectors need to be able to deliver the transgene into host cells but 
should be replication incompetent so that new virions are not made. This is 
achieved primarily by separating the genes needed for viral production in trans via 
separate plasmids.  
The transfer plasmid contains the transgene of interest between two long 
terminal repeats. It also includes a central polypurine tract, psi target site, promoter 
and woodchuck hepatitis virus post-regulatory element, all of which regulate and 
enhance transgene expression. One of the helper plasmids contains gag and pol, 
which is needed for structural proteins and reverse transcriptase respectively, 
whilst the third plasmid codes for the viral envelope. The most commonly envelope 
is based on the Vesicular stomatitis virus G (VSVG) glycoprotein, which provides a 
broad tropism for cells. All three plasmids are required for virus to be made and are 
transfected together into a packaging cell line, such as HEK-293T. Retroviruses can 
also be made in specialised helper-free cell lines which constitutively express gag, 
pol and env requiring only transfection of the transfer plasmid (Elsner and Bohne, 
2017).  
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2nd generation lentiviral vectors are made in a similar fashion requiring three 
plasmids: a transfer plasmid and 2 helper plasmids, one containing the envelope 
and the other gag, pol, rev and tat. Rev and tat are additional genes necessary for 
lentiviral vector generation. To improve safety further and decrease the risk of 
replication competent virus production. In a third generation system the Rev is 
placed on an additional plasmid to decrease this risk further. Further safety 
mechanisms can be introduced by introducing a self-inactivating mutation in the 3’ 
LTR which when transduced is copied to the 5’LTR negates inherent promoter 
activity (Zufferey et al., 1998).  
Concerns with regards to insertional mutagenesis arose following clinical 
trials with retroviral vectors to treat severe combined immunodeficiency (SCID), 
due to mutations of the IL-2 receptor  chain. Although gene therapy was able to 
restore immunity, 25% of the 20 patients treated developed leukaemia secondary 
to enhancer mediated mutagenesis (Hacein-Bey-Abina et al., 2003). This led to 
major investigation of the cause and remedies instituted to prevent this. More 
recent trials showing no evidence of leukaemia and long term follow up 
demonstrating safety (Hacein-Bey-Abina et al., 2014, Scholler et al., 2012). 
One of the major disadvantages of viral vectors, especially lentiviral vectors 
is their cost in the clinical grade setting. Manufacture, storage and quality 
certification can be prohibitively expensive and requires significant infrastructure 
and capital investment.  
 
1.3.4.2 CD19 CAR T Cells 
 
CAR T cells against a range of haematological and solid malignancy targets have 
been generated and tested in preclinical studies and transitioned to clinical trials. 
CD19 however, represents the gold standard by which other studies are assessed, 
due to early adoption combined with marked clinical success.  CD19 expression is 
highly regulated within the B cell lineage and absent from other tissues making it an 
attractive target for B cell related malignancies.  
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CD19 is a 61 kDa protein expressed all stages of B cell development, from pre-B 
cells onwards until it is lost on plasma cells. It is composed of two immunoglobulin 
domains separated by a linker region, which is involved with disulphide bonds. It 
interacts with CD21 and CD81 to regulate B cell signalling through its highly 
conserved intracellular cytoplasmic tails (Poe et al., 2001).  
A number of earlier studies using CD19 CAR T cells laid the foundation for the 
pivotal publication of 2 papers by the University of Pennsylvania group in 2011 
demonstrating efficacy in patients with CLL for CD19 CAR T cells with long term 
remissions over 2 years in duration and with attainment of MRD (Porter et al., 
2011, Kalos et al., 2011). Despite the early reported success of CD19 CAR T cells in 
CLL, subsequent studies have been less promising and a summary of the clinical 
trials with CD19 CAR T cells in CLL is shown in Table 1.3. 
In view of this some of the focus shifted to ALL and other non-Hodgkin 
lymphomas, in which higher and deeper response rates have been seen. For 
example in ALL response rates in the region of 90% have been reported in three 
centres (Maude et al., 2014, Davila et al., 2014, Turtle et al., 2016).  
More recent evidence demonstrates that T cells from patients on Ibrutinib for 
greater than 1 year show improved transduction, expansion and function in vitro 
and in vivo (Fraietta et al., 2016a). In addition the Fred Hutchinson group have 
shown with a defined composition of CD4 and CD8 T cells of 1:1 an overall response 
rate of 71% was achieved (Turtle et al., 2017). Finally the University of Pennsylvania 
demonstrate a MRD negativity rate of 89% by multicolour flow cytometry following 
CAR administration and at least 6 months of therapy with Ibrutinib (Gill et al., 
2017). However, such an impressive response rate would be expected given the low 
burden of disease at the time of CAR T cell infusion combined with the fact that 
these patients are not as heavily treated as the ones enrolling in earlier clinical 
trials. 
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1.3.4.3 Toxicity of CAR T cells  
 
Toxicity from engineered T cell has two forms. The first is ‘on target off tumour’ 
toxicity due to expression of the target antigen on normal healthy tissues. For CD19 
this is manifested by profound, but non-lethal B cell aplasia due to CD19 expression 
on normal B cells, which can be managed with intravenous immunoglobulin 
administration. ‘On target off tumour’ toxicity can however be severe as seen with 
the anti-Her2 CAR studies which led to fatal pulmonary toxicity in a patient with 
colonic cancer due to low levels of Erbb2 on lung epithelial cells. Similarly 3 patients 
treated with CAR T-cells against carbonic anhydrase IX developed hepatic toxicity 
due to its expression on bile duct cells (Lamers et al., 2006, Morgan et al., 2010). 
This concern extends to the whole breadth of gene engineered cells including TCR 
modified T cells as demonstrated by fatal cardiac toxicity when targeting MAGE-A3 
(Cameron et al., 2013).  
To try to model this and limit clinical complications, tissue cross reactivity 
studies and animal models including in non-human primates, form part of the 
extensive preclinical screening undertaken.  
Strategies to mitigate against this include the use of suicide systems in the 
engineered T cells, as a method by which to purge cells in the event of toxicity. This 
can be achieved via pharmacological methods, through small dimerisation 
molecules that trigger apoptosis (Straathof et al., 2005, Di Stasi et al., 2011). 
Alternatively cell surface proteins can be expressed independent of the CAR, which 
can be targeted efficiently by monoclonal antibodies. Examples pf these include 
RQR8 which incorporates the CD20 epitope targeted by Rituximab (Philip et al., 
2014) or truncated Epidermal Growth Factor Receptor (tEGFR) which is bound by 
Cetuximab (Paszkiewicz et al., 2016).  
Wu et al. created a system by which the ScFv and extracellular portion are 
spatially separated from the intracellular signalling domains and only combine in 
presence of a drug to allow T-cell activation. This provides a dose dependent and 
tuneable on and off switch (Wu et al., 2015). 
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The second form of toxicity arises due to tumour killing and resultant rapid 
expansion of CAR T cells. This manifests primarily as neurological disturbance, 
pyrexia, elevated inflammatory cytokines and is termed cytokine release syndrome 
(CRS) in which interleukin 6 (IL-6) plays a central role. Treatment of CRS is 
supportive in the most part but if severe high dose steroids with or without the anti 
IL6 antibody, Tocilizumab, which reverses the pro-inflammatory drive. Interestingly 
IL-6 is not released from the CAR T cell population but from bystander myeloid cells 
(Barrett et al., 2016).  
One of the major complications with regards to CRS includes neurotoxicity, 
which is thought to represent translocation of highly activated cytotoxic T cells into 
the cerebrospinal fluid with resultant neuronal irritation and is manifested by 
seizures, stupor and confusion. Knowledge gathered from numerous trials has led 
to a suggested management algorithm for the management of CRS incorporating 
early supportive measures, identification of biomarkers and criteria for therapeutic 
intervention. There is however some belief that a degree of CRS is required to 
generate a persistent T cell response (Davila et al., 2014, Lee et al., 2014a, Lee et 
al., 2014b). CRS has been responsible for patient deaths in clinical trials and 
therefore close clinical monitoring in centres with experience and facilities is 
essential for CAR T cell therapy. 
   
Overall CD19 CAR T cells represent an extremely exciting and potent 
immunotherapeutic with which to target CLL, with the potential for long term 
clinical remissions. 
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Publication CLL Patients Construct Conditioning Cell Dose 
CAR T cells 
x107/kg 
Response 
      
(Brentjens et al., 2011) 
MSKCC 
8 CD19 scFv SJ25C1 
Retrovirus 
CD3/28 Beads 
2nd Generation 28z 
None or Cyclophosphamide 0.4-3 3xNR, 1xPR, 2xSD, 
1xPD and 1xNA 
      
(Porter et al., 2011) 
(Kalos et al., 2011) 
UPenn 
3 CD19 scFv FMC63 
Lentivirus 
CD3/28 Beads 
2nd Generation 41BBz 
Pentostatin/Bendamustine +/- 
Cyclophosphamide 
1-1.6 2xCR, 1xPR 
      
(Kochenderfer et al., 2012) 
NCI 
4 CD19 scFv FMC63 
Retrovirus 
CD3 antibody + IL-2 




0.3-3 1xSD, 2xPR, 1xCR 
(Kochenderfer et al., 2013) 
NCI 
4 Post ASCT CD19 scFv FMC63 
Retrovirus 
CD3 antibody + IL2 
2nd Generation 28z 
None 0.4-2.4 2xPD, 1xSD, 1xCR 
      
      
(Porter et al., 2015) 
UPenn 
14 CD19 scFv FMC63 
Lentivirus 
CD3/28 Beads 
2nd Generation 41BBz 
Fludarabine/Cyclophosphamide or 
Pentostatin/Cyclophosphamide or  
Bendamustine 
1.4-110 4xCR, 4xPR, 6xNR 
CR>4 years in 2 
patients 
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Publication CLL Patients Construct Conditioning Cell Dose 
CAR T cells 
x107/kg 
Response 
      
(Porter et al., 2014) 
UPenn 
 
26 CD19 scFv FMC63 
Lentivirus 
CD3/28 Beads 
2nd Generation 41BBz 
Not specified 5 or 50 in 
total 
5xCR, 4xPR 
      
(Kochenderfer et al., 2015) 
NCI 
4 CD19 scFv FMC63 
Retrovirus 
CD3 antibody + IL2 
2nd Generation 28z 
Fludarabine and Cyclophosphamide 0.25-0.4 3xCR, 1xPR 
      
(Turtle et al., 2015) 
Fred Hutch 
6 CD19 scFv FMC63 
Lentivirus 
CD3/28 Beads 
2nd Generation 41BBz 
Defined CD4:CD8 of 1:1 
Fludarabine and Cyclophosphamide 0.02-2 3xCR, 2xPR, 1xNR 
      
(Turtle et al., 2017) 
Fred Hutch 
24 CD19 scFv FMC63 
Lentivirus 
CD3/28 Beads 
2nd Generation 41BBz 
Defined CD4:CD8 of 1:1 
Fludarabine and Cyclophosphamide 0.02-2 17 CR+PR 
 
      
TABLE 1.3 SUMMARY OF CLINICAL TRIALS UTILISING CD19 CAR T CELLS FOR THE TREATMENT OF CLL.  
CR = Complete Response, PR = Partial Response, NR = No Response, NA = Not assessable, SD = Stable Disease. MSKCC = Memorial Sloan Kettering Cancer Centre, UPenn = 
University of Pennsylvania, NCI = National Cancer Institute, Bethesda, Fred Hutch = Fred Hutchinson Cancer Centre, Seattle.  
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 Bispecific T Cell Engagers  
 
Conventional antibodies do not recruit or utilise T cells for their cytotoxic 
action. In order to utilise their potential however, bispecific monoclonal antibodies 
in which one arm binds a TAA and the other to CD3 were developed to recruit and 
redirect T cells to target tumour cells. Early attempts at this however demonstrated 
limited cytotoxicity (Perez et al., 1985, Riethmuller, 2012).  
To try and improve efficacy of bispecific antibodies Mack et al. engineered 
two antigen binding arms as scFvs and placed them as contiguous protein. To allow 
this both VH and VL sequences within a scFv and parallel scFvs were separated by 
flexible linkers (Figure 1.2). This bispecific antibody construct targeting the 17-1A 
antigen and CD3, was approximately 55kDa in size, retained specific binding and 
mediated T cell dependent cytotoxicity greater than the parental bispecific whole 
antibody (Mack et al., 1995).  
 
 
FIGURE 1.3 STRUCTURE OF BISPECIFIC T CELL ENGAGERS.  
The first reported Bispecific T cell engager was compose of a scFv targeting the TAA CO17-A along 
with a CD3 targeting scFv from the TR66 clone. From (Mack et al., 1995). 
 
This led to the eventual generation of a CD19 and CD3 bispecific construct 
using the same architecture (Loffler et al., 2000), which has subsequently been 
known by a variety of names including MT103 and AMG103, but most commonly 
Blinatumomab. The name is derived from B lineage-specific anti-tumour mouse 
monoclonal antibody and are widely known as BiTEs; Bispecific T cell engagers. 
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Within this construct the CD19 scFv is thought to derive from HD37 clone and CD3 
from the L2K murine antibodies (Nagorsen et al., 2012), although there will have 
been significant engineering of the parental sequences and the final complete 
sequence in Blinatumomab is unknown. This uncertainty is compounded in the by 
differing sequences deposited in different antibody databases.  
BiTEs allow for the formation of cytotoxic synapses between T cells and 
target cells independent of MHC and co-stimulatory molecules (Dreier et al., 2002). 
The majority of killing is thought to arise from effector and memory T cells as naïve 
T cells have a higher basal activation threshold. BiTEs lead to upregulation of CD25 
and CD69 activation markers, release of cytotoxic granules containing granzyme 
and perforins, increased cytokine secretion and T cell proliferation leading to target 
cell death mediated through pore formation as well as triggering of apoptotic 
pathways (Brandl et al., 2007). In addition BiTEs are able to mediate serial killing of 
target cells by a single T cell at low concentrations (Hoffmann et al., 2005).  
 
Blinatumomab has been extensively investigated in ALL, with studies 
demonstrating the potential of treatment in Philadelphia positive and negative ALL 
(Topp et al., 2014, Martinelli et al., 2017). The first Phase 3 trial using 
Blinatumomab compared to conventional therapy showed superiority of 
Blinatumomab with the trial being halted early due to improved survival, although 
this was only 7.7 vs. 4 months (Kantarjian et al., 2017).  
The first phase 1 trial of Blinatumomab was actually in relapsed refractory 
NHL patients (Bargou et al., 2008, Nagorsen et al., 2012) and further trails have 
focused on patients with follicular, mantle cell and diffuse large B cell lymphoma, 
some of which have maintained long term responses despite very low doses of BiTE 
being administered (Viardot et al., 2016, Goebeler et al., 2016).  
Toxicity with Blinatumomab is similar to CAR T cells comprising neurotoxicity 
thought to be secondary to T cell mediated toxicity through breach of the blood 
brain barrier. This however can be limited with pre-mediation with dexamethasone, 
which is a standard part of the treatment protocol. Although the management of 
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CRS in BiTEs is similar, the short half-life of the molecule in the circulation helps 
limit the pro-inflammatory drive, on cessation of the infusion.  
 
Both the original CD19xCD3 bispecific and subsequently Blinatumomab have 
demonstrated in vitro cytotoxicity against CLL, at high target to effector ratios 
representative of what would occur in patients. However these co-cultures with 
BiTEs were prolonged and read between 5-7 days, by which time there would have 
been an inherent decrease in CLL cell viability (Loffler et al., 2003, Wong et al., 
2013). In addition although one of the earliest Phase I clinical trials included 2 
patients with CLL, substantial Phase II and III trials in CLL are lacking.  
 
 ROR1 Therapeutics 
 
Targeting of ROR1 due to its expression profile is a logical developmental 
pathway especially as anti-ROR1 antibodies inhibit CLL survival and RNA 
interference suggested a survival role for ROR1 in cell lines and primary CLL cells 




Cytotoxic antibodies rely on three modes of action for their effect 
i) Antibody dependent cellular cytotoxicity (ADCC) which provides an 
“eat me” signal to the immune system 
ii) Complement dependent cytotoxicity (CDC), the terminal phase of 
which is the generation of a membrane attack complex generating 
pores in targeted cells 
iii) Direct antibody mediated cytotoxicity.  
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Rituximab, the most widely used antibody in oncology, targets CD20 and 
improves outcome measures in a range of B cell malignancies. Its ability to 
efficiently target B cells has also expanded its role into non-malignant conditions. 
Rituximab works mainly by CDC and newer type II antibodies, such as 
Obinutuzumab, have been engineered to maximise ADCC and direct cytotoxicity 
through engineering of the Fc region of the antibody to increase affinity to Fc 
receptors on macrophages (Boross and Leusen, 2012).  
Other antibodies in oncology, such as checkpoint inhibitors and the anti-
HER2 antibody trastuzumab, utilise inhibition of signalling as their modus operandi. 
This is also the main mechanism of action of Cirmtuzumab, the most clinically 
advanced monoclonal antibody against ROR1. The precursor antibody, D10, was 
identified from hybridomas due to its ability to inhibit ROR1 mediated signalling, 
unlike comparator antibodies such as 4A5 and 2A2. Its parental form was a 
relatively low affinity antibody but it was subject to humanisation and affinity 
matured. Its final format has shown the ability to inhibit EMT and survival of cancer 
cells (Zhang et al., 2014b) . A phase I study in 10 patients demonstrated its safety 
although no overt clinical responses were seen and further clinical trials have been 
expanded in CLL and initiated in breast cancer (Choi et al., 2015b).  
Other groups have developed their own antibodies against ROR1, with a 
rabbit immunisation programme yielding clones Y31, R11 and R12, which all show 
minimal CDC.  Although the R12 scFv has been utilised in a CAR format, it did 
demonstrate a degree of ADCC but required a supra-physiologically high 
concentrations of effector cells to achieve this (Yang et al., 2011).  
In comparison, Daneshmanesh et al developed a panel of anti-ROR1 
antibodies targeting the three extracellular domains of ROR1 following a mouse 
immunisation programme with distinct peptides from each domain. They noted 
direct cytotoxic potential with 5 of their antibodies, 3 of which were also able to 
induce CDC and one ADCC. The antibodies that bound to more membrane proximal 
epitopes appeared to show enhanced function (Daneshmanesh et al., 2014, 
Daneshmanesh et al., 2012). Despite this, no further translational development of 
these antibodies has been reported to have been undertaken.  
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1.5.2 Armed Antibodies 
 
In order to improve the cytotoxic potential of antibodies they can be linked 
with toxins or radioactive nucleotides. A prime example is Brentuximab Vedotin, an 
antibody drug conjugate which targets CD30, results in internalisation and releases 
Monomethyl auristatin E, triggering cell death (Francisco et al., 2003). The same 
strategy has been trialled with Cirmtuzumab but despite initial impressive in vitro 
functional data, no armed version of the antibody has been planned for assessment 
(Cui et al., 2013a). 
In the similar vein, a Pseudomonal exotoxin was conjugated to the 2A2 
ROR1 antibody, which was able to induce CLL and MCL cell death in vitro. This 
functions to activate phosphatases in B cell malignancies which are present at high 
levels in inactive forms, thereby triggering apoptosis. Again, despite initial 
encouraging data, no clinical trials have been planned (Mani et al., 2014, Mani et 
al., 2015).  
 
1.5.3 Chimeric Antigen Receptor T Cells 
 
The first ROR1 CAR T cell reported utilised the anti-ROR1 2A2 clone and 
demonstrated toxicity against cell lines and primary CLL cells but spared normal B 
cells (Hudecek et al., 2010). The same group went onto compare the 2A2 scFv with 
clone R12 and showed superior cytotoxicity with the latter. They claim this was due 
to R12 having a higher affinity, but as the epitopes that R12 and 2A2 bind differ, this 
is not a true comparison. They did however demonstrate the importance of the 
spacer with the finding that a hinge only spacer, derived from the IgG stalk, 
provided optimal cytotoxicity (Hudecek et al., 2013). 
The R12 CAR therefore became their lead candidate and has been tested in a 
non-human primates, as it cross reacts with macaque ROR1. Macaques showed no 
toxicity despite comparable ROR1 expression with humans and high doses of CAR T 
cells being infused (Berger et al., 2015). This group also demonstrated ROR1 CAR T 
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cells are able to target breast cancer, neuroblastoma and sarcoma cell lines 
(Elmacken et al., 2015, Liu et al., 2016). The R12 CAR has subsequently been 
licensed to Juno therapeutics and is being investigated in a Phase 1 clinical trial for 
all ROR1 positive malignancies (NCT02706392). 
Deniger et al. utilised the sleeping beauty system to engineer T cells expressing 
and ROR1 CAR utilising the 4A5 scFv clone derived from the Kipps group. Cytotoxic 
potential was demonstrated against cell lines, but the animal model undertaken 
required repeated IL-2 administration, which is not usually required with a 2nd 
generation CAR architecture that was used. This may be secondary to the sleeping 
beauty manufacturing process which requires significant ex vivo manipulation 
(Deniger et al., 2015). Sleeping beauty generated ROR1 CAR T cells, based on this 
construct, were due to be investigated in a clinical trial (NCT02194374) but this 
study has been withdrawn, citing a lack of available reagent, although the exact 
rate limiting reagent is not stipulated. 
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Trial Identification Reagent Target Stage of 
Development 
    
NCT02222688 






    
NCT02860676 
University of San Diego 
UC-961 
(Cirmtuzumab) 




    
NCT02776917 










    
NCT03088878 




CLL/MCL Not open 
    
NCT02194374 
MD Anderson  
Autologous ROR1 



















Non-small cell lung 
cancer 
Open 
    
TABLE 1.4 CLINICAL TRIALS WITH ROR1 THERAPEUTICS 
A current list of the pending, active and withdrawn clinical trials that target ROR1. From: 
https://clinicaltrials.gov/ct2/home, as of 28th October 2017.  
 
  




We hypothesise targeting ROR1 with immunotherapies will allow treatment for 
a broad range of malignancies, including but not limited to CLL and many with 
unmet therapeutic need.  
Our aim is therefore to identify novel antibodies against ROR1; develop these 
into best in class CARs and BiTEs and undertake pre-clinical evaluation to generate 
sufficient data to allow transition to clinical trials.  
 
 Isolate and characterise novel scFv against ROR1 
The starting point for CAR or BiTE development is the identification of ROR1 
specific scFvs. The first aim is to therefore isolate and characterise novel antibodies 
against ROR1 following a rat immunisation programme and transition these to a 
scFv format.  
 
 Develop Chimeric Antigen Receptor T Cells and assess their potential  
From the panel of scFv constructs identified, the next aim was to generate a 
panel of ROR1 CAR T cells, optimise them and select a lead candidate to take 
forward for more detailed analysis.  
 
 Undertake humanisation of the lead scFv 
To limit immune responses directed against a rat derived scFv, the next aim 
was to undertaken a humanisation programme to identify constructs that 
maintained or enhanced functional activity, whilst limited immunogenicity.  
 
 Develop Bispecific T Cell Engagers and assess their potential 
In conjunction with CAR development we also aimed to generate a ROR1 BITEs 
and assess their function in a range of malignancies, to diversify 
immunotherapeutic approaches of targeting ROR1 in addition to CAR T cells.   




 Molecular Biology 
 
3.1.1 Transgene Construction  
 
DNA sequences encoding proteins of interest were generated using overlap 
extension PCR using Phusion DNA polymerase (New England Biolabs). Starting DNA 
originated from pre-existing plasmid constructs (from Martin Pule). Novel DNA 
sequences were from G-blocks (Integrated DNA Technologies) or synthesised 
commercially (Genscript) depending on length and complexity. For commercially 
sourced DNA sequences, either from G-blocks or plasmids, an initial round of PCR 
was undertaken to amplify sufficient quantities of DNA for downstream cloning. 
Codon optimisation for human expression was employed for these constructs.  
Were necessary primers were designed to introduce restriction sites at the 
5’ and 3’ positions for downstream cloning. For multiple fragment ligation, 
amplicons were generated with complementary overhangs. Some sequences 
required insertion into a subcloning vector for which we used Topo TA (Thermo 
Fisher).  
The PCR cycle for Phusion comprised: 98oC for 2 minutes to denature and 
activate the polymerase followed by 35 cycles of, 98oC for 40 seconds to denature 
DNA, 65oC for 40 seconds for annealing, 72oC for 1 minute/kb of amplification. There 
was a final 10 minutes at 72oC.  
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FIGURE 3.1 OPTIMISED TRANSFER PLASMID USED FOR CAR T-CELL PRODUCTION 
The CAR sequence of choice was cloned into a 3rd generation lentiviral construct with a human PGK 
promoter. mCherry was used as a transduction marker and followed by a T2A ribosomal skipping 
element. The scFv sequence was placed in a heavy chain, linker, light chain format and utilised the 
hinge spacer from human IgG1. This was followed by a CD8 transmembrane domain with 41BB and 
CD3 intracellular signalling arms. The design was modular such that each component could be 
switched with simple cut and paste cloning.  
 
3.1.2 Gel Electrophoresis 
 
PCR products and DNA from restriction digests were separated using 
Tris/Borate/EDTA (TBE) gel electrophoresis and stained with 0.005% Sybrsafe 
(Thermo Fisher) or 0.01% Ethidium Bromide (Sigma Aldrich). Samples were mixed 
with a loading dye to aid visualization and deposition into wells. The percentage of 
TBE used varied from 0.75-2% depending on the size of the expected products. Gels 
were run at 120V until sufficient separation of DNA had occurred, size was 
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estimated in comparison with Hyperladder standards (Bioline) and DNA bands 
corresponding to the correct size were excised with a clean scalpel. Gels were 
visualised on a transilluminator (Ngene) to avoid ultraviolet degradation.  
 
3.1.3 Gel and PCR Purification  
 
Isolation of DNA from TBE gel fragments as well as purification of PCR 
products was undertaken with Wizard SV Gel and PCR-Clean Up Kit (Promega) 
following the manufacturer’s instructions. Elution was undertaken with double 
distilled H20.   
 
3.1.4 DNA quantification 
 
DNA was assessed using a ND-1000 Nanodrop spectrophotometer (Thermo 
Fischer) at 260nm to calculate concentration. We also looked at the 260:280nm 
ratio to gauge quality of the isolated DNA samples for downstream use.  
 
3.1.5 Restriction Digestion 
 
All restriction digests were undertaken using enzymes from New England 
Biolabs in appropriate buffer. Where double digests required enzymes with 
incompatible buffers, DNA was subjected to sequential digestion.  
5g of vector backbone was used as starting material in restriction digests. For 
PCR products all of the DNA obtained following gel purification was used. The final 
volume for digestion was 100l and the total enzyme content was 2.5-5% 
depending on enzymes used.  
When using enzymes leaving blunt ends at both sides of the DNA sequence we 
undertook de-phosphorylation to prevent recircularization of the backbone using 
Antarctic Phosphatase (New England Biolabs).  
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3.1.6 DNA ligation 
 
Ligation of DNA with complementary ends was undertaken with Quickligase 
(New England Biolabs). Digested vector backbone and insert were mixed in a 1:1 
ratio in appropriate buffer with 0.5l of ligase per 10l reaction. This reaction was 
left at room temperature for 5 minutes before placing back onto ice and was read 
for E.coli transformation.  
 
3.1.7 DNA Sequencing 
 
Generated plasmid constructs were sent for Sanger sequencing using 
appropriate forward and reverse primers (Source Bioscience). Data was analysed 
using Snapgene Software (GSL Biotech).  
 
 5’ Rapid Amplification of cDNA ends (RACE) 
 
Oligoclonal hybridomas were separated into single cell clones either by 
limited dilution or single cell sorting into 96 well plates and colonies grown until 
confluent (approximately 2 weeks) with hybridoma cell supplement (Roche). 
Supernatant was screened against ROR1 positive and negative cell lines to ensure 
the presence of a specific anti-ROR1 antibody and screened using rat 
immunoglobulin isotyping ELISA kits (eBioscience or BD Bioscience).  
Clones were grown until confluence in 6 well or 10cm plates and then 
pelleted into RNAlater (Life Technologies) before RNA was extracted using RNA 
MiniPlus Kit (Qiagen). RNA was reverse transcribed to cDNA using Quantitect 
Reverse Transcriptase (Qiagen). An aliquot of this cDNA was assessed with GAPDH 
primers (forward GCCGAGCCACATCGCTCAGA and reverse 
GAGGCATTGCTGATGATCTTG respectively), which were able to differentiate 
genomic and cDNA to ensure quality of samples. 
  cDNA had a poly-C tail added with Terminal Transferase (New England 
Biolabs) and nested PCR reactions were performed based on the isotyping results 
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(Phusion: New England Biolabs or Platinum Taq High Fidelity: Life Technologies) to 
identify the variable regions of the heavy and light chains, using primers specific for 
light chain isotype and heavy chain isotype.  
PCR products were run on a 1% TBE gel and post-stained with Gelstar 
(Lonza) which provided better resolution of low levels of DNA compared to 
SybrSafe and Ethidium bromide. Bands of the correct size between 300 and 1000 
base pairs were extracted and sent for direct sequencing or inserted into Topo TA 
or Topo Zero subcloning vectors (Life Technologies) for subsequent sequencing.  
To allow us to directly sequence the PCR products, primers were designed 
such that they bound further within the constant regions and allowed read through 
of the sequencing reactions without omission of the terminal variable region 
thereby obviating the need for Topo subcloning.  
 
Primers for 5’RACE 
Description DNA Sequence 5' - 3' 
PolyC_Anchor_Outer ACGGTGCAAACCTTCCTCCAAATCGGG 
PolyC_Anchor_Inner ACGGTGCAAACCTTCCTCCAA 
Rat Lambda Outer GACAGACTCTTCTCCACAGTGTTC 
Rat Kappa Outer CTTGACACTGATGTCTCTGGGATAGAA 
Rat Kappa Inner CACGACTGAGGCACCTCCAGTTGCTAA 
Rat IgH Outer CCCAGACTGCAGGACAGCTGGGAA 
Rat IgH Inner GCTGGACAGGGCTCCAGAGTTCCA 
Rat IgM Outer GTTCTGGTAGTTCCAGGAGAAGGAAA 
Rat IgM Inner CAGGCAGCCCATGGCCACCAAA 
 
Sequence data was compared to the IMGT V-QUEST database of Rat germline 
immunoglobulin sequences and consensus sequences obtained that were 
productive and had an in frame signal sequence (Brochet et al., 2008, Alamyar et 
al., 2012).  
Overlap extension primers were designed to amplify the heavy and light 
chains whilst introducing a GGGGSGGGGSGGGGS linker sequence to generate ScFv 
constructs. A secreted version of the ScFv was produced by cloning the ScFv 
sequence in frame with murine IgG2a constant region using NcoI and BamHI sites 
Page | 62 
 
(or if needed the compatible BglII or BclI sites) and into the pCCL.PGK lentiviral 
backbone which included an extracellular spacer, 41BB and CD3 using SalI and 
BamHI sites.  
 
 Bacterial Work  
 
3.3.1 Bacterial transformation  
 
Plasmid amplification was undertaken in C2987H chemically competent 
DH5E. coli (New England Biolabs). In isolated cases where enzymes were dam and 
dcm methyltransferase dependent we utilised the C2925I dam-/dcm- competent E. 
coli (New England Biolabs).  
2l of Quickligase reaction or 100ng of plasmid for re-transformation was 
mixed with competent E. coli for 30 minutes on ice before heat shocking at 42oC for 
30 seconds. The reaction mixture was returned to ice for 5 minutes before addition 
of 250l SOC media (New England Biolabs) and agitated at 37oC for 60 minutes at 
220 revolutions per minute before plating onto agar plates with appropriate 
antibiotic for screening. The antibiotics we used were Ampicillin or Kanamycin 
depending on the plasmid (Sigma). Plates were incubated at 37oC overnight and 
single colonies selected and grown in 4 ml of Luria-Bertani (LB) or Terrific broth (TB) 
overnight with appropriate antibiotic in a rotational shaker.  
 
3.3.2 DNA Isolation from E.Coli Cultures 
 
The method of DNA isolation varied depending on the volume of starting 
material. For screening purposes we undertook minipreps using Macherey-Nagel 
miniprep kit with a starting volume of 1.5ml of medium. These were subjected to 
restriction digest to assess the digest pattern to delineate the correct sequence. For 
larger quantities of DNA we utilised Macherey-Nagel Midi kits (100ml media), Maxi 
kits (300ml media) or Qiagen Megaprep Kits (400ml media). DNA was eluted into 
ddH2O and quantified as described above. DNA was stored at -20oC until required 
for use.  
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 Protein Work 
 
3.4.1 Protein Electrophoresis 
 
For protein separation we utilised the NuPage Novex system. Samples were 
prepared in a final volume of 60l with sample reducing reagent and LDS sample 
buffer. The sample was then boiled at 95oC for 5 minutes. 15L of each sample was 
run on a premade 4-12% Tris-Bis gels at 200V, 500mA for 45 minutes on constant 
voltage mode. A protein standard was incorporated for size estimation (All Novex 
reagent, Thermo Fisher).  
 
3.4.2 Coomassie staining of protein gels 
 
Following separation gels were stained overnight with Coomassie Blue 
0.25% in a rotating agitator. The next day, de-stain was added to remove excess dye 
and the protein gel photographed. For protein estimate we generated a standard 
curve using Pierce Bovine Serum Albumin Standards (Thermo Fisher). Protein 
concentrations were calculated using ImageJ software (Schneider et al., 2012).  
 
3.4.3 Western blotting 
 
Post-separation, protein was transferred from Tris-Bis gels to polyvinylidene 
difluoride membrane by semi-dry transfer. Sandwich transfer was undertaken at 
15V for 15 minutes in transfer buffer (Novex, Thermo Fisher). Following transfer, 
membranes were blocked with PBS supplemented with 5% milk powder overnight 
with circular rotation. Staining was undertaken with an anti-His Horseradish 
Peroxidase antibody (Biolegend) at a concentration of 1:2000 for 1 hour with gentle 
rotation supplied by rotating plate shaker. The sample was then washed 3 times 
with PBS supplemented with 0.1% tween for 15 minutes each time. The membrane 
was developed by addition of Pierce ECL plus Western Blotting Substrate (Thermo 
Fisher) for 5 minutes. Visualisation of protein bands was undertaken by exposure of 
X-ray film (Fujifilm) to the membrane for 10-600 seconds depending on signal 
intensity.  
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3.4.4 Antibody and fusion Fc protein production 
 
For full length antibodies the light chain sequence was clones in frame with 
the human kappa light chain constant region in a plasmid co-expressing BFP and in 
a separate plasmid, the heavy chain in frame with the human IgG1 heavy chain 
constant region co-expressing GFP (both from Martin Pule). Co-transfection of 
these into HEK-293T cells liberated antibodies into the supernatant.  
For Fc fusion proteins, the ligand of interest (ROR1 or scFv usually) was 
cloned in frame with the murine IgG2a Fc stalk in the pFUSE-mIgG2a-Fc plasmid 
(Invivogen, from Martin Pule). As with the antibody, transient transfection of HEK-
293T cells led to secretion of Fc fusion proteins into the supernatant which was 
used for downstream processing.  
 
3.4.5 BiTE purification  
 
3.4.5.1 Screening Purification 
 
When large numbers of BiTEs had to be purified we utilised gravity columns. 
Supernatant containing BiTE was diluted 1:1 in loading buffer and passed through 
HiTrap Talon 1ml gravity columns (General Electric), washed and eluted with 3ml of 
elution buffer containing a final concentration of 150mM Imidazole. Purity and 
concentration was assessed against a BSA standard in a Coomassie gel. Binding 
buffer: 50 mM sodium phosphate, 300 mM NaCl1, pH 7.4. Wash buffer: 50 mM 
sodium phosphate, 300 mM NaCl1, 5 mM imidazole, pH 7.4. Elution buffer: 50 mM 
sodium phosphate, 300 mM NaCl1, 150 mM imidazole, pH 7.4 
 
3.4.5.2 Large Scale Purification  
 
Media containing BiTE was diluted 1:1 with loading buffer and subjected to 
fast Protein Liquid Chromatography (FPLC) using 1ml or 5ml HiTrap Talon binding 
columns with an AKTA Explorer (GE Healthcare Life Sciences). Following loading, 
washing was undertaken with at least 10 column volumes of wash buffer, elution 
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was undertaken with a three step process using differential imidazole 
concentrations and fractionated. Fractions were run on a Coomassie to ascertain 
BiTE containing aliquots and pooled and subjected to dialysis in Slide-A-Lyzer 
cassettes (Thermo Fisher) with a molecular cut off of 10 kDa in 5 litres of PBS 
overnight. Purified, dialysed BiTE was then quantified in A Coomassie gel and 1% 
BSA added to act as a stabiliser and limit aggregation.  
 
3.4.6 Size Exclusion Chromatography  
 
Purified ROR1 BiTE was subjected to Size exclusion chromatography, 
undertaken with a Shimadzu Nexera XR HPLC machine and Waters size exclusion 
chromatography column at Bio-Analysis Centre London, who provided graphical 
and analytical data with regards to the runs.  
 
3.4.7 Biacore SPR 
 
Surface plasmon resonance was undertaken on a Biacore X100 machine 
(General Electric). CM5 chips were labelled with mouse capture antibody using the 
mouse antibody capture kit. Supernatants containing scFvs of interest (with a 
murine Fc stalk) were then captured on the anti-murine antibodies on the chip. SPR 
readings were undertaken with dilutions of full length ROR1 conjugated to His (Acro 
Biosystems). Data was analysed with X100 software to generate kinetics data. 
 
3.4.8 Peptide library ELISA 
 
An ROR1 peptide library for the extracellular domain of ROR1 was generated 
by Mimotopes. Peptide fragments were composed of an N-terminal biotin, a linker 
sequence and then 11 amino acids of ROR1, followed by a C-terminal amide group. 
Each 11 amino acid peptide had 8 amino acids that overlapped the previous peptide 
whilst introducing 3 new amino acid to its sequence. Lyophilised eROR1 peptides 
were solubilised in 50% Acetonitrile using a water bath sonicator. Peptides were 
then diluted in 0.1% Azide in PBS-Tween 20 (PBS-T). Control peptides (Mimotopes) 
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were treated and processed in the same way. Control antibodies, also provided by 
Mimotopes, were dissolved in purified water as per manufacturer’s instructions.  
Briefly, 96-well plates were coated with Neutravidin, blocked with 1% sodium 
caseinate and washed thoroughly before incubation with the solubilised peptides. 
After 1 hour of incubation, plates were washed again and incubated overnight with 
clones SA1 and F. On the next day, plates were washed and incubated for 1 hour 
with an anti-human IgG antibody conjugated to horseradish peroxidase (HRP). 
Plates were washed, and antibody signal detected with Tetramethylbenzidine 
(TMB); the reaction was then stopped with H2SO4. Samples were read in a plate 
reader at a wavelength of 450nm.  
 
3.4.9 Commercial Protein Production 
 
Absolute antibody limited were used as a commercial manufacturing 
organisation for large scale antibody, BiTE and bispecific scFv-Fc antibody 
production. 
 
 Tissue Culture 
 
3.5.1 Cell Lines & Culture 
 
Cells lines were obtained from American Type Culture Collection (ATCC), 
Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ), from within 
institutional banks within the Cancer Institute or University of Verona. Cells were 
grown in Roswell Park Memorial Institute (RPMI), Dulbecco's Modified Eagle 
Medium (DMEM) or Iscove's Modified Dulbecco's Medium (IMDM) supplemented 
with GlutaMAX and 10% South American Origin Foetal Calf Serum (Thermo Fisher). 
RPMI had HEPES incorporated at a final concentration of 25mM. No antibiotics 
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Cell Line Origin Media Nature 
    
HEK293T ATCC IMDM Adherent 
SKW6.4 ATCC RPMI Suspension 
Jeko1 ATCC PRMI Suspension 
Raji ATCC RMPI Suspension 
Kasumi2 DSMZ RPMI Suspension 
PCL12 DSMZ RPMI Suspension  
 
697 DSMZ RPMI Suspension 
MEC1 University College London RPMI Suspension 
PANC1 ATCC RPMI Adherent 
MiaPaCa2 University of Verona RPMI Adherent 
CFPAC ATCC RPMI Adherent 
PSN1 University of Verona RPMI Adherent 
SUIT2 University of Verona RPMI Adherent 
MDA-MB-231 University College London RPMI Adherent 
MCF7 DSMZ RPMI Adherent 
SKOV3 ATCC RPMI Adherent 
HOC7 University College London RPMI Adherent 
HEY University College London RPMI Adherent 
SK-Hep-1 University College London RPMI Adherent 
HUH7 
 
University College London RPMI Adherent 
U251 University College London RPMI Adherent 
A72 University College London RPMI Adherent 
T618A University College London RPMI Adherent 
DU145 University College London RPMI Adherent 
PC3 University College London RPMI Adherent 
TABLE 3.1 CELL LINES USED WITHIN THIS PROJECT, THEIR PROVENANCE, CULTURE MEDIA AND 
CHARACTERISTICS 
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Suspension cell lines were split every 2 to 3 days depending on confluence 
and diluted 1:10 to 1:20 with fresh media. For adherent cell lines, we washed the 
adherent layer once with PBS and then added Trypsin-EDTA for 5 minutes at 37oC 
before adding fresh media with FCS to neutralise the trypsin. Adherent cells were 
split 1:10 in new culture flasks twice a week.  
 
3.5.2 Transient Transfection 
 
Transient transfection was performed with HEK293T cells in tissue culture 
dishes or plates using Polyethylenimine (PEI) or GeneJuice (Merck) at the below 
ratios depending on experimental requirements. HEK293T cells were plates 24 to 48 
hours prior to transfection and assessed for optimal confluency. Transfection 
reagent and serum free media were mixed well and left for 10 minutes before 
addition of DNA, mixed again and left for 15 minutes before being pipetted onto 
293T cells in a drop wise fashion. The mixture was agitated in the plate to ensure 
optimal distribution and cells returned to the incubator for 3-5 days before cells or 
supernatant was harvested.  
 
Culture Vessel PEI/GeneJuice Serum Free Media Total DNA 
    
10cm Dish 30l 470l 12.5g 
6 well 5l 95l 2g 
12 well 
 
2.5l 47.5l 1g 
24 well 1.25l 23.75l 0.5g 
 
 
3.5.3 Stable BiTE producer cell line 
 
Retroviral vectors containing the BiTE sequence of interest along with a GFP 
reporter gene were produced. HEK293T cells at low levels of confluency were 
infected in 6 well plates, followed by expansion. GFP positive cells were sorted to 
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high levels of purity (>99%) and BiTE collected from subsequent passages of stably 
transduced cells.  
 
3.5.4 Peripheral blood mononuclear cell isolation  
 
Whole blood was obtained by venesection from consenting donors into 
EDTA containing syringes (final concentration 5mM EDTA). Blood was diluted with 
RPMI with no FCS in a 1:1 ratio and 25ml of this diluted blood was layered onto 
10ml of Ficoll-Paque Plus (General Electric Health Care) in 50ml centrifuge tubes. 
Tubes were centrifuged at 750G for 40 minutes at room temperature with no 
acceleration or deceleration. The buffy coat layer was removed using Pasteur 
pipettes and PBMCs were washed twice with RPMI media with 10% FCS and 
adjusted to the appropriate concentration.  
 
3.5.5 Magnetic Cell Manipulation  
 
For CAR T cell cultured we removed CD56+ cells comprising NK cells which 
may lead to false positive non-specific killing in our co-culture assays. This was 
undertaken with CD56 beads and magnetic columns following the depletion steps. 
For CLL cell isolation we used a pan CLL negative isolation kit and for isolation of T 
cells specifically from PBMCs we utilised Pan T cell isolation kit, again a negative 
selection kit (All Miltenyi Biotec).  
 
3.5.6 Retronectin coating preparation of tissue culture plates 
 
Non tissue culture treated 24 well plates were coated with retronectin 
(Takara Bio)  in preparation for T cell transduction with 500ul of PBS and 4ml of 
retronectin per well. Plates were sealed with film and left at 4oC for at least 16 
hours or until required.  
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 Viral Vector Production  
 
3.6.1 Retroviral vectors 
 
We utilised the SFG retroviral vector system for use in cell lines which was 
kindly provided by Martin Pule. RD114-pseudotyped transient retroviral 
supernatant was generated by triple transfection of 4.69μg Peq-Pam plasmid 
(GagPol), 3.125μg RDF plasmid (RD114 envelope), and 4.69μg SFG (transfer 
plasmid), per 10cm plate as above. Supernatant was harvested at 72 hours and 
used fresh or snap frozen and stored at -80oC.  
 
3.6.2 Lentiviral vectors 
 
For lentiviral vectors we utilised a 3rd generation packaging system 
developed by Didier Trono through Addgene. This included 3.13g of pRSV-Rev 
(contains rev), 4.06g of pMDLg/pRRE (contains gag and pol), 2.19g of pMDG.2 
(containing VSVG envelope) and 3.13g of the transfer plasmid based on a pCCL 
backbone. HEK293T cells were plated at 2x106 cells/10cm plate and 48 hours later 
the above plasmids were mixed with plain media and GeneJuice. Supernatant 
containing vectors was harvested 48 hours later and used fresh after filtering 
through 0.22m filters or snap frozen.  
 
3.6.3 Primary Cell Transduction  
 
T cells for in vitro and in vivo work were transduced with 3rd generation 
lentiviral vectors. PBMCs were re-suspended at 2x106/ml and seeded at 1ml per 24 
well plate and activated with CD3 and CD28 antibodies at 0.5mg/ml (Miltenyi 
Biotec) or CD3/CD28 Beads (Invitrogen). The next day fresh media was added with 
IL-2 to a final concentration of 100IU/ml and 6 hours later cells were harvested, 
counted and re-suspended at 0.6x106/ml and 0.5ml was seeded into a 24 well plate 
pre-coated with retronectin. 1.5ml of lentiviral supernatant was added to each well 
with fresh IL-2 to a final concentration of 100IU/ml and spun for 40 minutes at 
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1000G. Two days later cells were harvested, re-suspended at 0.5x106/ml with 
50IU/ml of IL-2 and left to expand.  
 
 Flow Cytometry & Sorting 
 
Flow cytometry was undertaken on Becton Dickinson (BD) machines 
comprising BD Accuri, BD FacsVerse, BD LSR Fortessa or BD Symphony. Cell sorting 
was undertaken by the UCL Cancer Institute Core Facility on a BD FACS Aria.  
Cells of interest were washed with PBS, stained with directly conjugated 
antibodies +/- viability dye and incubated at 4oC for 30 minutes. Cells were washed 
again and re-suspended in 500ml of PBS. Isotype controls and non-stained cell 
populations were included to allow generation of appropriate gates. Where 
necessary OneComp beads (eBioscience) were used to adjust compensation 
settings. Data was analysed on FlowJo Software.  
For sorting we included Normocin, a broad spectrum antibiotic and antifungal 
into the media at the time of the sort and for 24-48 hours post sort. Cells were 
sorted into enriched RPMI media containing 20% FCS and upon healthy recovery of 
the sorted population the FCS percentage was reduced to 10%.  
All antibodies were sourced from Biolegend. 
 
3.7.1 Antigen Binding Capacity measurements 
 
 Qifikit beads were used to assess number of target antigens per cell using 
the manufacturer’s instructions (Dako, Agilent Technologies). In brief the cells of 
interest were incubated with the same concentration of unconjugated murine anti-
human ROR1 or CD19 antibodies, washed twice with PBS and then stained with 
anti-murine Fc conjugated antibody linked to FITC or APC. Calibrated beads with 
known numbers of binding sites were stained in the same way allowing the 
construction of a standard curve with mean fluorescence intensity measurements 
relating to absolute antigens per cell.  
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 Functional Assays  
 
3.8.1 Chromium Release Assay  
 
Target cells (1x106) were harvested and centrifuged. The cell pellet was 
incubated with 3.7 Mega Becquerel of 51Sodium Chromate for one hour, with 
agitation every 15 minutes, before being washed 3 times with fresh media. 50,000 
cells were plated per well in a 96 well plate. Effector cells, comprising CAR T cells, 
were added at various ratios to a final volume of 200l per well. Plates were spun 
at 400G for 5 minutes before incubating at 37o C for 4 hours. 100l of supernatant 
was removed and Chromium release quantified by a Gamma Counter (Perkin 
Elmer). Maximal lysis was calculated with supernatant with cells incubated with 1% 
Triton-X.  
 
Chromium release was calculated based on (Experimental Release – 
Background Release) / (Maximal Release – Background Release) x 100.  
 
3.8.2 Flow Cytometry Based Cytotoxicity Assay 
 
3.8.2.1 Target Cell Preparation 
 
To facilitate a flow cytometry based cytotoxicity assay we found that pre-
labelled target cells were optimum to allow accurate delineation of cell number. For 
cell lines this was primarily achieved by transducing them to express GFP using a 
retroviral vector with subsequent single cell dilution or flow based cell sorting. For 
some cell lines and primary CLL samples we labelled cells with Carboxyfluorescein 
succinimidyl ester (CFSE; CellTrace CFSE Cell Proliferation Kit, Thermo Fisher).  
Cells of interest are suspended in 1mL of warm PBS + BSA 0.1%. The working 
dilution of CFSE in 1mL of warm PBS + BSA 0.1% to give a final concentration of 
1M. Both solutions are mixed in a 1:1 ratio and incubated at 37oC for 10 minutes. 
The reaction is quenched by adding 5 volumes of cold RPMI and incubate 10 min on 
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ice. Cells are washed in media for and re-suspended to 0.25x106/ml and 100ml 
added to each well of a 96 well plate. 
 
3.8.2.2 Effector Cell Preparation  
 
For CAR T cell assays it is vital to normalise expression levels and 
transduction efficiencies to allow comparable assessment between constructs. 
Transduction efficiency is assessed the day prior to set up and normalised to the 
lowest population, through the addition of un-transduced cells. Cells are counted 
and re-suspended typically at 0.5x106/ml and 100ul added to each 96 well. This 
gives an effector to target ratio of 2:1 but this can be adjusted depending on the 
experimental conditions.  
 
3.8.2.3 Assay Conditions 
 
Each condition is undertaken in triplicate to allow statistical analysis to be 
undertaken. Following mixture of effector and target cells, 96 well plates are spun 
at 400G for 5 minutes and returned to the incubator overnight. The next day 100l 
of supernatant is removed for cytokine ELISA.  
A master mix of viability dye (Propidium Iodide from Sigma and Fixable 
Viability Dye, ebioscience), anti-CD3 antibody (Clone SK7) is added to each well. The 
master mix also contains Flowcheck Microspheres (Beckman Coulter) to act as an 
internal control and allow normalisation between individual wells. After 30 minutes 
at 4oC, the plate is washed and samples transferred to micro-rack FACS tubes and 
analysed by flow cytometry. The stopping criteria are a 1000 beads per well.  
 
3.8.3 CD107a Degranulation Assay  
 
For CD107a Degranulation Assays we undertook the same process as above 
with a 2:1 effector to target ratio. At the same time as the assay was established we 
added 10ml of anti-CD107a antibody (Biolegend or BD Bioscience, Clone H4A3) and 
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was incubated at 37oC. An hour later we added 2ml of Golgistop (BD Bioscience), a 
protein transport inhibitor containing Momensin and left to incubate for 2 hours 
before staining and assessment of CD107a expression on T cells.  
 
3.8.4 MTS Based Cytotoxicity Assay  
 
Co-culture with adherent cells were also undertaken in 96 well plates, 
containing 1x104 target cells, 1x104 T cells, and purified BiTE at concentrations of 
0.1 ng/mL–1 mg/ml. The effector to target ratio was adjusted based on 
transduction efficiency and no BiTE was added. Twenty-four hours after the 
addition of ROR1 BiTE or CD19 BiTE, supernatant was collected for cytokine 
evaluation. To assess cytotoxicity, we washed the plate of effector cells and used 
the CellTiter 96 AQueous One Solution Cell Proliferation Assay MTS assay 
(Promega). This is a colorimetric assay in which the colour change of the media is 
proportional to the activity and hence survival of cells. 
 
 
3.8.5 Cytokine ELISA 
 
Interferon- and IL2 cytokine levels were quantified using sandwich ELISA 
(Biolegend) following manufacturers recommendations. For CLL co-cultures we 
utilised Legendplex Cytokine assay (Biolegend) which is a bead based flow 
cytometry ELISA assay.  
 
 Immunohistochemistry  
 
All immunohistochemistry was undertaken at the University of Verona by our 
collaborators, Dr Claudio Sorio and Dr Marzia Vezzalini. The heavy and light chains 
of our ROR1 scFv were cloned in frame with the murine IgG1 constant and kappa 
constant regions, respectively, and antibody was produced by Absolute Antibody 
Ltd. Normal pancreas and pancreatic tissue microarrays were obtained from US-
Biomax. Slides were prepared using the standard laboratory protocols. Briefly, 
Page | 75 
 
antigen retrieval was undertaken by immersing slides in 0.01 M sodium citrate 
buffer, pH 6.0 at 95oC for 15 min before cooling and rinsing once with PBS, and then 
blocked and stained with ROR1 antibody (1:250) in PBS/Tween20, 0.05% BSA, 1% 
NaN34 mM for 60 min at room temperature. Slides were incubated with the HRP-
conjugated secondary, Histofine Simple Stain MAX PO (Nichirei), and developed 
using Stable DAB Plus (Diagnostic Biosystems). 
 
 Animal Studies 
 
All animal works were performed under the authority of the United Kingdom 
Home Office Project and Personal License regulations and were compliant with 
University College London guidelines.  
 
3.10.1 Solid Tumour Studies 
 
3.10.1.1 Intraperitoneal Model  
 
Six- to eight-week-old female Hsd:Athymic Nude-Foxn1 mice (Charles Rivers 
Laboratories) received 2x106 PANC-1 cell transduced to express firefly luciferase or 
5x106 SKOV3 cells transduced to express firefly luciferase by intraperitoneal 
injection. Luciferase expression was detected using D-Luciferin (Melford 
Laboratories), which was injected intraperitoneally (IP) at a dose of 200 mg/mouse. 
Bioluminescence imaging (BLI) was undertaken using the IVIS Imaging System 100 
Series (Perkin Elmer) at multiple time points. Living Image 4.4 software (Perkin 
Elmer) was used to quantify the BLI signal. T-Cells and BiTE was injected ip at the 
same time at ratios and concentrations described within the experiments.  
 
3.10.1.2 Subcutaneous Model 
 
5x106of PANC-1 cells were mixed in an equal volume of Matrigel (Corning) 
and were injected in the flank of 6–8-week-old Hsd:Athymic Nude-Foxn1. Once the 
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xenograft were established (minimum size 100 mm3), mice received 5x106 T cells by 
single tail vein injection, followed by a daily injection of PBS, ROR1, or CD19 BiTE 
suspended in 0.1% BSA in PBS mg/kg/mouse). Tumour volume was calculated using 
the ellipsoidal formula (length × width2)/2.  
 
3.10.2 Haematological Model 
 
6-8 week old Nod-SCID IL2 mice (Charles Rivers Laboratories) were used 
for in vivo experiments with haematological cell lines. 0.5x106 SKW6.4 or Jeko1 cells 
were injected into mice via tail vein on Day 0 before being allowed to engraft 
uniformly.  Mice were subsequently randomised and followed by BLI until uniform 
signals detected. Mice were injected with a single T-cell infusion and BiTE 
(10g/kg)/PBS as per the experimental procedure and followed up by BLI 
expression and survival.  
 
3.10.3 Intravenous injection of mice 
 
Animals were briefly heated in a warming box to 39oC to encourage 
peripheral vasodilatation. Tail vein cannulation was performed using a 27 gauge 
needle, followed by intravenous injection of tumour cells (200l volume). Tumour 
samples or T-cells were suspended at appropriate concentration in PBS.  
 
 
3.10.4 Monitoring and euthanasia of experimental animals 
 
Mice were monitored daily for evidence of poor health including poor 
grooming, hunched posture, piloerection, etc. Animals were culled if found not to 
be in satisfactory condition, if hind leg paralysis developed, or at pre-specified 
experimental time points. Termination was by inhalation of escalating 
concentration of carbon dioxide, with confirmation of death by cervical dislocation. 
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 Statistical Analysis 
 
Graphs, standard curves and statistical analysis was undertaken using Prism 
Software v7.03 (Graphpad). Error bars represent standard deviation where 
depicted. When two groups of variables were being analysed we used the non-
paired t-test, when multiple groups were analysed with used either a one way or 
two way ANOVA with Bonferroni post-test correction depending on the number of 
variables. A p value <0.05 was taken as significant and where indicated: * p≤0.05,  
**p≤0.01,  *** p≤0.001,  **** p≤0.0001.








Emil von Behring and Shibasaburo Kitasato were amongst the first to 
describe the role of passive immunity when they demonstrated serum from 
diphtheria or tetanus treated animals protected naïve controls (Kaufmann, 2017). 
In addition, the side chain hypothesis proposed by Paul Ehrling stipulated cells had 
distinct receptors on the surface, which in reaction with specific targets, were 
amplified and released into the blood. These studies laid the foundations to the  
identification and characterisation of antibodies (Winau et al., 2004).  
Antibodies were produced for a number of years in in a range of host 
organisms, but mainly small rodents and rabbits but their polyclonal nature limited 
their potential. In 1975 lymphocytes from immunised animals were fused with a 
myeloma cell line, generating a population of immortal monoclonal antibody 
secreting cells. This ability to generate and subsequently purify a single defined 
antibody species, revolutionised both science and clinical therapeutics (Kohler and 
Milstein, 1975).  
The basic building block of both CAR T cells and BiTEs is the antigen 
recognition domain, which is typically composed of an antibody derived scFv but 
can use naturally occurring ligands (Shaffer et al., 2011).  
Existing antibodies against ROR1 have been generated through murine and 
rabbit immunisation programmes as discussed in section 1.5. We therefore 
undertook a rat immunisation programme, to increase the likelihood of targeting 
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4.1.2 Rat Immunisation 
 
Aldevron GmBH undertook an immunisation programme in 3 Wistar rats 
using their proprietary technology. This involved initial immunisation with a plasmid 
encoding full length extracellular ROR1, followed by 2 rounds of repeated DNA 
immunisation using gene gun technology. Genetic immunisation involves delivery of 
DNA coated on gold micro particles directly into tissue where it is processed into 
protein, taken up by antigen presenting cells, primarily dendritic cells and 
presented via MHC, leading to potent cell mediated and humoral immunity (Wolff 
et al., 1990, Tang et al., 1992, Gurunathan et al., 2000). 
 
 
FIGURE 4.1 SEROCONVERSION ASSESSMENT IN IMMUNISED RATS.  
The MEC1 cell line is derived from a CLL patient undergoing prolymphocytic transformation but does 
not constitutively express ROR1 (data not shown). MEC1-GFP cells lines were transduced to express 
GFP (MEC1-GFP) or full length extracellular ROR1 fused to GFP (MEC1-ROR1). Cells were incubated 
with pre and post immunisation serum from vaccinated rats followed by incubation with an anti-Rat 
Fc directed secondary antibody.   
 
 
Baseline and post-immunisation serum from the three animals was assessed 
for polyclonal anti-ROR1 antibodies, with rat 1 and 3 demonstrating production of 
ROR1-specific antibodies (Figure 4.1). Aldevron GmBH subsequently isolated lymph 
nodes from these animals and resulting lymphocytes were fused with a myeloma 
cell line resulting in 38 oligoclonal hybridoma clones. 
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These were transferred to University College London and expanded in 
culture. Resulting supernatant was screened for antibodies with the ability to 
differentially bind to a ROR1 positive and negative cell line. Of the 38 clones tested, 
antibodies against ROR1 were detected in 36, with only clones N and Beta showing 





FIGURE 4.2 SCREENING OLIGOCLONAL CLONES. 
Non-transduced SupT1 cells (SupT1-NT: GFP negative and ROR1 negative) and SupT1 cells 
transduced to express ROR1 and GFP (SupT1-ROR1) were mixed in a 1:1 ratio and the two 
populations differentiated based on GFP expression.  
Supernatant from oligoclonal hybridomas was incubated with the mixture of SupT1-NT and SupT1-
ROR1 cells, followed by incubation with an anti-Rat Fc directed secondary. A positive shift in the GFP 
positive population representing the SupT1-ROR1 cells, combined with a lack of a shift in the GFP 
negative population, demonstrated the presence of a specific anti-ROR1 antibodies.  
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4.1.3 Derivation of Rat anti-ROR1 antibody sequences  
 
 
4.1.3.1 Monoclonal hybridoma screening 
 
 
The 36 oligoclonal hybridomas containing specific anti-ROR1 antibodies 
were single cell sorted, to yield monoclonal populations. This was essential given 
that the parental clones may have included multiple clones with differing specificity 
and therefore AA sequence. The resulting monoclonal hybridoma supernatants 
were re-screened with ROR1 positive and negative cell lines to determine whether 
they contained an antibody of interest (Figure 4.3).   
Of the multiple single cell clones produced, only 27 of the 36 oligoclonal 
populations yielded productive monoclonal populations with ROR1 antibodies. The 
root cause for failure in the remaining 9 clones is unclear as they were subjected to 
the same methods and processes as the clones which were successfully single cell 
cloned.   
 
 
 FIGURE 4.3 SCREENING SINGLE CELL CLONES FOR PRESENCE OF ANTI-ROR1 ANTIBODIES 
Representative figure: Supernatant from single cell sorted monoclonal cell populations was assessed 
for the presence of anti-ROR1 antibodies. Two of 4 subclones (1&2) demonstrated presence of anti-
ROR1 antibody producing cells and were taken forward to the 5’RACE. Non-binding clones were 
discarded from further analysis.   
 
 
4.1.3.2 5’ Rapid Amplification of cDNA Ends (5’RACE) 
 
To elucidate the DNA sequence we employed 5’RACE, as depicted in Figure 
4.4. This required identification of the light chain (kappa or lambda) and heavy 
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chain subclass of the parental antibody, which was undertaken using a rat isotyping 
ELISA kit. This enabled us to select appropriate primers to amplify the variable 
region of the antibodies using primers targeting sequences within the constant 
region of the light or heavy chain. The majority were kappa restricted and most 
frequently utilised the IgG2a and IgG2b heavy chain subclass.  
PCR products generated by the 5’RACE were inserted into subcloning 
vectors and subjected to Sanger sequencing. This was undertaken independently 
for the light chain and heavy chain for each clone with multiple light chain and 
heavy chain sequences analysed per clone to identify a consensus sequence. These 
were compared and assessed within the immunogenetic information system V-
Quest (IMGT/V-Quest) database of rat germline sequences to identify productive 
antibody sequences (Figure 4.5) (Brochet et al., 2008).  
 
 
FIGURE 4.4 SCHEMATIC OF 5’RACE 
Following mRNA isolation, a high fidelity reverse transcriptase is used to generate a cDNA product. 
This is subject to a poly-C reaction at the 3’ end using terminal transferase, with the resulting poly C 
tail the backbone for an anchor primer ending in GGG. The other primer is specific for the light chain 
constant domain or IgG subclass constant domain as identified by isotyping. A nested PCR reaction is 
then undertaken to amplify the region of interest before being sent for sequencing either directly or 
via Topo subcloning vectors.  
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We initially transferred the amplified DNA into Topo subcloning vectors for 
expansion and sequencing but given the number of clones we were working with, 
this was a time and resource intensive. PCR products based on the initial primers 
could not be sent for direct sequencing as the resulting fragments were too short 
and would not include the entire length of the variable regions. To improve 
throughput we designed novel light and heavy chain specific primers, which bound 
further downstream within the constant domain to allow for non-subclass specific 
primer usage. These new primers were able to amplify cDNA as well as the original 
primers and when the corresponding DNA was sent for sequencing, it yielded the 
full variable domain of the antibody.  
 
 
FIGURE 4.5 REPRESENTATIVE IMGT V-QUEST OUTPUT 
In this example the sequence for light chain clone J, generated through the 5’RACE was inputted into 
the V-Quest database, revealing a productive IgG kappa rearranged sequence with corresponding 
homology to a germline rat V gene (highlighted in orange). This was undertaken for all sequencing 
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4.1.3.3 Antibody and scFv production and testing 
 
To assess whether the sequences identified led to productive anti-ROR1 
antibodies, the variable regions of the rat light and heavy chains were cloned in 
frame with a human kappa constant and human IgG1 constant antibody production 
plasmids respectively. Co-transfection of both plasmids into HEK293T cells resulted 
in antibody production that was secreted into the supernatant. Supernatant was 
tested against ROR1 positive and negative cells lines as previously described.  
 
 
TABLE 4.1 SUMMARY OF THE 5’RACE TO IDENTIFY NOVEL ANTI-ROR1 ANTIBODIES 
The identity of the solved clones are shown in the first column, along with their ability to bind as 
antibody or scFv. Clones with identical amino acid composition are highlighted, as well as those 
which IMGT revealed to have productive sequences but failed to bind to ROR1. The final column 
identifies clones which were single cell sorted and were shown to have anti-ROR1 antibodies but in 
which the 5’RACE procedure failed (number of subclones solved per oligoclonal clone) 
 
Over 150 single cell hybridoma clones were subjected to 5’RACE, of which 
61 generated PCR bands that we were able to send for sequencing. Of these, 13/27 
(48%) of oligoclonal clones were found to have unique anti-ROR1 antibodies based 
on composition of the complementary determining regions (CDR) of the variable 
domains, with 4 clones having identical sequences to others. A further 6 clones had 
productive sequences as identified by IMGT, but the resulting antibodies did not 
demonstrate binding to ROR1 and 4 clones failed multiple attempts at 5’RACE 
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despite being single cell sorted and having sufficient levels of cDNA (Table 4.1 and 
4.2).  
Analysis of the AA sequences showed some to vary by only a few amino 
acids, such as Clone Z and J. To ensure fidelity of the process, the 5’RACE was 
repeated to ensure there was no error in the sequencing reads or in the PCR 
reaction and this confirmed unique sequence identity. As alteration of one amino 
acid can have dramatic consequences on antibody binding characteristics, they 
were included for further downstream analysis.  
We next generated scFv constructs using overlapping fusion PCR. The 
sequences were cloned in a heavy chain – linker – light chain format, utilising the 
GGGGSGGGGSGGGGS motif as linker between heavy and light chain. This was 
cloned in frame with a signal peptide and murine IgG constant domain allowing for 
a secreted scFv protein that allowed us to assess binding.  
10 of the 13 antibodies bound in scFv format, as assessed by flow 
cytometry. Modification of the scFv format from heavy-linker-light to light-linker-
heavy did not restore binding (data not shown) suggesting conversion from 
antibody to scFv format abrogated the ability to bind ROR1. Other strategies to try 
and overcome this limitation include substitution of the linker from (GGGGS)3 to an 
alternative such the Whitlow linker, which is utilised in the 4A5 scFv format 











TABLE 4.2 AMINO ACID SEQUENCE OF 13 NOVEL ANTI-ROR1 ANTIBODIES 
The final consensus amino acid sequences of the heavy and light chains of the 13 novel anti-ROR1 antibodies are provided and we have also included the sequences for the 
R12 and 4A5 antibodies. Complementary determining regions (CDR) and framework regions (FR) were identified as per IMGT. 
Heavy Chain FR1 CDR1 FR2 CDR2 FR3 CDR3 FR4
                          
Lambda EVQLQESGPGLVKPAQSLSLTCSVT GYSITNMYR WNWIRKFPGNKLEWMGY INTAGST DYSPSLRGRVSITGDTSKNQFFLHLTSVTTEDTATYYC AGFITNPFDF WGQGVMVTVSS
Omega EVQVVESGGGLVQPGRSLKLSCVPS GFTFNNYW MTWIRQAPGKAPEWVAS ISNTGGST FYPDSVRGRFSISRDNTKGTLYLHMTSLRSEDTATYYC IRNMDA WGQGTSVTVSS
Z GKLVESGGGLLKPGGSLKLSCVAS GFTFDKYW MHWVRQAPGKGLEWIAE IEYDGTET NYAPSIKDRFTISRDNAKNTLYLQMSNVRSEDAATYFC TTEEMYTTDYYYGFAY WGQGTLVTVSS
J DVKLVESGGGLLKPGGSLKLSCVAS GFSFSKYW MHWVRQAPGQGLEWIAE IEYDGTET NYAPSIKDRFTISRDNAKNTLYLQMSNVRFEDAATYFC TTEEMHTTDYYYGFAY WGQGTLVTVSS
F EVQLVESGGGLVQPGRSLKLSCAAS GFIFSEHN MAWVRQAPKKGLEWVAT ISDDGRNT YYRDSMRGRFTISRENARSTLYLQLDSLRSEDTATYYC ASHRYNLFDS WGQGVMVTVSS
B DVQLEESGGGLVRPGRSLKLSCADS GVNFSNRG MAWVRQAPTKGLEWVAT ISYDGRII YYRDSVKGRFSISRENAKSTLYLQMDSLRSEDTATYYC ARHPIAADWYFDF WGPGTMVTVSS
A QVQLQQSGTELVKPASSVRISCKAS GYTLTTNY MHWIRQQPGNGLEWIGW IYPGNGNT KFNHKFDGRTTLTADKSSSIVYMQLSSLTSEDSAVYFC ARSDFDY WGQGVMXTVSS
I EVQLVESGGGSVQPGRSLKLSCAAS GFTFSDYN MAWVRQAPKKGPEWVAT ITYDVHNA YYRDSVKGRFTISRDDAKSTLYLQMDSLRSEDTATYFC ARPGAY WGQGTLVTVSS
O QVRLLQSGAALVKPGASVKMSCKAS GYTFTDYW MSWVKQSHGKSLEWIGE IYPNSGAT NFNEKFKDKATLTVDRSTSTAYMELSRLTSEDSAIYYC ARGFPNNYLSWFAY WGQGTLVTVSS
Pi EVQLVESGGGLVQPGRSLTLSCSAS GFTFRDYN MAWVRQAPRKGLEWVAT ISFDDYNT YYRDSVKGRFTISRDDAKSTLYLQMDSLRSEDTATYYC ARPGTY WGQGTLVTVSS
Mu QVQLQQSGAELVKPGSSVRISCKAS GYTITSYD MHWIKQQPGNGLEGIGW IHPGNGKI KYNQKFNGKATLTVDKSSSTAYMQLSSLTSEDSAVYFC ARGTTRVFPWFAY WGQGTLVTVSS
V EVQLVESGGGLVQPGRSLKLSCAAS GFSFSNYG MHWIRQAPTKGLEWVAS ISPTGGNT YYRDSVKGRFTISRDNTKSTLYLQMDSLRSEDTATYYC ATDDLYYSGPFAY WGQGTLVTVSS
R QIQLVQSGPELKKPGESVKISCKAS GYTFTNYG MYWVKQAPGQGLQYMGW INTETGKP TYADDFKGRFVFFLETSASTAYLQINNLKNEDMATYFC AREVKHGLFHWFAY WGQGTLVTVSS
R12 EQLVESGGRLVTPGGSLTLSCKAS GFDFSAYY MSWVRQAPGKGLEWIAT IYPSSGKT YYATWVNGRFTISSDNAQNTVDLQMNSLTAADRATYFCARDSYADDGALFNI WGPGTLVTISS
4A5 EVKLVESGGGLVKPGGSLKLSCAAS GFTFSSYA MSWVRQIPEKRLEWVAS ISRGGTT YYPDSVKGRFTISRDNVRNILYLQMSSLRSEDTAMYYC GRYDYDGYYAMDY WGQGTSVTVSS
Light Chain FR1 CDR1 FR2 CDR2 FR3 CDR3 FR4
Lambda DVVMTQTPVSLPVSLGGQVSISCRSS QSLEHSNGDTF LHWYLQKPGQSPRLLIY RVS NRFSGVPDRFSGSGSGTDFTLKISRIEPEDLGDYYC LQSTHFPNT FGAGTKLELK
Omega DIQLTQSPSTLSASLGERVTISCRAS QSISNS LNWYQQKPDGTVKRLIY STS TLESGVPSRFSGSGSGTDFSLSISSLESEDFAMYYC LQFATYPQVT FGSGTKLEIK
Z DIVLTQSPALAVSVGQRATISCRAS QSVSISRYNF MHWYQQKPGQQPKLLIY RAS NLASGIPARFSGSGSGTDFTLTINPVQADDIATYYC QQNRESPRT FGGGTKLELK
J DIVLTQSPALAVSVGQRATISCRAS QSVSISRYDF MHWYQQKPGQQPKLLIY RAS NLASGIPARFSGSGSGTDFTLTINPVQADDIATYYC QQNRESPRT FGGGTKLELK
F DIQMTQSPSFLSASVGDRVTINCKAS QNIDRY LNWYQQKLGEAPKRLLY NTN KLQTGIPSRFSGSGSATDFTLTISSLQPEDFATYFC LQYNSLPLT FGSGTKLEIK
B DIRMTQSPASLSASLGETVTIECLTS EDIYSD LAWFQQKPGKSPQLLIY DAN SLQNGVPSRFGGCGSGTQYSLQISSLQSEDVATYFC QQYKNYPPT FGGGTKLVLK
A DIQMTQSPSSMSASLGDRVTFTCQAS QDIGNN LIWFQQKPGKSPRPLMY FAT SLANGVPSRFSGSRSGSDYSLTISSLESEDLADYHC LQYREYPLT FGSGTKLDLK
I DIQLTQSPSSMSASLGDRVSLTCQSS QGIGKY LSWYQHKPGKPPKAMIY YAT KLADGVPSRFSGSRSGSDFSLTISSLESEDIAIYYC LQFDDYPWT FGGGTKLELK
O DIVLTQSPALAVSLEQRVTIACKTS QNVDNHGISY MHWYQQKSGQEPKLLIY EGS NLAVGIPARFSGSGSGTDFTLTIDPVEADDIETYYC QQSKDDPRT FGGGTKLELK
Pi DIQLTQSPSSLSASLGDRVSLTCQSS QGIGKY LSWFQHKPGKPPKPVIN YAT NLADGVPSRFSGRRSGSDFSLTISSLESEDTAIYYC LQFDDFRWT VGGGTKLELK
Mu QFTLTQPKSVSGSLRSTITIPCERS SGDIGDNY VSWYQQHLGRPPINVIY ADD QRPSEVSDRFSGSIDSSSNSASLTITNLQMDDEADYFC QSFDSNFDIPV FGGGTKLTVL
V DIKMTQSPSFLSASVGDRVTINCKAS QNITRF LNWYQQELGEAPTLLIY NTN NLQTGIPSRFSGSGSGTDFTLTISSLQPEDVATYFC LQHGSRPRT FGGGTKLELK
R QFTLTQPKSVSGSLRSTITIPCERS SGDIGDSY VSWYQQHLGRPPINVIY ADD QRPSEVSDRFSGSIDSSSNSASLTITNLQMDDEADYFC QSYDRNVDFNTV FGGGTKVTVL
R12 ELVLTQSPSVSAALGSPAKITCTLS SAHKTDT IDWYQQLQGEAPRYLMQ  VQSDGSY TKRPGVPDRFSGSSSGADRYLIIPSVQADDEADYYC GADYIGGYV FGGGTQLTVT
4A5 DIKMTQSPSSMYASLGERVTITCKAS PDINSY LSWFQQKPGKSPKTLIY RAN RLVDGVPSRFSGGGSGQDYSLTINSLEYEDMGIYYC LQYDEFPYT FGGGTKLEMK
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4.1.4 Domain binding characterisation 
 
To characterise which of the three extracellular domains of ROR1 specific 
scFvs bound, we generated a panel of SupT1 based cell lines expressing truncated 
forms of ROR1 (Figure 4.6). Screening our scFvs against this panel demonstrated 8 
bound solely to the membrane distal immunoglobulin domain, whilst clone F was 
unique in its binding to the frizzled domain. Clone V bound only when both 
immunoglobulin and frizzled domains were present, suggesting the conformation of 
the mature protein generated the target epitope. We also assessed the binding 
profile of the previously described R12 and 4A5 scFvs generated by other groups, 
demonstrating they both bound the immunoglobulin domain. 
We further screened the original oligoclonal hybridoma supernatants 
against this panel of cell lines. Of the 36 clones with anti-ROR1 antibodies, only 2 
bound the Frizzled domain (Clones F and U), one bound the Immunoglobulin-
Frizzled domain (Clone V), whilst the remaining 33 were all directed against the 
Immunoglobulin domain.  
To better understand this bias we undertook a multi-protein alignment of 
human, murine, rabbit and rat ROR1 using deposited sequences, to assess for 
differential amino acid usage in the extracellular domains. The region with the 
highest sequence variation occurred within the immunoglobulin domain, thus 
providing an explanation of the preferential targeting of this domain. Within the 
frizzled domain there were two amino acid substitutions between human and rat 











FIGURE 4.6 SCFV DOMAIN MAPPING 
The extracellular domains of ROR1 are shown in the schematic (Ig = Immunoglobulin, Fz = Frizzled, Kr 
= Kringle). Supernatant containing scFvs fused the murine IgG2a constant domain was incubated 
with SupT1-NT (ROR1 negative) or a panel of SupT1 cell lines transduced to express various 
truncated extracellular domains. Binding was assessed with an anti-murine Fc conjugated secondary 
antibody. In addition to the 10 scFv clones we identified, we also included the R12 and 4A5 scFvs 
reported by other groups. With the exception of clone F, which binds the frizzled domain and clone 
V, which binds only the Ig-Fz protein, all other clones bound the immunoglobulin domain.  
 
 




FIGURE 4.7 INTERSPECIES ROR1 ALIGNMENT 
Human, murine, rabbit and rat ROR1 protein sequences were aligned using Uniprot web based 
software (http://www.uniprot.org/align/). The signal peptide, transmembrane and three 
extracellular domains are highlighted. Variation between species is highlighted. Uniprot accession 
numbers: Human (Q01973), Murine (Q9Z139) and Rabbit (G1U5L1). For rat ROR1 we used NCBI 




Page | 90 
 
4.1.5 Section Discussion 
 
 
Within this section of work we have demonstrated how from 38 oligoclonal 
hybridomas we arrived to 13 novel anti-ROR1 antibodies and 10 scFvs. These form 
the antigen recognition domain critical for the next phase of this project.  
At the outset of the project we were informed that the oligoclonal 
hybridomas contained a mixture of clones, with the possibility of each having 
multiple antibodies of differing specificity and therefore AA sequence. However, 
our 5’RACE analysis found this to be an incorrect assumption, with all of the 
subclones demonstrating a single antibody sequence. Had we had access to this 
information at the beginning it would have significantly reduced the amount of 
clones that were screened.  
Characterisation revealed the majority of antibodies targeted the 
membrane distal immunoglobulin domain, which is in keeping with the lower 
homology between human and rat ROR1 in this region. We identified 2 oligoclonal 
clones with anti-frizzled domain antibodies (Clone F and U) but were only able to 
solve 1 using 5’RACE, which was disappointing as an additional unique binder 
against the frizzled domain would have allowed for an interesting functional 
assessment, especially had there been substantial differences in affinity.  
We found no binders against the kringle domain, likely due to the high 
homology of this region between all species. Daneshmanesh et al. have however 
developed a kringle specific anti-ROR1 antibody, although their strategy involved 
using domain specific vaccination compared to use of full length protein that we 
undertook (Daneshmanesh et al., 2012). The same group also found that naturally 
occurring antibodies against ROR1 preferentially targeted the Kringle domain in CLL 
patient samples, and although these were able to mediate some in vitro 
cytotoxicity, they were not associated with clinically relevant side effects (Hojjat-
Farsangi et al., 2015).  
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Mice are by far the commonest laboratory animal used to generate 
therapeutic antibodies, although rats and rabbits can also be used. As others groups 
utilised murine and rabbit based immunisation programmes we utilised rats in an 
attempt to generate novel antibodies. Indeed despite strong similarities across 
species, there exists unique amino acid differences between human and rat ROR1 
that are not seen in murine or rabbit ROR1, increasing the likelihood of novel 
antibody identification.  
The method I utilised to identify antibodies, based on screening hybridomas 
and solving antibody sequences by 5’RACE is a well-established pathway in 
antibody discovery. We were able to solve 47% (17/36) of the clones of which 4 
were identical antibody sequences. Although 19 clones remain unsolved, on 
balance it was felt progressing the 10 scFvs we had already identified to the next 
stage of work took priority over continuing to solve hybridoma clones.  
An alternative strategy to solve these would be the use of next generation 
sequencing to generate consensus light and heavy chain variable sequences 
without the need for manual 5’RACE. This would, if optimised, allow for a high 
throughout and mass resolution of the antibody repertoire and has been utilised by 
other groups (Fischer, 2011).  
The use of phage display technology to isolate and characterise novel 
antibodies is standard practice. Bacteriophages are viruses which infect bacteria 
and are composed of an extracellular protein core that can be engineered to 
express Fab or scFv molecules. Phages expressing the antibody fragment of interest 
could be selected for through serial panning rounds to lead to a final cohort of 
antibodies which are subsequently sequenced (McCafferty et al., 1990). Phage 
display libraries can be generated from naïve or immunised cell populations 
including with a human repertoire to abrogate the need for downstream 
humanisation of the sequence. Libraries can include huge numbers of potential 
binders, with Iontas, a commercial antibody discovery company having a 
humanised library with 40 billion distinct binders (Iontas, 2017). 
For this process, the variable light and heavy chains are cloned into the 
extracellular protein coat of the bacteriophage, which subsequently expresses the 
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scFv on its surface. The next stage involves screening the phages for specific binding 
to the target antigen; unbound phages are washed off, whilst phages which bind 
are enriched. This process is repeated to yield a selection that is highly specific for 
the antigen in question and from which the sequence can be identified in a high 
throughput automated manner. An added advantage of this process is that the 
phage display antibodies in a scFv format, which is the format required for CAR and 
BITE production. Screening scFvs at the outset, rather than antibodies requiring 
conversion to scFv would avoid the loss of binding demonstrated with 3 of the 
isolated clones. This process also leads to access to antibodies with a much broader 
range of affinities, up to and including into the femtomolar range, unlike that 
obtained by traditional immunisation programmes. In keeping with this all of the 
antibodies we isolated had affinities in the nM range as assessed by Biacore analysis 
(KD: 1.5-5.5nM).  
 
 
TABLE 4.3 AFFINITY CONSTANTS FOR 10 OF THE IDENTIFIED ROR1 ANTIBODIES.  
Antibodies for above clones were generated with a human Fc stalk and affinity assessed by Biacore 
SPR analysis (Data generated by Solange Paredes-Mosscosso).  
 
Despite being unable to solve all of the hybridomas clones, we generated 
sufficient number of scFvs to allow us to transition onto the next phase of the 
project and begin construction of ROR1 CARs and BiTEs.  
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 ROR1 Chimeric Antigen Receptor T Cells 
 
 
4.2.1 Introduction  
 
 
The basic structure of a chimeric antigen receptor was depicted in Figure 
1.2, with the scFvs identified forming the membrane distal antigen recognition 
domain. We first needed to formalise the viral vector and intracellular signalling 
domains to utilise for our functional assessment. Given the success of the University 
of Pennsylvania group with lentiviral vectors using a 2nd generation CAR with 41BB 
as the co-stimulatory domain along with CD3, we sought to use the same 
configuration as the starting point for our CAR studies (Porter et al., 2011, Kalos et 
al., 2011).  
The overall aim of this section of work was to narrow the 10 scFvs identified 
above to a final lead scFv as a CAR T cell clinical therapeutic.  
 




The scFvs along with their native signal peptide were cloned in frame to a 3rd 
generation lentiviral vector backbone, downstream of a phosphoglycerate kinase 
(PGK) promoter. T cells were transduced using lentiviral vectors to generate ROR1 
CAR T cells with a CD8 spacer domain and 41BB and CD3signalling domains 
(Figure 4.8A).  
Expression of CARs on the T cell surface was assessed by binding to 
recombinant ROR1, for which we utilised in house generated full length ROR1 
protein fused to a murine IgG stalk (Figure 4.8B). Function of the ROR1 CAR T cells 
was typically assessed in a flow cytometry based cytotoxicity assay in which T cells 
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and target cells were co-cultured for 24 hours before assessment of target cell 
survival.  
We utilised the ROR1 negative T-lymphoblastic leukaemia, SupT1 cell line 
(Smith et al., 1984) and SupT1 cells transduced to express ROR1 as negative and 
positive controls (SupT1-NT and SupT1-ROR1 respectively) (Figures 4.8C-D). We also 
included ROR1 CAR T cells utilising the previously published R12 scFv sequence as a 
comparator (Berger et al., 2015, Hudecek et al., 2013).  Constructs demonstrated 
minimal off target cytotoxicity against SupT1-NT cells, whilst all constructs 
generated marked cytotoxicity of SupT1-ROR1 cells, without clear superiority for 
one scFv in particular (Figure 4.8E&F).  
SupT1-ROR1 cells express ROR1 at high levels due to expression being 
mediated through retroviral transduction (Figure 4.8C). We therefore assessed 
cytotoxicity against cells which constitutively expresses ROR1 at more clinically 
relevant levels and chose the EBV transformed SKW6.4, B lymphoblastoid cell line 
(Saiki and Ralph, 1983)(Figure 4.8G). For this work we also included a CD19 CAR as 
comparator, utilising the fmc63 scFv as per the University of Pennsylvania group 
(Khalil et al., 2016). 
Unlike the cytotoxicity with SupT1-ROR1 cells, in which the normalised 
survival range was 1.4-20.2% between scFvs, in the assay with SKW6.4 cells, there 
was much more variable cytotoxicity, despite the same effector to target ratio 
being used, with normalised survival from 8.4% to 108.2% (Figure 4.8H). Despite 
the minimal cytotoxicity seen with some CAR T cell constructs, we knew the CAR T 
cells were active as the same transgenic T cells were able to kill the SupT1-ROR1 
population.  
Inter-clone variation for some of the constructs, namely clones Omega, A 
and B, was likely due to using different donors between experiments with 
subsequent variation in donor T cell fitness, CD8:CD4 ratio and transduction 
efficiency. Despite this, there was a clear superiority demonstrated for CD19, with 
mean target cell survival of 2.17% (n=2 donors) compared to median survival across 
all ROR1 scFv clones of 85.1% (Range 8.4-108.2%). The one exception was ROR1 
CAR T cells expressing the clone F scFv, with mean survival of 8.7% (n=6 donors).  
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FIGURE 4.8 INITIAL ASSESSMENT OF ROR1 CAR T CELLS EXPRESSING SCFVS IDENTIFIED THROUGH 
HYBRIDOMA SCREENING 
A. Schematic representation of CAR structure:  The signal peptide (SigP) and scFv sequence 
comprising VH-Linker (L)-VL sequences were cloned in frame with a CD8 spacer, transmembrane 
domain (TM) and 41BB and CD3 intracellular signalling elements.  B. Transduction was assessed by 
incubating ROR1 CAR T cells with ROR1 protein fused to a murine Fc stalk (ROR1mFc) followed by 
staining with anti-murine Fc secondary conjugated to AlexaFluor647. C. SupT1-NT and SupT1-ROR1 
cells were stained with isotype control or anti-ROR1 antibody (Clone 2A2) to demonstrate ROR1 
surface expression. D. Representative flow cytometry plots demonstrating cytotoxicity assay: Target 
cells (GFP+CD3-) and T cells (GFP-CD3+) were co-cultured for 24 hours and viable cells assessed 
compared to un-transduced (UT) T cells.  E&F. Cumulative cytotoxicity of our 10 novel and the 
previously published R12 scFv based ROR1 CAR T cell constructs against SupT1-NT and SupT1-ROR1 
cell lines at an effector to target ratio of 2:1 following 24 hours of co-culture (n=number of individual 
donors assessed). G. ROR1 expression on the SKW6.4 cell line. H. Cumulative cytotoxicity against 
SKW6.4 cell line with inclusion of a CD19 CAR T cell control arm comprising the fmc63 scFv. 
 
 
Page | 96 
 
4.2.2.2 CD107a Degranulation  
 
As part of the initial assessment we also analysed CD107a degranulation of 
CAR T cells when cultured with SupT1-NT, SupT1-ROR1 and SKW6.4 cell lines. 
CD107a or lysosomal associated membrane protein 1 (LAMP1) is a component of 
the lysosomal membrane which form intracellular vesicles. Upon T and NK cell 
activation these cytotoxic vesicles, which contain granzyme and perforins, 
translocate to the cell surface, allowing CD107a expression to be detected.  
All CAR T cell constructs led to CD107a degranulation in response to SupT1-
ROR1 cell lines, with mean CD107a expression in ROR1 CAR T cells of 31.4% 
compared with 1.33% un-transduced T cells. However clone F showed higher 
CD107a degranulation in this context at 54.3% compared to the next ROR1 CAR 
construct at 29.5% (clone I). 
This was further highlighted at lower antigen density with SKW6.4 cells, as 
only clone F CAR T cells resulted in marked CD107a degranulation at 4 hours; 47.2% 
of T cells were CD107a positive, compared with an average of 14.2% for the other 
clones and 4.08% for un-transduced T cells (Figure 4.9). The corresponding 
cytotoxicity assessment at 24 hours using the same T cells plated at the same time, 
correlated with CD107a expression for all cell lines. 
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FIGURE 4.9 CD107A DEGRANULATION ASSAY  
SupT1-NT, SupT1-ROR1 and SKW6.4 cells were co-cultured with Un-transduced (UT) or ROR1 CAR T cells expressing clone F, Pi, Mu, I, O or V scFvs (representative for other 
immunoglobulin constructs). Co-cultures were undertaken at a 2:1 effector to target ratio for 4 hours and resulting T cell degranulation assessed via detection of surface 
CD107a by flow cytometry. Corresponding cytotoxicity at 24 hours for the identical cultures represented as histograms under each scFv construct. Although significant 
CD107a degranulation was seen with all constructs against SupT1-ROR1, only clone F led to an increase against SKW6.4 cells.  
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4.2.3 Extracellular Spacer Optimisation 
 
From this initial analysis, clone F emerged as the lead scFv, however as it 
was the only scFv that bound to the frizzled domain we investigated whether 
modification of the extracellular spacer, which modulates the distance between 
CAR T cell and target cell, would enhance effector function.  
  We selected a panel of extracellular spacers that generated a range of inter-
cellular distances between target and effector T cells. The largest was the HCH2CH3 
spacer comprising the hinge and constant region of the human IgG1 heavy chain 
(239 AA). The next was the CD8 stalk which was used in our initial assessment (81 
AA). The third was solely the hinge region of human IgG1 (19 AA) and the final 
spacer was a short 15 AA sequence that comprised the (GGGGS)3 linker motif 
(Figure 4.10A).  
To allow for assessment of spacer function in relation to ROR1 binding 
domain we selected clone F as the frizzled binder and selected Clone A to be 
representative for immunoglobulin domain binding scFvs (Figure 4.10B). CAR T cells 
with these 4 spacer iterations were generated for each clone A and F and assessed 
in a cytotoxicity assay against SupT1-ROR1 and SKW6.4 cells with corresponding 
analysis of CD107a degranulation (Figure 4.10C). The spacer made a significant 
difference in terms of cytotoxicity and T cell degranulation. Overall, the hinge 
spacer provided optimal cytotoxicity for both clone A and F, against SupT1-ROR1 
(<1% survival) and SKW6.4 (3.1% survival) cell lines.  
We noted a reciprocal relationship between the scFv binding domain, spacer 
length and cytotoxicity. For clone A, the longer spacers, both HCH2CH3 and CD8 
resulted in lower cytotoxicity compared to the shorter Hinge and Linker spacers 
(80% and 45.8% vs 3.6% and 6.7% respectively for SKW6.4). In comparison, 
cytotoxicity with clone F improved with shortening the length up to the Hinge 
spacer, but further reduction resulted in a dramatic loss of function (2.5% vs 69.9% 
for Hinge vs Linker spacer).  
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The Hinge and Linker spacer differ by only 4 amino acids suggesting that the 
four extra AA modulates a critical distance for clone F and its epitope. An 
alternative is that the linker spacer does not allow accurate scFv presentation but 
this can be discounted as it allowed clone A CAR T cells to function well.  
In the context of TCR and peptide:MHC interaction the optimal distance 
excludes negative inhibitory phosphatases such as CD45 and CD148 and this may 
not occur with a suboptimal spacer length. Therefore a similar situation likely exists 
with CAR T cells such that too long a spacer increases the inter-cellular distance 
allowing these inhibitory signalling motifs to dominate the immunological synapse, 
whilst too short results in suboptimal scFv and antigen binding (Srivastava and 
Riddell, 2015).   
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FIGURE 4.10 EXTRACELLULAR SPACER OPTIMISATION 
A. Schematic of the different extracellular spacers constructed which include the HCH2CH3 domain of human IgG1 heavy chain, the CD8 extracellular stalk, the hinge 
region only of the IgG1 stalk and a short flexible linker. B.  Schematic of binding domains for clone A (Immunoglobulin) and clone F (Frizzled). C. CAR T cells expressing clone 
A or F scFvs with all of the spacer domain configurations were generated and co-cultured with SupT1-ROR1 and SKW6.4 target cells. Cytotoxicity and CD107a T cell 
degranulation was assessed at 24 and 4 hours respectively. 
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To confirm which CAR structure to take forward, we repeated this 
experiment with the leading spacers for each scFv. For clone A we selected the 
hinge and linker spacer, whilst for clone F, we used the CD8 and hinge spacer. We 
focused on the SKW6.4 cell line as this represented a more challenging target and 
used lower effector to target ratios to highlight functional differences between the 
spacers. This confirmed that the hinge spacer afforded significant benefit for clone 
A over the linker spacer and for clone F over the CD8 spacer (Figure 4.11).   
 
 
FIGURE 4.11 HINGE SPACERS PROVIDE SUPERIOR CYTOTOXICITY AGAINST SKW6.4 CELLS 
CAR T cells expressing the clone A scFv with a hinge spacer or linker spacer or clone F scFv with the 
CD8 or hinge spacer were co-cultured with SKW6.4 cells at varying effector to target ratios for 24 
hours in a standard cytotoxicity assay. There was significantly higher cytotoxicity with the hinge 
constructs irrespective of scFv. Clone A hinge vs linker (p=0.004 and 0.002 at 1:4 and 1:2 ratio 
respectively) and clone F hinge vs CD8 spacer (p=0.01 and p=0.00004 at 1:4 and 1:2 ratio 
respectively). No significant difference was seen between clones A & F hinge constructs at the 1:1 
ratio. Statistical analysis: unpaired t-test.  
 
 
4.2.4 Assessment with Hinge Spacer 
 
Having demonstrated the hinge spacer provided optimal cytotoxicity for 
both Immunoglobulin and Frizzled binding scFvs, we substituted the CD8 spacer 
for the hinge spacer for all 10 scFvs in the CAR format. Repeat assessment with the 
hinge spacer demonstrated improved cytotoxicity compared with CD8 spacer 
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FIGURE 4.12 CYTOTOXICITY WITH HINGE SPACER DOMAIN.  
ROR1 CAR T cells were generated for all 10 scFvs we had identified as well as the previously 
published R12 scFv but in which the CD8 spacer has been replaced by the hinge spacer. CAR T cells 
were co-cultured with A. SupT1-NT and SupT1-ROR1 cells in a 2:1 effector to target ratio. At 24 
hours no off target cytotoxicity was seen against SupT1-NT cell line compared to almost complete 
eradication of SupT1-ROR1 cells, with the exception of clone V. B. Cytotoxicity against SKW6.4 cells 
at a 1:1 and 1:2 effector to target ratio showed more variable cytotoxicity with clones A, F and Mu 
demonstrating the highest levels of cytotoxicity.  
 
As before the SupT1-ROR1 cell line was highly sensitive to CAR T cell 
mediated killing with almost complete eradication of target cells. The one exception 
was with clone V which showed incomplete killing of SupT1-ROR1 cells, suggesting 
the unique epitope it binds to limits cytotoxicity in this format. It is possible that 
alternate spacers may improve function of clone V CAR T cells, although this was 
not assessed (Figure 4.12A).  
When we assessed CAR T cells with a hinge spacer against the SKW6.4 cells, we 
saw improved killing compared to the corresponding constructs with a CD8 
spacer. Clones A, F and Mu provided the highest levels of cytotoxicity (at 1:1 
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effector to target ratio normalised survival of 3.14%, 4.8% and 9.85% respectively) 
(Figure 4.12B). 
 
In view of this, repeat assessment was undertaken using T cells comprising 
these scFvs against SKW6.4 cells (Figure 4.13A) and also primary CLL cells (Figure 
4.13B). Cytotoxicity was similar and not statistically different between constructs, 
but cytokine secretion in CLL cells, was significantly enhanced with clone A and 
clone F co-cultures compared to those with clone Mu. These constructs were 
therefore selected to take forward for more detailed analysis.  
 
 
FIGURE 4.13 LEAD CONSTRUCT ASSESSMENT 
A. CAR T cells expressing the clone A, clone F and clone Mu scFvs were co-cultured with SKW6.4 cell 
line in a 1:1 effector to target ratio and cytotoxicity, IL-2 and IFN cytokine secretion assessed at 24 
hours. B. Healthy donor T cells were transduced to generate clone A, F and Mu CAR T cells and 
cultured against primary CLL cells. Flow cytometry plots demonstrate ROR1 expression on CLL cells. 
Cytotoxicity at 24 hours at 2:1 effector to target ratio demonstrates significant cytotoxicity with all 
constructs compared to un-transduced T cells. IL-2 and IFN cytokine secretion at 24 hours was also 
assessed. Statistical analysis: One way ANOVA with Mu CAR T cells as control arm comparator. 
Figure representative of 2 independent experiments.   
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4.2.5 CAR construct optimisation  
 
When using shorter spacer sequences, such as the hinge or linker, the 
apparent transduction efficiency (TE) as determined by binding to ROR1mFc was 
consistently lower than with longer spacers (Figure 4.14A). For clone A, the CD8 
spacer routinely gave apparent transduction efficiencies in the region of 70-80%, 
but this dropped to 10-20% with the linker spacer. We hypothesised this was an 
artefactual due to steric hindrance and inefficient binding of ROR1mFc to the scFv  
when located more membrane proximally in a CAR format, as opposed to actually 
representing true TE.  
To better define this we transferred the CAR sequences into a bicistronic 
construct which included the blue fluorescent protein (BFP) gene separated by the 
foot and mouth disease virus 2A peptide (FMD2A). The former acted as an 
independent and inherent transduction marker, whilst the latter is a self-cleaving 
small peptide allowing equimolar expression of both transgenes from a single 
construct (Figure 4.14B). Transduction efficiencies were comparable with these 
constructs when assessing BFP expression but shorter spacers showed significantly 
lower ROR1mFc binding (Figure 4.14C) confirming our earlier hypothesis.  
Accurate assessment of TE provides critical information with regards to the 
fidelity of vector production, T cell transduction, functional readouts and 
subsequent data interpretation. To overcome this limitation, we assessed whether 
an anti-rat Fab’ specific antibody directed against the framework regions of the 
clone A and F scFv would provide an accurate measure of CAR expression. However, 
we were only able to detect expression of the clone F scFv but not clone A on the 
surface of transduced T cells, thereby limiting the utility of this approach (Figure 
4.14D).  
In parallel, we also assessed whether CAR expression could be enhanced by 
substitution of the parental signal peptide from the rat hybridoma library to the 
human albumin or IL-2 signal peptides. We found that for a given level of 
transduction as measured by BFP expression the signal peptide had no bearing on 
Page | 105 
 
CAR expression. This provided valuable information with respect to the design of 
our subsequent lentiviral vectors. 
 
 
FIGURE 4.14 CAR DETECTION AND SIGNAL PEPTIDE OPTIMISATION  
A. Flow cytometry plots demonstrating lower levels of ROR1eFc expression with linker spacer 
compared to CD8 spacer despite using identically synthesises viral vectors, representative of 
multiple repeats. B. Schematic of a bicistronic plasmid in which the CAR is separated from the BFP 
open reading frame by a FMD2A skipping element.  C. CAR T cells were generated for clones A & F 
with the CD8, hinge and linker spacer, all of which included the BFP marker gene. Apparent 
transduction, as measured by ROR1mFc binding was lower with shorter spacer domains despite 
equivalent expression of BFP. D. Assessment with anti-Rat Fab directed antibody to detect CAR 
expression compared with ROR1mFc binding demonstrated ability to detect clone F but not clone A 
scFv E. Assessment of the parental rat derived antibody signal peptide with the albumin or IL-2 signal 
peptides showing identical levels of expression irrespective of signal peptide.  
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FIGURE 4.15 NORMALISED CO-CULTURE 
A. Schematic of optimised CAR transgene used for functional assessment. The CAR sequence 
comprising scFv, spacer domain and intracellular signalling domain lies in frame with the human 
albumin signal peptide which is within a bicistronic construct separated by the FMD2A peptide 
allowing expression of CAR and mCherry in a 1:1 ratio. B. Example of normalisation of CAR 
populations: CAR T cells for Clone A and F were generated and transduction efficiency assessed by 
mCherry expression. Post transduction there was a difference in transduced T cells within the bulk 
population (57.5 vs 40.4%).  Un-transduced T cells were added back resulting in more comparable 
populations (46.8 vs 42.9%) C. Normalised co-culture against SKW6.4 cells demonstrates significant 
cytotoxicity compared with mCherry alone cells for SupT1-ROR1 and SKW6.4 cell lines with 
corresponding IFN secretion. Statistical Analysis: One way ANOVA with GD2 CAR T cells as the 
control group.  
 
 
We therefore generated a bicistronic construct in which the CAR and 
fluorescent protein mCherry (Shaner et al., 2004), were separated by a FMD2A 
peptide. All constructs utilised the human albumin signal peptide due to ease of 
cloning and restriction site usage. This also removed the rat derived signal peptide, 
limiting immunogenicity. Inclusion of mCherry allowed for a simple flow cytometry 
based method to delineate transduction efficiency without affecting T cell function. 
It also allowed for normalisation of different CAR populations to enable a more 
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meaningful comparisons between different constructs, by decreasing bias 
introduced by variation in transduction efficiencies. We also incorporated the 
previously published anti-disialoganglioside (GD2) scFv (Pule et al., 2008) into this 
backbone to act as a more suitable and representative negative control as opposed 
to un-transduced T cells. GD2 is expressed on a range of tumours with 
neuroectodermal origin and GD2 CAR T cells are being developed for 
neuroblastoma (Pule et al., 2008) 
 
4.2.6 Jeko1 Model  
 
 
We next assessed the potential of clone A and F CAR T cells against the 
Jeko1 cell line, which was originally derived from a patient with mantle cell 
lymphoma (Jeon et al., 1998). This cell line expresses ROR1 at higher levels 
compared to SKW6.4 cells, although ROR1 expression is still lower than CD19 
(Figure 4.16A). We also included fmc63 CD19 CAR T cells within this comparison to 
provide an insight into functional differences of targeting these common 
haematological antigens. Our control was CAR T cells expressing a GD2 specific scFv. 
In a standard co-culture assay cytotoxicity was seen with CD19 fmc63 as well as 
ROR1 clone A and clone F CAR T cells with similar IFN secretion. However IL-2 
secretion was significantly enhanced with CD19 CAR T cell co-cultures above that 
for the comparator ROR1 CAR cultures (Mean IL-2 10807pg/ml for CD19 vs 1532 
and 2812 for clones A and F respectively, p<0.001) .  
We next undertook a murine model based on the published work of the 
Riddell group (Hudecek et al., 2013). Mice were injected with firefly luciferase 
transduced Jeko1 cells and allowed to establish before treatment with CAR T-cells. 
Control T cells expressed an anti-GD2 scFv based CAR as a negative control. There 
was a clear reduction in the tumour burden in mice treated with Clone A and F CAR 
T cells, although disease was still present at Day 21. In comparison the CD19 CAR 
treated animals were virtually tumour free as assessed by bioluminescence imaging 
at the same time point. We noted a spontaneous decrease in bioluminescence 
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signal from day 17 onwards in the control animals and this is in keeping with 




FIGURE 4.16 IN VITRO AND IN VIVO JEKO1 MODEL WITH ROR1 AND CD19 CAR T CELLS 
A. Comparison of CD19 and ROR1 expression in SKW6.4 and Jeko1 cell lines. B. Co-culture of Jeko1 
cells with CAR T cells expressing the CD19fmc63, Clone A and Clone F scFv at 2:1 effector to target 
ratio, resulted in significant cytotoxicity and cytokine secretion compared to T cells transduced to 
express just mCherry. Statistical analysis: One way ANOVA with GD2 as the comparator arm .C. 
Mouse model. Nod SCID gamma-/- mice were injected with 0.5x106 Jeko1 cells via tail vein 
transduced to express firefly luciferase and allowed to engraft. On Day 6 mice were treated with 
4x106 GD2, Clone A, Clone F or CD19 CAR T cells. The GD2 CAR was used as a negative control and 
CD19 CAR as a positive control. Mice treated with clone A and clone F CAR T cells demonstrated 
lower tumour burden compared to control mice at day 21, however mice treated with CD19 CAR T 
cells demonstrated almost complete loss of bioluminescence signal.  
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4.2.7 ROR1 CAR T cells demonstrate cytotoxicity against a range of solid tumour 
cell lines  
 
As discussed earlier, a wide variety of cancer subtypes express ROR1 and co-
culture of clone A or F CAR T cells with the pancreatic adenocarcinoma PANC-1 cell 
line demonstrated T cell activation as evidenced by clustering and expansion. This 
was not seen with CD19 CAR T or un-transduced T cells under the same conditions 
(Figure 4.17).  
We therefore assessed whether they could target a panel of solid tumour 
cell lines and included pancreatic adenocarcinoma (PANC1), breast cancer (MDA-
MB-231), ovarian cancer (SKOV-3, HOC7 & HEY), hepatic origin cancers (SK-Hep-1 & 
HUH7), glioblastoma (U251 & A172), melanoma (T168A) and prostate cancer 
(DU145 & PC3) in the analysis. Cytotoxicity was seen with clone A and F CAR T cells 
but not control CD19 CAR T cells. It did not however correlate with ROR1 
expression, implying intrinsic cell line mediators modulate susceptibility. In keeping 
with this cytokine secretion was variable between cell lines, despite being cultured 
with identical CAR T cells from the same donor. Only co-cultures with PANC1, 
DU145, PC3 and MDA-MB-2331 cell lines showed marked IFN and IL-2 secretion 
(Figure 4.18). Although clone A based CAR T cells tended to lead to higher rates of 
cytotoxicity compared with Clone F, this was not statistically significant and so we 
took both clone A and F forward for humanisation.  
 
 
FIGURE 4.17 CLONE A AND F CAR T CELLS SHOW ACTIVATION IN CO-CULTURES WITH ROR1 POSITIVE 
TARGETS 
Representative photographs of co-cultures between un-transduced (UT) and CD19, clone A and 
clone F CAR T-cells with PANC-1 cell lines. Clone A and F T cells demonstrate expansion and 
clustering with loss of background PANC-1 cells unlike CD19 and UT controls.  
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FIGURE 4.18 ROR1 CAR T CELLS MEDIATE CYTOTOXICITY AGAINST A PANEL OF SOLID TUMOUR CELL 
LINES.  
Solid tumour cell lines expressing ROR1 representing pancreatic, ovarian, hepatic, glioblastoma, 
melanoma, prostate, and breast cancer were co-cultured with ROR1 CAR T cells at 8:1 effector to 
target ratio and survival assessed via a MTS assay at 24 hours in triplicate. ROR1 CAR T cells 
mediated significant cytotoxicity against all cell lines irrespective of ROR1 expression. Cytokine 
secretion did not correlate with killing with only PANC1, DU145, PC3 and MDA-MD-231 cells 
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4.2.8 Epitope Discovery 
 
To better characterise clone A and F, we wanted to delineate the exact 
epitope of ROR1 which they bound, whilst ensuring no cross reactivity to ROR2.  
 
4.2.8.1 Clone A and F do not cross react with human ROR2 
 
Human ROR1 shares 58% homology with ROR2 (Figure 4.19A) and to ensure 
there was no unintended non-specific binding we transduced the SupT1 cell line to 
express human ROR2 (SupT1-ROR2). Using clone A and F scFv-mIgG fusion proteins 
we confirmed no cross reactive binding by flow cytometry (Figure 4.19B). 





FIGURE 4.19 ASSESSMENT OF ROR2 BINDING 
A. Alignment of human ROR1 and ROR2 with the signal peptide highlighted by shaded red and transmembrane domain by shaded yellow: Uniprot accessions Q01973 and 
Q01974 respectively. B. We generated a SupT1 cell line expressing ROR2 (SupT1-ROR2) in addition to our established SupT1-ROR1 cell line. Clone A and F scFvs were fused 
to murine IgG stalk and produced, followed by incubation with either SupT1-ROR1 or SupT1-ROR2 cells. Binding was detected with an anti-murine IgG antibody but neither 
clone A or F bound to SupT1-ROR2 cells. 
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4.2.8.2 Epitope mapping 
 
To better characterise the exact epitopes targeted we panned the 
extracellular domain of ROR1 with clone A and F antibodies. This was undertaken 
with a panel of ninety 11 amino acid peptide fragments representing the 
immunoglobulin and frizzled domains of ROR1. Protein fragments overlapped by 8 
amino acids in order to take into account conformational change and maximise 
potential epitope expression, to allow detection of binding with clone A and F 
antibodies.  
For clone A the ELISA readings were highest for protein fragments at the 
beginning of the immunoglobulin domain, just after the signal peptide (Figure 
4.20A). In keeping with this a SupT1 cell line transduced to express a truncated 
immunoglobulin domain demonstrated loss of binding with clone A, although both 
competitor R12 and 4A5 antibodies were still able to bind (data not shown). This 
provided evidence that clone A bound an epitope distinct from other reported anti-
immunoglobulin domain ROR1 antibodies.  
Within the region highlighted there was a single AA at position 48 that 
differed between human and rat ROR1, which was isoleucine and threonine 
respectively. To confirm that clone A bound to this epitope, we next generated a 
panel of SupT1-ROR1 cell lines with single amino acids substitutions at positions 47, 
48 and 50. Substitution of isoleucine at position 48 of ROR1 resulted in complete loss 
of binding with clone A. The adjacent asparagine at position 47 was also required 
for binding but was not as critical. This was in comparison with the serine at positon 
50, modification of which did not disrupt binding.  
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FIGURE 4.20 EPITOPE MAPPING 
A. 11 amino acid peptide fragments corresponding to the signal peptide and immunoglobulin 
domain of ROR1 were panned with a clone A antibody with a human IgG1 stalk. Binding was 
detected using anti-human HRP conjugated secondary. Peptide fragments 14, 15 and 16 
demonstrating a positive signal. B. SupT1 cells transduced to express a truncated ROR1 protein show 
no binding with a Clone A antibodies compared to full length ROR1. C. Single amino acid 
substitutions within human ROR1 were undertaken at positions 47, 48 and 50. These modified 
proteins were transduced into SupT1 cells and demonstrated the binding epitope focused on 
isoleucine at positon 48. D. 11 amino acid peptide fragments corresponding to the linker between 
the Immunoglobulin domain and frizzled domain as well as the entire frizzled domain were panned 
with a Clone F antibody, as above. A positive signal was detected with peptide fragments 66 and 67 
and 90. Differences in amino acid sequences between human and rat was only seen within peptide 
fragment 90. E. Single amino acid substitutions at position 254, 261 or both of ROR1 were 
undertaken and SupT1 cells transduced to express these modified ROR1 proteins. Modification of 
glutamine at position 261 showed complete loss of binding to Clone F, highlighting its target epitope.  
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We undertook the same process for Clone F, with the ELISA highlighting 
potential binding sites within two regions of the frizzled protein. The first was with 
peptides 66 and 67, but as there was complete homology between human and rat 
ROR1 within the amino acid sequence represented by these fragments, this was felt 
to be a false positive. By comparison, peptide 90 corresponded to ILENVLCQ in 
humans and VLENVLCH in rats, and contained the 2 AA different between human 
and rat. We therefore created 3 SupT1-ROR1 clones with substitutions within these 
amino acids and found that glutamine at position 261.  





One of the rationales for targeting ROR1 as opposed to CD19, is sparing of 
the normal ROR1 negative B cell population. However at the same time, continued 
presence of normal CD19+ B cells allows for immune responses directed against a 
rat derived scFv. This has been seen with murine scFvs and have led to clinically 
significant outcomes, including anaphylaxis with mRNA modified mesothelin CAR T 
cells (Maus et al., 2013) or antibody responses, with  -folate receptor or carbonic 
anhydrase IX specific CAR T cells (Lamers et al., 2006, Kershaw et al., 2006). T cell 
mediated immune responses are also possible due to cross presentation of 
components of the CAR on MHC.  
CD19 CAR T cells by comparison, inherently neutralise the risk of antibody 
based immune responses by eradicating the normal B cell population, with B cell 
recurrence associated with a higher risk of relapse.  
 
Humanisation of the antigen binding arms of antibodies was first described 
in 1986 when the complementary determining regions of the B1-8 murine antibody 
were grafted onto the framework region of a human antibody, whilst preserving 
the binding characteristics (Jones et al., 1986).  
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We attempted to undertake this in house and grafted CDR from clone F onto 
a homologous human framework identified by IgBLAST software (Ye et al., 2013), 
but the resulting humanised scFv lost its ability to bind ROR1 (data not shown). We 
therefore outsourced sequence design to Genscript Limited, who provided 5 
potential humanised sequences for both the heavy and light chains for clones A and 
F, resulting in potentially 25 novel humanised scFvs for each clone.  
 
4.2.9.1 Generation and screening of humanised scFv constructs 
 
To screen which of the humanised scFvs retained binding we cloned all 50 
constructs in a secreted scFv format fused to a murine IgG stalk. We chose to 
screen scFvs rather than full length antibodies as this was the final configuration we 
required for the CAR structure. All 50 scFv constructs were tested against SupT1 
cells expressing either the Ig domain (to screen for Clone A) or Fz domain (for Clone 
F). 3 of 25 scFvs bound for clone F, and in all cases the scFv utilised humanised light 
chain 1, suggesting the other light chains disrupted antigen binding. For Clone A 
there were 17 binders which utilised a more varied heavy and light chain mix, but 
all constructs incorporating heavy chain 3 and light chain 1 demonstrating binding 
to ROR1.  
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FIGURE 4.21 SCREENING OF HUMANISED SCFV  
5 humanised heavy and 5 light chain sequences were designed by Genscript resulting in 25 potential 
scFvs each for clone A and F. All 50 scFvs were generated by Phusion PCR from G-blocks and cloned 
in frame with a murine IgG stalk. Secreted scFv-Fc was produced in HEK293T cells and supernatant 
screened against SupT1 cell lines expressing either the immunoglobulin domain (BFP negative) or 
frizzled domain (BFP positive). Binding was detected with an anti-murine IgG secondary. Of the 
potential 25 binders, 3 humanised scFvs for clone F and 17 for clone A bound their respective target. 
scFv. Heavy chain/Light Chain combinations that bound are highlighted with green underscore.  
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4.2.9.2 Functional screening of humanised CAR constructs  
 
As binding does not necessarily correlate with function, the 20 scFv 
sequences that bound for both clone A and F were cloned into our CAR backbone. 
Initial assessment was based on CD107a degranulation, with all 3 humanised Clone 
F constructs being comparable to the parental F. For clone A however, only 
constructs incorporating humanised light chain 1 afforded CD107a degranulation 
against target cells, implying the framework sequence imparted by this variant 
contributed to the stability and/or affinity of the scFv and its subsequent 
interaction with ROR1 (Figure 4.22).  
Importantly we saw higher levels of background CD107a degranulation with 
certain clone A constructs (1x1, 1x3 and 4x1) when co-cultured with the ROR1 
negative SupT1-NT cell line. To further investigate this we assessed cytotoxicity with 
humanised clone A and F constructs. For clone F, cytotoxicity and cytokine secretion 
was similar between parental and humanised constructs, although there was a 
trend for higher IL-2 secretion with the humanised construct.  
In comparison for clone A constructs, we saw non-specific cytotoxicity 
against SupT1-NT cells, especially with (3x1) and (4x1). This was accompanied by 
significantly enhanced IFN secretion, irrespective of ROR1 expression (Figure 4.22).  
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FIGURE 4.22 CD107A DEGRANULATION SCREEN OF HUMANISED BINDERS.  
ScFvs identified to bind ROR1 were cloned into a CAR format and CAR T cells generated and cultured 
with target cells for 4 hours before assessment of CD107a expression by flow cytometry. Humanised 
constructs labelled heavy chain number x light chain number. A. CD107a degranulation with 
humanised clone F scFvs was similar to the parental scFv. B. Humanised clone A constructs 
demonstrated variation in degranulation with only those incorporating the humanised light chain 1 
showing comparable CD107a expression to the parental construct. We noted higher background 
CD107a degranulation with humanised constructs (1x1), (1x3) and (4x1).  
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FIGURE 4.23 CYTOTOXICITY AND IFN SECRETION OF LEAD HUMANISED CONSTRUCTS 
CAR T cells expressing humanised scFvs for Clone F (shaded red) or clone A (shaded green) were 
cultured with SupT1-NT or SupT1-ROR1 at a 2:1 effector to target ratio and cytotoxicity assessed at 
24 hours. Humanised clone F constructs showed no significant cytotoxicity against SupT1-NT cell 
lines and similar cytotoxicity against SupT1-ROR1. For Clone A constructs non-specific cytotoxicity 
was seen with A(3x1) and A(4x1) with corresponding non-specific IFN secretion. Representative of 2 
independent experiments.  
 
We next assessed cytotoxicity in other ROR1 negative cell lines to better 
interpret the CD107a results. The K562 cell line, which was originally derived from a 
patient with chronic myeloid leukaemia (Lozzio and Lozzio, 1975), is ROR1 negative. 
Despite this, co-culture with all humanised clone A CAR T cell constructs resulted in 
cytotoxicity at 24 and 96 hours (Figure 4.24A-B).  
We expanded upon this finding and used A(1x1) as a representative 
humanised clone A CAR T cell against the ROR1 negative MCF7 breast cancer cell 
line, which also demonstrated non-specific cytotoxicity and IFN secretion (Figure 
4.24C-D).  
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FIGURE 4.24 CLONE A MEDIATES NON-SPECIFIC KILLING OF ROR1 NEGATIVE TARGET CELLS 
A. The K562 chronic myeloid leukaemia cell line does not express ROR1. B. ROR1 CAR T cells 
expressing humanised clone A scFvs were co-cultured with K562 cells with resultant cytotoxicity at 
96 hours compared to a CD19 CAR control construct, in 2 independent donors. Effector to target 
ratio 2:1. C. The MCF7 breast cancer cell line lacks ROR1. D. Co-culture of MCF7 cells with CAR T cells 
expressing the humanised clone A construct 1x1 resulted in significant cytotoxicity at 24 hours based 
on a MTS assay with corresponding IFN secretion. This was not seen with the humanised F 
construct 1x1. Statistical analysis: One way ANOVA with CD19 CAR T cells as control arm.  
 
The non-specific killing seen with clone A could have been a result of the 
humanisation process. We re-assessed parental clone A CAR T cells with K562 and 
MCF7 cell lines but still demonstrated off target toxicity (data not shown), 
suggesting inherent non-specific binding with this scFv. This had not envisaged 
based on our earlier screen with SupT1-NT cell lines and in hindsight, a more 
detailed cross-examination with a panel of ROR1 negative cell lines, much like that 
undertaken with panel of solid tumour cell lines, may have detected this at an 
earlier stage.  
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These findings led us excluding clone A constructs from our future work plan 
and promoted humanised clone F(1x1) to the lead construct, to be taken forward. 
Further analysis with CAR T cells expressing F(1x1)  did not show any evidence of 
spontaneous cytokine secretion in resting cultures, nor any features of tonic T cell 
activation or exhaustion as measured by PD-1 expression compared to un-
transduced or CD19 CAR T cells (data not shown).  
 
4.2.9.3 Affinity of parental and humanised clone F scFv 
 
 
FIGURE 4.25 SURFACE PLASMON RESONANCE TRACES FOR PARENTAL CLONE F AND HUMANISED F(1X1) 
CONSTRUCT 
Affinity of clone F and humanised hF(1x1) was undertaken with a Biacore X100. ScFv-Fc was 
immobilised on a CM5 chip using a mouse antibody capture kit and traces obtained by passing 
across varying concentrations of ROR1-His (1.5625nM to 100nM). ka = association rate constant, kd 
= dissociation rate constant and KD = equilibrium dissociation constant.  
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To better characterise our lead and parental clone F scFv we undertook 
surface plasmon resonance to define affinity constants for their interaction with 
ROR1. This was especially true as modification of the framework region can affect 
affinity. The reported KD for parental F was 2.03x10-9 M compared with 7.31x10-9 M 
for the humanised scFv. This alteration in affinity did not result in differential 
cytotoxicity but may have accounted for the slightly higher IL-2 secretion seen with 
the humanised construct. Although not undertaken SPR analysis of hF(3x1) and 
hF(4x1) would have demonstrated whether their inferiority with respect to hF(1x1) 
was secondary to differences in affinity.  
 
4.2.9.4 Assessment of lead humanised F, hF(1x1), construct against a panel of 
haematological cell lines 
 
Having selected our lead construct, we next assessed its cytotoxic potential 
along with IFN and IL-2 secretion against a range of haematological cell lines 
constitutively expressing ROR1. Within this screen we compared CAR T cells 
expressing the hF(1x1) construct with previously published R12 and 4A5 scFv 
constructs. To allow direct comparison, all constructs shared the same lentiviral 
vector backbone including signal peptide, hinge spacer domain and 41BB-CD3 
intracellular signalling domains. As before we included the fmc63 CD19 CAR as 
control as haematological malignancies can be targeted by both ROR1 and CD19 
CAR T cells.  The CD19 construct was identical to the ROR1 CAR construct except it 
contained the CD8 spacer. 
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FIGURE 4.26 EXTENDED PANEL OF ROR1 POSITIVE CELLS 
A. ROR1 and CD19 expression for Raji, PCL12, 697 and Kasumi2 cell lines was undertaken by flow 
cytometry, compared to an isotype control. B. RT-PCR using ROR1 and GAPDH specific primers in the 
above cell lines as well as for Jeko1, SKW6.4 and SupT1-NT.  
 
Our panel included Kasumi2 and 697 ALL cell lines; Raji, Burkitt’s lymphoma 
cell line and PCL12, a CD5+ EBV transformed CLL cell line along with SKW6.4 cells 
that we had used from the outset of the project.  
PCL12 and Raji cells demonstrated only a minor shift by flow cytometry 
(Figure 4.24A) and to confirm this expression we undertook RT-PCR demonstrating 
a band for ROR1 at the correct size. This was especially important for the Raji cell 
line, as it had previously been reported to be ROR1 negative (Baskar et al., 2012), 
but in keeping with our findings a an independent group has also reported Raji cells 
to be ROR1 positive (Li et al., 2013)  
With regards to ROR1 CAR T cells, across 2 donors, hF(1x1) led to 
significantly higher cytotoxicity against SKW6.4, Raji, PCL12 and Kasumi2 cells 
compared to both R12 and 4A5. Against 697 cells cytotoxicity with hF(1x1) was 
comparable with R12 but still superior to 4A5.  IFN secretion was variable between 
donors and ROR1 CAR T cell constructs, however, IL-2 was consistently higher with 
hF(1x1) over R12 or 4A5.  
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Inclusion of CD19 CAR T cells allowed a more complete comparison and 
demonstrated both cytotoxicity and cytokine secretion was superior with CD19 CAR 
T cells as opposed to ROR1 CAR T cells when targeting haematological cell lines that 
express both antigens, although at markedly different levels.  
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FIGURE 4.27 CYTOTOXICITY AND CYTOKINE SECRETION WITH ROR1 CAR T CELL AND CD19 CAR T CELLS AGAINST A PANEL OF HAEMATOLOGICAL CELL LINES.  
CAR T cells expressing the CD19 fmc63 scFv or ROR1 CAR constructs expressing either the R12, 4A5 of hF scFv were generated for 2 donors, normalised based on mCherry 
expression and cultured with a panel of haematological cell lines (SKW6.4, Raji, PCL12, 697 and Kasumi2) at a 2:1 effector to target ratio and cytotoxicity and IFN and IL-2 
secretion assessed at 24 hours.  Statistical analysis undertaken with two way ANOVA with hF as the comparator arm. 
Page | 127 
 
4.2.10 Cytotoxicity against primary CLL cells 
 
We next tested cytotoxicity against primary patient samples. Although ROR1 
is expressed on CLL, ALL and MCL, it is best described in CLL cells where it is 
expressed in greater than 95% of patients (Cui et al., 2016). To better understand 
our target we assessed the antigen density of ROR1 and CD19 in 20 CLL patients.  
Median antigen binding capacity (ABC) for ROR1 was 2304 molecules/cell with a 
range of 800-4828, whilst CD19 was expressed at significantly higher levels: median 
12583 molecules/cell (Range 5894-23652). This level of ROR1 expression is in 
keeping with a more limited assessment undertaken in only 5 CLL samples (Baskar 
et al., 2008). Our calculated CD19 antigen density was also comparable with other 
published series in CLL (Ginaldi et al., 1998, Cabezudo et al., 1999).  
We next co-cultured primary CLL cells from 6 patients with CAR T cells 
generated from healthy donors expressing the CD19 fmc63 scFv or the ROR1 R12, 
4A5 or hF constructs. In keeping with the cell line data, hF(1x1) provided higher 
levels of cytotoxicity compared to R12 and 4A5 but was inferior to CD19 CAR T cells.  
 
 
FIGURE 4.28 ROR1 AND CD19 ANTIGEN DENSITY ON PRIMARY CLL CELLS AND CYTOTOXICITY 
A. Antigen binding capacity assessment in 20 primary CLL samples demonstrated a log lower 
expression of ROR1 compared to CD19. B. CAR T cells expressing the CD19 fmc63 scFv or ROR1 R12 
4A5 and hF(1x1) scFvs were co-cultured with 6 CLL samples. hF(1x1) resulted in higher cytotoxicity 
compared to R12 and 4A5, whilst CD19 showed enhanced cytotoxicity. Statistical analysis: one way 
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4.2.11 3rd Generation and costimulatory CAR T Cells 
 
We hypothesised that the low antigen density of ROR1 on cell lines and CLL 
cells contributed to reduced effector function in comparison to CD19.  In an 
attempt to enhance function we generated a panel of alternative intracellular 
signalling domains. This included addition of either CD28 or OX40, both of which 
are involved with T cell co-stimulation and activation in a third generation CAR 
format. We also generated a further two variants, one with an addition 41BB 
domain and one with a further 41BB and CD3z domain (Figure 4.27A).  
Despite these additional intracellular signalling modules there was no clear 
improvement in cytotoxicity or cytokine secretion compared to the original 2nd 
generation construct (Figure 4.27B). Although we did not compare these constructs 
with CD19 CAR T cells or use primary CLL cells for cytotoxicity, the lack of enhanced 
cytotoxicity or cytokine secretion, especially IL-2 suggested that these would be no 
better than the original 2nd generation construct.  
 
As an alternative, T cells can be made to express 2 or more distinct CARs on 
their surface, either through multiple vectors or within a single vector. CoCAR 
constructs were initially designed to limit off target toxicity by delivering the CD3 
through one CAR and co-stimulatory signal 41BB or CD28 through a second CAR 
(Kloss et al., 2013). We modified this approach by leaving the ROR1 scFv coupled 
with both 41BB and CD3 but introduced a CD19 CAR that provided additional CD28 
stimulation (Figure 4.27B).  
The aim of this approach was to lower the activation threshold and nullify 
the limitation of low ROR1 density. There was no off target toxicity against SupT1-
NT cells and showed comparable killing of SupT1-ROR1 cells in a 4 hour chromium 
cytotoxicity assay. However, co-culture of the CoCAR construct with SupT1-CD19 
cells demonstrated high levels of cytotoxicity, which was not initially envisaged. We 
hypothesised that CD28 stimulation through a CD19 CAR would not lead to killing 
without a corresponding CD3 signal. Possible reasons for cytotoxicity of CD19 
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targets with a CD19-CD28 CoCAR include cross pairing of the intracellular signalling 
domains such that CD19 CAR co-opts the ROR1 CAR CD3domain, which we can 
investigate with the use of a non-signalling CD3. Alternatively aberrant clustering, 
induced by multiple CARs on the T cell surface may lead to non-specific activation 
via tonic signalling and exhaustion (Long et al., 2015).
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FIGURE 4.29 3RD GENERATION SIGNALLING DOMAINS AND COCAR CONSTRUCTS DO NOT ENHANCE ROR1 CAR T CELL FUNCTION 
A. We generated a panel of 3rd generation signalling domains that included CD28 or OX40 in addition to 41BB-CD3.Alternative constructs included an addition 41BB or 
41BB-CD3 domain. ROR1 CAR T cells with the hF scFv were generated and co-cultured with SKW6.4 cells at a 2:1 effector to target ratio and cytotoxicity and cytokine 
secretion assessed at 24 hours. There was no significant different in cytotoxicity between the 2nd generation construct and 3rd generation signalling domains.  B. CoCAR T 
cells expressing a 2nd generation hF based ROR1 CAR and 2nd CD19 fmc63 CAR signalling to CD28 were generated and compared with  traditional ROR1 CAR T cells. A 4 hour 
chromium release assay demonstrated comparable cytotoxicity of SupT1-ROR1 cells with both constructs but high levels of CD19 toxicity with the CoCAR construct. 
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4.2.12 CAR Section Discussion 
 
Within this section of work we detailed how starting from 10 scFvs we 
reached our final humanised hF(1x1) construct, with the aim of incorporation into 
CAR T cells for the treatment of ROR1 positive malignancies, specifically CLL.  
 
4.2.12.1 ScFv selection and comparison 
 
Initial screening of the different scFvs followed by iterative optimisation of 
spacer length allowed us to compare different ROR1 scFvs. The extracellular spacer 
was a key factor in improving efficacy of CAR T cells, with the 19 AA hinge spacer of 
human IgG1 leading to optimal cytotoxicity irrespective whether the scFv bound to 
the immunoglobulin or frizzled domain of ROR1. The importance of spacer length 
has also been demonstrated for a range of other scFvs including the R12 scFv that 
also targets ROR1 (James et al., 2008, Hudecek et al., 2013).  
The introduction mCherry, as a reliable and easy to detect transduction 
marker allowed us to undertake accurate comparison between constructs. 
Although this was suitable for pre-clinical assessment, it is unsuitable for clinical 
translation due to immunogenicity. Other strategies to allow accurate assessment 
of TE, include the inclusion RQR8 or tEGFR, both of which can be stained for with 
monoclonal antibodies. An added functionality of these marker proteins is that they 
can also be targeted as suicide system for therapeutic purging of CAR T cells as a 
strategy to minimise toxicity (Philip et al., 2014, Paszkiewicz et al., 2016).  
An alternative is the inclusion of a protein tag within the structure of the 
CAR, such as StrepTagII, although this inherently increases immunogenicity and is 
therefore unsuitable for clinical use (Liu et al., 2016).  
To allow for accurate detection of transduced cells in vitro and for future 
clinical trials we have embarked on the generation of a monoclonal type 2 anti-
idiotype antibody through collaboration with BioRad Limited, that specifically 
Page | 132 
 
detects humanised clone F on the surface of T cells, irrespective of whether it has 
bound to ROR1 (Jena et al., 2013).  
 
4.2.12.2 Humanisation as a mechanism to decrease immunogenicity and enhance 
persistence. 
 
Our 2 lead candidates from initial selection, clones A and F, were subjected 
to a humanisation process to decrease the risk of immune responses directed 
against the rat derived scFv. These can be antibody mediated resulting in decreased 
persistence of transgenic T cells (Lamers et al., 2006, Kershaw et al., 2006), 
especially when there is retention of the normal B cell population as occurs with the 
majority of CAR T cells not targeting CD19 (Berger et al., 2015). Persistence can also 
be limited by T cell immune responses, even for CD19 CAR T cells (Turtle et al., 
2016).  
Humanisation is therefore an integral component of CAR design and in 
keeping with this, humanised CD19 CAR T cells have led to clinical responses in 
patients previously treated with murine CD19 CAR T cells who had lost expression 
of transduced cells (Maude et al., 2016a, Maude et al., 2016b). More recent 
humanisation strategies aim to minimise immunogenicity further by modification of 
the of the intracellular signalling domains, such as the fusion site between 41BB and 
CD3, due to potential presentation on MHC class I (Sommermeyer et al., 2017).  
The innate arm of the immune system can also limit persistence, as CAR T 
cells incorporating a full IgG stalk spacer, bind to Fc  receptors on monocytes and 
NK cells. This however can be abrogated by introducing mutations residues amino 
acids within the IgG required for FcR engagement (Hombach et al., 2010), although 
this is not seen with the hinge spacer we have selected.  
Humanisation itself does not guarantee a lack of immunogenicity. To model 
this CAR constructs can be screened against a large panel of donor derived 
dendritic, B and T cells to assess for immune responses in the context of a wide 
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range of MHC classes, such as that provided by Lonza through their Epibase in vitro 
platform.  
 
4.2.12.3 hF(1x1) provides superior cytotoxicity of low density antigen targets 
compared to R12 and 4A5 CAR T cells  
 
Comparison of our hF(1x1) scFv demonstrated superior cytotoxicity against 
a panel of haematologically derived cell lines and primary CLL cells compared with 
comparator non humanised ROR1 CAR T cells (R12 and 4A5), with the added 
advantage of having a humanised binder. 
The affinity of hF and 4A5 scFvs are similar (KD 7nM and 4nM respectively) 
and thus the difference in effector function is likely due to the epitope-spacer 
dynamic. The KD value for the R12 Fab is 0.56 nM but is unknown for R12 in the scFv 
format, thus not allowing a direct comparison. Nevertheless, hF(1x1) imparted 
superior cytotoxicity and cytokine secretion compared to R12. Overall I believe that 
the superior efficacy seen with hF(1x1) was in part due to it targeting the more 
membrane proximal frizzled domain rather than the affinity of the scFv per se, 
although generation of affinity matured or limited variants would allow for 
interesting functional assessments to be made.  
A consequence of the humanisation process is the potential alteration of 
scFv affinity, due to modification in the framework region. Our humanised hF(1x1) 
construct showed higher affinity compared to the parental rat scFv (7nM vs 2nM) 
and this difference may have mediated higher levels of IL-2 secretion we saw. 
Affinity can have significant consequences on CAR T cell function. For 
example, with EGFRvIII CAR T cells, higher affinity variants induce greater IFN and 
IL-2 secretion, as well as being able to successfully target lower antigen density cells 
(Liu et al., 2015a). In keeping with this, and in relation to ROR1, the high affinity R12 
demonstrated tumour eradication in vitro and in vivo compared to lower affinity 
2A2 bearing CAR T cells (Hudecek et al., 2013). There is however a limit to affinity, 
as excessively high affinity levels can lead to activation induced cell death and 
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decreased effector function (Watanabe et al., 2014). This finding is in contrast to 
TCR gene modified cells in which the converse is true, with high affinity TCR peptide 
interactions limiting killing of low peptide targets and increasing the risk of non-
specific activation (Thomas et al., 2011).  
One of the major limitations of this aspect of the project was the relatively 
narrow assessment of effector function, as only cytotoxicity and cytokine secretion 
at 24 hours was assessed. Prolonged co-cultures, in vitro re-challenge, assessment 
of T cell proliferation and exhaustion profiles as well as wider cytokine secretion are 
vital in understanding difference in biology.  
Moreover more complex in vivo models may allow for difference in survival, 
disease burden and T cell expansion to be better defined, especially between the 
parental and humanised F scFv, thereby assessing the wider functional 
consequences of the higher IL-2 secretion seen. 
Analysis was abbreviated in part, based on the comparison of ROR1 and 
CD19 CAR T cells, focusing our efforts on improving ROR1 CAR T cell function before 
more detailed assessment.  
 
4.2.12.4 Antigen density limits efficacy of ROR1 CAR T cells in comparison with CD19 
for the treatment of CLL 
 
Our primary focus was the development of ROR1 CAR T cells as a 
therapeutic for patients with CLL. One of the challenges is the low antigen density 
of ROR1, especially compared with CD19. Therefore, although hF(1x1) was the 
leading ROR1 CAR construct against haematological cell lines and CLL cells, it was 
inferior to a CD19 CAR T cells, which represents the gold standard in current clinical 
trials.  
This corroborates the work of others and highlights that although 
cytotoxicity can be preserved at a low antigen density, it nevertheless limits the 
necessary cytokine production and proliferation required to support prolonged 
tumour eradication. For example, for a CD20 CAR encompassing a CD28 and CD3 
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intracellular signalling domains, approximately 200 molecules/target was needed 
for lysis but around 2000 needed for cytokine production (Watanabe et al., 2015). 
This has been confirmed by a group targeting CD123 who found similar findings, 
such that approximately 1600 CD123 molecules were able to lead to target cell 
killing and cytokine secretion, but approximately 5000 were needed for robust 
proliferation (Arcangeli et al., 2017) and unsurprisingly a similar finding occurs with 
normal TCR signalling (Valitutti et al., 1996). Given that the mean ROR1 antigen 
density on CLL cells is approximately 2000 molecules, this presents a limitation with 
standard 2nd generation CAR T cells.  
 
One of the theoretical advantages of targeting ROR1 as opposed to CD19 is 
the sparing of the normal cell population, thus limiting hypogammaglobulinaemia 
secondary to B cell aplasia. Despite initial concerns, this has not emerged as a 
limiting factor with CD19 CAR T cell therapy, as routine infusion of intravenous 
immunoglobulin minimises associated risks. In addition for those patients who 
achieve prolonged disease eradication, the inclusion of suicide systems allow for 
purging of the transduced T cell population and reversal of B cell aplasia 
(Paszkiewicz et al., 2016). 
A potential contributing factor to the success of CD19 CAR T cell therapy 
may be due to the continued production of CD19+ B cells within the marrow. These 
act to stimulate and promote ongoing turnover of CD19 CAR T cells, thus enhancing 
persistence. In comparison, ROR1 CAR T cells would not receive this continued drive 
for proliferation within the marrow and is unlikely to receive this from normal 
tissue expressing ROR1.  
 
This brings us to the inherent paradox of targeting ROR1 with CAR T cells. 
We require them to effectively target low levels of ROR1 on CLL but this increases 
the inherent risk of targeting normal tissues such as pancreatic islets cells, areas of 
the gastrointestinal tract and parathyroid cells which also express ROR1 at low 
levels. Indeed given that R12 based CAR T cells become activated and release IFN 
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in co-cultures with adipocytes and pancreatic islet cells (Balakrishnan et al., 2017), 
we would expect a similar finding with hF(1x1) CAR T cells.  
ROR1 CAR T cells expressing the R12 CAR showed safety in non-human 
primates, despite them having a similar expression profile of ROR1 with no 
gastrointestinal or pancreatic toxicity noted suggesting ROR1 expression at these 
sites may be shielded from circulating CAR T cells, although whether this would still 
be the case following a systemic pro-inflammatory state such as cytokine release 
syndrome is unknown (Berger et al., 2015). 
CRS is a limiting feature of CD19 CAR T cell therapy, with sometimes fatal 
consequences, although algorithms to guide its management have been refined 
with increasing knowledge of the biology and kinetics driving it (Teachey et al., 
2016, Lee et al., 2014b). ROR1 therapy, secondary to lower antigen density may 
limit severe CRS, thereby improving safety for patients with CLL, the majority of 
whom are elderly and have co-morbidities, thus allowing expansion of CAR T cell 
therapy. This has to be balanced against the slower rate of killing and cytokine 
secretion, which increases risk of T cell exhaustion, due to chronic stimulation 
through the CAR, a feature common in chronic viral infections and cancer (Wherry 
and Kurachi, 2015). 
 
4.2.12.5 Strategies to enhance ROR1 CAR T cell 
 
Despite the above, ROR1 remains an attractive target for CLL. One possible 
method to circumvent limitation of low antigen density, would be to 
pharmacologically increase ROR1 levels, thus modulating enhanced cytotoxicity. 
Proof of this approach comes from evidence with decitabine, which increases CD33 
expression on AML blasts, sensitising them to a monoclonal antibody (Vasu et al., 
2016). Dasatinib has been shown to increases ROR1 gene expression in t(1;19) cell 
lines (Bicocca et al., 2012), but we found no increase in ROR1 in CLL cells cultured 
with dasatinib. Other platforms screening large numbers of drug candidates to 
assess for enhanced ROR1 expression may yield an alternative candidate.  
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In an attempt to enhance the inherent function of hF(1x1) CAR T cells we 
assessed a variety of 3rd generation signalling domains, but did not see convincing 
evidence of improved function. This is in comparison to 3rd generation CD19 CAR 
constructs where they have demonstrated higher cytokine secretion and 
persistence (Pule et al., 2005). Whether this is also due to antigen density or the 
specific combination of scFv epitope and affinity remains unknown but requires 
further validation. Although 2nd generation CAR constructs remain the gold 
standard in clinical trials, investigation of third generation constructs with a CD19 
targeting scFv are underway (Tang et al., 2016). The most interesting is the SAGAN 
trial which undertakes co-infusion of 2nd generation and 3rd generation CAR T cells, 
with an aim to map fate and persistence in a range of lymphoid malignancies 
including ALL, NHL and CLL (NCT01853631). 
 
A further method to try and improve ROR1 CAR T cell function was the 
introduction of a costimulatory CAR to lower the activation threshold. Assessment 
of this was terminated due to unintended cytotoxicity against CD19+ROR1- targets, 
which was not the aim of when solely supplying a CD28 signal through the CoCAR. 
Had this shown more promise, an additional advantage of utilising the 
CoCAR was that co-stimulation through CD19 may allow the CAR T cell population 
to be preserved, even in the absence of ROR1 targets in the bone marrow, leading 
to prolonged persistence. 
We are currently refining this approach with the substitution of the CD19 
with a CD5 CoCAR, taking advantage of the aberrant CD5 expression on CLL cells. As 
part of this we have undertaken modification of the spacer and transmembrane 
domain to limit cytotoxicity to solely ROR1+CD5+ CLL cells and not normal CD5+ T 
cells. Proof of using CD5 as a target comes from the treatment of T cell 
leukaemia/lymphoma  and concerns with regards to elimination of the entire 
normal and CAR T cell population was not realised as fratricide was limited, 
although it is yet to be tested in clinical trials (Mamonkin et al., 2015).  
Page | 138 
 
The use of multiple CAR on the surface of the same T cell can be 
manipulated in a variety of ways using Boolean logic. For example the use of 2 CARS 
targeting different antigens on the surface of tumour cells, with both leading to a 
full activation signal is an example of an ‘OR’ gate that can be used to limit antigen 
negative escape (Zah et al., 2016). As described by Kloss et al. this can be modified 
to be an ‘AND’ gate require the presence of both antigen to fully activate T cells, 
thus acting as a safety system (Kloss et al., 2013). The costimulatory CAR can be 
switched to having an inhibitory effect such that T cell activation by normal tissues 
is limited even in the presence of a tumour antigen (Fedorov et al., 2013).  
Other strategies to enhance CAR T cells is through the release of pro-
inflammatory cytokines to enhance function (Koneru et al., 2015), accessory trans 
co-stimulation through 41BBL (Zhao et al., 2015) and intrinsic PDL-1 checkpoint 
inhibition (Cherkassky et al., 2016). More advanced gene editing has allowed 
expression of the CAR to be driven by the TCR  locus as opposed to a constitutive 
promoter, further enhancing CAR T cell function by allowing physiological recycling 
of the CAR on and off the cell surface, thereby limiting tonic signalling and 
preventing exhaustion (Eyquem et al., 2017). 
Furthermore, the entire design and manufacture process can be 
manipulated to enhance CAR T cell function. For example cells manufactured with 
CD3/CD28 activation beads demonstrate superior function compared to those 
activated with anti-CD3 antibodies and IL-2 (Barrett et al., 2014), although this has 
been further refined to demonstrate limited stimulation leads to a superior CAR T 
cell product compared to continuous stimulation (Kagoya et al., 2017). Additionally, 
the use of IL-7 and IL-15 improve T cell fitness, by increasing the percentage of T 
memory stem cells (Xu et al., 2014). Other strategies include the selection and 
transduction of specific T cell subsets with high effector and proliferation potential, 
such as memory T cells (Berger et al., 2008, Wang et al., 2011b), to the use of 
defined subsets of CD4 and CD8 T cells to generate a more consistent T cell product 
between patients (Sommermeyer et al., 2015). These manufacturing variations 
have to be balanced against the need for extra manipulation of cell fractions in a 
GMP environment, with associated costs and longer turnaround times.  
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Within the clinical trial setting, optimisation of conditioning regimens, 
management of CRS (Ruella et al., 2016, Lee et al., 2014b, Lee et al., 2014a) and 
combinational therapy or small molecule inhibitors are allowing for enhanced 
response rates. Given the success of checkpoint inhibitors with solid malignancies, 
natural synergy between these and CAR T cells are being exploited with co-
administration (Chong et al., 2017). CAR R cells can also be manipulated to secrete 
checkpoint inhibitors (Li et al., 2017b) or through CRISPR/Cas9 mediated disruption 
of the PD-1 locus within T cells (Rupp et al., 2017). 
 
All of the above strategies could be utilised to enhance ROR1 CAR T cell 
therapy, but it is unclear whether these modifications would make them 
comparable to existing 2nd generation CD19 CAR T cells, which themselves can be 
improved with these modifications.  
This does raise the question as to whether there is a role for ROR1 CAR T 
cells for CLL. However given that response rates for CLL are lower than for ALL 
(Fraietta et al., 2016b); development of ROR1 CAR T cells as a therapeutic remains a 
valid aim, with optimisation beyond the traditional 2nd/3rd generation format 
required. Additionally, patients who fail CD19 CAR therapy, through a variety of  
escape mechanisms including alternative splicing (Sotillo et al., 2015), 
differentiation to other phenotypes (Gardner et al., 2016, Evans et al., 2015) or loss 
of persistence, may benefit with ROR1 CAR T cell challenger.  
Although we have focused on CLL, ROR1 is expressed on Mantle Cell and 
ALL, but characterisation has not been as detailed as CLL. In ALL, its expression is 
limited to 5% of patients with t(1;19) translocation, but this cohort tend to do well 
with intensive chemotherapy, limiting their potential.  
Furthermore, a key advantage of developing ROR1 CAR T cells is that it is not 
limited to haematological malignancies and the ideal therapeutic setting may 
therefore be in solid cancers, where CD19 is not expressed. We have demonstrated 
proof of concept with this approach against a panel of solid tumour cell lines and 
have expanded this more recently to focus on neuroblastoma cell lines with the aim 
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of undertaking assessment against primary human tumour samples via patient 
derived xenograft (PDX) modelling.  
Despite this, demonstrating efficacy with CAR T cell therapy against solid 
malignancies has been more difficult, despite a range of target antigens being 
investigated (Gilham et al., 2012). There is however some evidence of progress, 
such as with the IL-12 receptor 2 CAR for glioblastoma (Brown et al., 2016), but 
more in order to achieve success, the immunosuppressive tumour 
microenvironment in solid malignancies has to be overcome. At a starting point 
however, transition of our hF(1x1) ROR1 CAR, in a standard 2nd generation format, 
for the treatment of high risk tumours with unmet need (such as pancreatic cancer) 
would allow us to demonstrate initial safety and feasibility, which can be built upon 
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The basic structure of a BiTE comprises two single chain variable fragments 
joined in tandem with a flexible linker. We consulted the IMGT database of 
antibodies and utilised the deposited sequence for Blinatumomab as the basic 
structure of our ROR1 BiTE (Lefranc et al., 1999). This comprises the fmc63 CD19 
scFv in a light chain-linker-heavy chain format, followed by the OKT3 CD3 scFv in a 
heavy chain-linker-light chain format. We substituted the CD19 scFv for our panel of 
ROR1 scFvs and utilised the same CD3 scFv. The OKT3 CD3 antibody was the first  
monoclonal antibody licensed for use in humans to prevent transplant rejection 
and is a potent activator of T cells (Smith, 1996). It is unlikely this is the actual 
sequence of Blinatumomab used clinically, which has never been published in any 
scientific papers and in hidden within the patent filings made by Micromet and 
subsequently Amgen.  
 
 
FIGURE 4.30 BLINATUMOMAB SEQUENCE AS PER IMGT 
The amino acid sequence and structure of Blinatumomab as deposited with IMGT. The CD19 scFv is 
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4.3.2 Construct and initial generation  
 
We generated ROR1 BiTEs through overlapping PCR using G-blocks that 
were codon optimised. As the structure of our scFvs was heavy chain-linker-light 
chain we maintained this in the BiTE configuration. We also maintained the 
GGGGSGGGGGSGGGGS linkers between the heavy and light chains of the scFv but 
wobbled them to limit the potential of homologous recombination in viral vectors. 
As with the IMGT sequence of Blinatumomab we maintained the GGGGS linker 
between the CD19 and CD3 scFvs.  
In keeping with other reported BiTEs we included a hexa-histidine tag at the 
N terminus of the BiTE to allow for detection and purification (Figure 4.25A). This 
did not affect binding compared to BiTE without a hexa-histidine tag (data not 
shown).  
The construct was transferred into a retroviral vector and BiTE produced in 
HEK-293T cells through either transient transfection or retroviral transduction to 
generate a stable producer cell line. Supernatant containing either ROR1 or CD19 
BiTE, demonstrated binding to target cells and T cells (Figure 4.25B) and cytotoxicity 
against ROR1 target cells in the presence of effector T cells (Figure 4.25C), although 
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FIGURE 4.31 STRUCTURE, BINDING AND INITIAL CYTOTOXICITY OF OUR ROR1 BITE 
A. The basic schematic of our ROR1 BiTE construct which comprises an ROR1 scFv in tandem with a 
CD3 scFv with an N terminal hexa-histidine tag. B. Supernatant from HEK-293T transduced cells 
comprising either CD19 BiTE (CD19xCD3) or a ROR1 BiTE (ROR1xCD3) was incubated with target 
cells. This was followed by incubation with an anti-His secondary and assessment by flow cytometry. 
SupT1-WT cells, which lack CD19, ROR1 and CD3 showed no binding with either CD19 or ROR1 BiTE. 
SupT1-CD19 and SupT1-ROR1 cells showed specific binding to the CD19 and ROR1 BiTE respectively. 
T cells bound both CD19 and ROR1 BiTEs through CD3. C. Supernatant from CD19 BiTE or ROR1 BiTE 
producing HEK-293T cells was cultured with SupT1-ROR1 cells with PMBCs in a 1:1 effector to target 
ratio. ROR1 BiTE mediated significant cytotoxicity of target cells compared to CD19 BiTE.  
 
 
4.3.3 BiTE Purification & Characterisation 
 
We next focused on developing a method to purify and characterise the 
produced BiTEs to allow for direct comparison based on equivalent concentrations.  
Our final protocol utilised FPLC HiTrap TALON binding columns. These contain a 
mixture of agarose beads with immobilised cobalt which binds to the hexa-histidine 
tag and provided superior purification compared to nickel based columns. Elution 
was undertaken using an Imidazole gradient. The resulting elution fractions 
contained two peaks, the first of which corresponded to non-specific protein 
binding at low concentrations of Imidazole whilst the second peak contained the 
BiTE, as demonstrated by Coomassie stain of eluted fractions. The corresponding 
Western blot demonstrates a high degree of purify, although this was under 
reducing conditions. The purified BiTEs were quantified using a standard curve 
generated with dilutions of a BSA protein standard and BiTEs were stored at 4oC, 
with 1% BSA. Storage at lower temperatures or without of BSA as stabiliser, 
resulted in loss of function, likely secondary to aggregation.  
 







FIGURE 4.32 BITE PURIFICATION AND QUANTIFICATION 
Supernatant from HEK-293T cells producing BiTE was passed through a HisTALON column using an 
AKTA FPLC system with elution via an Imidazole gradient.  
A. UV chromatography (blue line) of the elution phase of purification with two peaks. The first 
corresponds to elution of non-speciifc binding proteins, whilst the second conatins the BiTE. The 
green line corresponds to the Imidazole concentraion and dashed red lines at the botton the 
fractions collected. B. Coomassie stain demonstrating that the first peak is non-specific protein 
eluted at a lower imidazole concentration, whilst the second peak corresponds to fractions with 
BiTE. C. Western blot using an anti-His-HRP secondary demonstrates His portein at the expected size 
with significant purity. D. Quantification was based on the generation of a BSA protein standard 
curve as analysed on a Coomasie using ImageJ software to generate a standard curve.   
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4.3.4 ROR1 BiTE binding epitope dictates effector function  
 
Once we were able to reliably purify and quantify BiTE across multiple runs, 
we were in a position to compare BiTEs with different ROR1 scFvs. We found that 
against a panel of pancreatic adenocarcinoma cell lines, a ROR1 BiTE targeting the 
frizzled domain (Clone F, as used in the CAR) provided enhanced killing at lower 
concentrations compared to BiTEs targeting the immunoglobulin domain: At 
0.1g/ml cytotoxicity with clone F was 23.5% and 4.2% for MiaPaCa2 and SUIT2 
cells respectively with clone F compared with 56.4 and71.5% for clone omega 
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F  0 .1 0 0  u g / m l
F  1 .0 0 0  u g / m l
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FIGURE 4.33 SCREENING ROR1 BITE BASED ON TARGET EPITOPE 
A panel of pancreatic adenocarcinoma cell lines were cultured with peripheral blood mononuclear 
cells at a 1:1 T cell to target ratio in the presence of a frizzled targeting BITE (F) or an 
Immunoglobulin targeting BiTE (Omega) at 1ug/ml or 0.1ug/ml. Cytotoxicity between F and Omega 
BiTEs was similar for Panc1, CFPAC1, PSN-I and HPAF-II cell lines but against MiaPaCa2 and SUIT2 we 
saw superior killing with F BiTE. Representative of 2 independent experiments.  
 
BiTEs bring T cells and target cells into close proximity to allow for MHC 
independent activation. The inter-cellular distance between T cell and target cell is 
vital for effector function, akin to that seen with CAR T cells and physiological TCR 
signalling. The importance of this aspect of immunotherapy has also been 
demonstrated for both BiTEs and bispecific antibodies (Bluemel et al., 2010, Li et 
al., 2017a). We therefore selected clone F as our lead BiTE, in keeping with the scFv 
chosen for the CAR.  
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4.3.5 ROR1 BiTE Mediates toxicity against multiple solid tumour cell lines 
 
At this stage the primary focus of the ROR1 CAR project was haematological 
malignancies. To diversify the range of potential therapeutic targets to include non 
CD19 targets, we chose to focus our BiTE characterisation on solid tumours.  
 
4.3.5.1 Pancreatic Adenocarcinoma 
 
Pancreatic adenocarcinoma is one of the leading causes of cancer deaths 
with overall 5 year survival of less than 10%, despite significant investment in novel 
therapies. Major advances have been lacking in part due to late presentation, 
inherent resistance to chemotherapy and a lack of targets amenable to therapeutic 
intervention. In addition there is a clear lack of efficacy with immune checkpoint 
inhibitors (Kleeff et al., 2016).  
A proportion of pancreatic cancers express ROR1 and in order to assess 
whether our ROR1 BiTE could be used as a potential therapeutic, we assessed 
function against the PANC1 cell line, which expresses ROR1 (Lieber et al., 1975). 
 Co-culture of T cell and 1g/ml ROR1 BiTE with PANC1 cells results in 
significant cytotoxicity at 24 hours compared to T cell cultured with a CD19 BiTE, 
with resulting T cell clustering and proliferation. This was also associated with 
significant IL-2 and IFN release. 
BiTEs are active at extremely low concentrations and we therefore assessed 
cytotoxicity against a panel of pancreatic adenocarcinoma cell lines from 
1000ng/ml to 0.1ng/ml. There was variation in target cell susceptibility highlighted 
by the difference between PANC1 and MiaPaCa2 cell lines, which cannot be 
explained by target cell expression. We nevertheless demonstrated cytotoxicity at 
0.1ng/ml of BiTE compared to control cultures with no BiTE across the panel of cell 
lines.  
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FIGURE 4.34 ROR1 BITE MEDIATES CYTOTOXICITY AGAINST A PANEL OF PANCREATIC ADENOCARCINOMA CELL LINES.  
PANC1 cells cultured with T cells and ROR1 BiTE in a 1:1 effector to target ratio demonstrates A. significant toxicity compared to control BiTE. B. It is associated with T cell 
clustering and results in C. significant IL-2 and IFN secretion. D. A panel of pancreatic adenocarcinoma were cultured with T cells and ROR1 BiTE from 1000ng/ml to 
0.1ng/ml, demonstrating cytotoxicity at low concentrations, but which did not correlate ROR1 expression levels (inset flow cytometry plots).  
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4.3.5.1.1 In vivo evaluation of ROR1 BiTE against PANC1 cell lines 
 
We next undertook two distinct mouse models. In the first mice were 
injected intraperitoneally with PANC1 cells and human T cells along with CD19 BiTE 
or ROR1 BiTE. BiTE treatment was administered for 5 days intraperitoneally, with 
ROR1 BiTE treated animals showing a reduction in the bioluminescence signal at 1:4 
and 1:2 target to effector ratio, compared with CD19 BiTE treated animals (Figure 
4.33A).  
We next undertook a more challenging subcutaneous model in which 
PANC1 tumours were established in the flank of mice until average volume were 
100mm3. Control mice were treated with a single infusion of T cells and 7 days of 
PBS or CD19 BiTE and compared with mice treated with ROR1 BiTE. There was a 
significant decrease in tumour size in ROR1 BiTE treated animals compared to 
control mice cohorts. At a longer follow up at day 28, ROR1 BiTE treated mice had 
smaller tumours due to a reduced growth rate.  
Page | 149 
 
 
FIGURE 4.35 ROR1 BITE REDUCES TUMOUR BURDEN IN MURINE MODELS OF PANCREATIC 
ADENOCARCINOMA 
A. Intraperitoneal Engraftment: 2×106 PANC-1 luciferase cells were administered per athymic nude 
mouse followed by a single dose of purified human T cells injection intraperitoneally (8×106 T cells 
for the CD19 BiTE group; 8×106 and 4×106 T cells for the ROR1 BiTE groups to yield 1:4 and 1:2 target 
to effector ratio). BiTEs were injected daily at 10 μg/kg/mouse for 5 days and PANC-1 engraftment 
was assessed by in vivo bioluminescent imaging (BLI) with decreased BLI signals at day 8.  
B. Established xenograft model: PANC-1 cell lines (5×106) were injected in the right flank of 
immunocompromised athymic nude mice and xenografts were established to a minimum size of 100 
mm3. Mice then received a single intravenous injection of purified T cells (5×106) and were treated 
with ROR1 BiTE, CD19 BiTE or PBS at 10 μg/kg/day intravenously daily for 7 days and the size of the 
tumour measured by a caliper. Follow-up of these animals at day 28 showed that ROR1 BiTE treated 
mice had lower tumour volumes compared with the control cohorts despite no additional ROR1 BiTE 
administration. 
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4.3.5.2 ROR1 Mediates cytotoxicity against a broad range of solid tumour cell lines 
 
Having established proof of concept against pancreatic adenocarcinoma we 
next assessed breast and ovarian cancer cell lines. Although treatments for both of 
these has advanced, patients with resistant and metastatic disease have an unmet 
therapeutic need and may benefit from ROR1 targeted therapy.  
We therefore assessed ROR1 expression in breast (MDA-MB-231 and MCF7) 
and ovarian (SKOV-3, HOC-7 and HEY) cell lines. We took advantage of the lack of 
expression of ROR1 on MCF7 cell lines to act as a control for non-specific activation 
and killing.  Our ROR1 BiTE mediated significant toxicity of MDA-MB-231 cell line 
with resulting cytokine secretion but not the MCF7 cell line. Importantly, there was 
no significant cytokine secretion above background with co-culture of T cells and 
ROR1 BiTE in the absence of the ROR1 on the cell surface. Cytotoxicity and IFN and 
IL-2 secretion was also seen against SKOV3, HOC7 and HEY cell lines. An in vivo 
model using SKOV3 cells expressing firefly luciferase, injected intraperitoneally with 
T cells and ROR1 BiTE, demonstrated the potential to reduce disease burden in 
mice.  
We next assessed cytotoxicity with ROR1 BiTE against hepatic origin cancers 
(SK-Hep-1 and HUH7), glioblastoma (U251 and A172), melanoma (T618A) and 
prostate cancer (DU145 and PC-3) and demonstrated significant cytotoxicity 
compared with CD19 BITE. As before target cell killing was associated with IFN and 
IL-2 secretion, but this was variable and non-related to ROR1 expression, as seen 
with CAR T cells.  
 




FIGURE 4.36 ROR1 BITE PROVIDES IN VITRO AND IN VIVO SPECIFIC CYTOTOXICITY AGAINST BREAST AND 
OVARIAN CANCER CELL LINES. 
A. Flow cytometry staining of ROR1 on MDA-MB-231, MCF7 breast cancer cell lines and SKOV-3, 
HOC-7 and HEY ovarian cancer cell lines, compared with isotype control. Values represent fold 
increase in MFI value. B. Cytotoxicity and cytokine secretion against ROR1 positive MDA-MB-231 but 
not ROR1 negative MCF7 cell lines as assessed by a cell viability assay using 1 μg/mL ROR1 BiTE at 24 
h compared with CD19 BiTE (1:1 Effector: Target ratio). C. Cytotoxicity and IFNγ secretion of ovarian 
cancer cell lines as assessed by a cell viability MTS assay using 1 μg/mL ROR1 BiTE at 24 h compared 
with CD19 BiTE. D. 5×106 SKOV-3 cells expressing firefly luciferase per mouse were administered 
intraperitoneally, followed by a single dose of 10×106 human T cells. BiTEs were injected daily at 10 
μg/kg/mouse for 5 days. SKOV3.Luc engraftment was assessed by BLI.  
  




FIGURE 4.37 ROR1 BITE ENABLES TARGETING OF A RANGE OF TUMOUR SUBTYPES. 
A. ROR1 expression was assessed on SK-Hep1, HUH7, U251, A172, T618A, DU145 and PC-3 cell lines 
representative of hepatic, glioblastoma, melanoma and prostate cancer; values within plots indicate 
fold increase of MFI compared to isotype control. B. Significant cytotoxicity against ROR1 positive 
cell lines compared with control CD19 BiTE (1:1 effector to target ratio; 1g/ml BiTE). 
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4.3.6 Humanisation of our ROR1 BiTE 
 
4.3.6.1 ROR1 scFv humanisation  
 
The next step, as with the CAR, was to undertake humanisation of the ROR1 
BiTE. Given that we were using clone F as our scFv we substituted the parental rat 
sequence with the 3 humanised binders identified earlier.  
We confirmed that the hF(1x1) provided superior cytotoxicity compared to 
the other humanised constructs. This was not apparent at high concentration of 
BiTE (from 1000 to 100ng/ml) but became pronounced at 1ng/ml where mean 
survival for parental F and F(1x1) was 5.3% and 9.7% respectively compared with 
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FIGURE 4.38 ASSESSMENT OF BITE CONSTRUCTS WITH HUMANISED AROR1 SCFV  
The humanised clone F scFv constructs F(1x1), F(3x1) and F(4x1) were cloned into the ROR1 BiTE 
backbone with OKT3 CD3 scFv and produced in HEK293T cells followed by purification with HiTrap 
TALON gravity columns. Concentrations were normalised and cytotoxicity assessed against SKW6.4 
cell line with T cell to target ratio of 1:1. The construct with humanised F(1x1) provided similar 
cytotoxicity to the parental clone, unlike clones F(3x1) and F(4x1), which although retained function 
at BiTE concentrations up to 100ng/ml, lost function at further dilutions.  
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4.3.6.2 CD3 scFv Humanisation  
 
To maximise the utility of humanised the ROR1 scFv we next undertook 
humanisation of the CD3 scFv to further decrease immunogenicity. Genscript 
provided 5 humanised heavy and 5 humanised light chains based on the parental 
OKT3 antibody sequence. These were combined in a scFv format and 12 of the 25 
constructs retained binding to CD3 in a secreted scFv format, as previously 
demonstrated (data not shown).  
All 12 of these CD3 binders were transitioned into our BiTE format with 
hF(1x1) as the partner scFv. Supernatants were purified using gravity columns and 
concentrations normalised as before. Cytotoxicity was similar with all of these 
constructs compared to the parental OKT3 scFv for SKW6.4 and PANC1 cell lines. 
However, higher cytokine secretion was consistently seen with humanised 
constructs that included the light chain 5 sequence CD3 sequence (corresponding to 
nx5). Overall, the ROR1 BiTE containing the CD3(3x5) scFv resulted in higher 
cytokine secretion and was selected as our lead humanised CD3 binder.  
The fully humanised ROR1 BiTE hF(1x1) and CD3(3x5), showed a similar 
binding profile to the parental construct. In an in vivo intraperitoneal model, it 
retained effector function as before.  
Compared to the prior PANC1 in vivo intraperitoneal model, there superior 
tumour eradication was seen as assessed by bioluminescence imaging. However 
direct comparison was not possible as mice were treated with 3 injections of T cells 
and weekly BiTE compared with a single T cell administration and 5 consecutive 
days of BiTE in order to demonstrate the potential for enhanced tumour 
eradication, using a treatment regimen that would be more clinically relevant that 










FIGURE 4.39 FUNCTIONAL ASSESSMENT OF HUMANISED CD3 SCFVS IN A FULLY HUMANISED ROR1 BITE 
12 humanised CD3 scFvs were combined with our humanised hF(1x1) scFv to generate a panel of 
fully humanised ROR1 BiTEs. Following purification the concentration of BiTE was normalised to 
5.5ng/ml and functional differences with regards to cytotoxicity and cytokine secretion assessed 
with SKW6.4 (A) and PANC1 (B) cell lines. Humanised constructs with light chain 5 showed higher 
cytokine secretion, with CD3(3x5) showing consistently higher secretion. C. Binding of the fully 
humanised hF(1x1)xCD3(3x5) BiTE was comparable with the non-humanised BiTE by flow cytometry 
at identical concentrations. D. Mice received 2×106 PANC-1.Luc cells/mouse intraperitoneally 
followed by three doses of purified human T cells (4×106). Humanised BiTE was injected once per 
week at 10 µg/kg/mouse and PANC-1.Luc engraftment was assessed by in vivo bioluminescent 
imaging.   
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4.3.6.3 Size Exclusion High Pressure Liquid Chromatography 
 
Coomassie and western blotting demonstrated a single band at the correct 
size for the BiTE. Although this may represent a pure product, the reducing 
conditions means that we are unable comment on the formation of BiTE aggregates 
which can due to interactions of the scFv arms (Gil and Schrum, 2013).  
To elucidate whether this was an issue, we undertook size exclusion high 
pressure liquid chromatography, through Bio-Analysis Centre, London.  This 
demonstrated, at the highest concentrations of 10ug/ml there was a small peak 
suggestive of aggregation (Figure 4.40, depicted by * and enlarged view 
underneath), but this corresponded to less than 5% of the total BiTE. In addition, 
the main BiTE peak was preceded by a non-specific double peak. Here, the 
chromatogram trace for the BiTE runs overlapped with that of buffer alone and 























FIGURE 4.40 SIZE EXCLUSION CHROMATOGRAPHY DEMONSTRATES NO SIGNIFICANT AGGREGATION OF 
OUR ROR1 BITE 
Purified fully humanised ROR1 BiTE was subjected to size exclusion HPLC at 10, 5 and 1 g/ml and 
compared with buffer alone. There was a small aggregation peak (* and magnified in the lower 
panel, which corresponded to <5% of total protein at 10g/ml. Assessment of the double peak 
before the main BiTE peak (magnified figure) overlap with the buffer alone, confirming this is not 
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4.3.7 BiTE mediates significant cytotoxicity against haematological cell lines 
 
Having demonstrated the potential to target a range of solid malignancy cell 
lines we next assessed function against haematological cell line. We confirmed 
cytotoxicity at low concentrations against SKW6.4, Jeko1 and Kasumi2 cell lines 
(Normalised survival 9.7%, 20.1% and 31.3% at 1ng/ml respectively).  
In an in vivo model, Nod-SCID IL2 mice received SKW6.4 cells 
intravenously and were monitored until systemic disease established. On day 4 they 
were treated with a single dose of T cells and 5 days of ROR1 BiTE or control PBS. 
ROR1 BiTE treated animals demonstrated a significant survival advantage (Log Rank 
test, p=0.025).  
 
 
FIGURE 4.41 ROR1 BITE EVALUATION IN HAEMATOLOGICAL CELL LINES. 
A. Co-culture of target cell lines with T-cells at a 3:1 effector to target ratio with ROR1 BiTE at various 
concentrations leads to significant cytotoxicity of SKW6.4, Jeko1 and Kasumi2 cell lines at 24 hours 
based on a FACS based killing assay. Data representative of at least 2 independent experiments. B. 
ROR1 BiTE improves survival in an in vivo model of disseminated B-cell leukaemia. 0.5x106 SKW6.4 
cells were engrafted in NOD SCID gamma mice for 4 days before infusion with 107 T cells and 5 days 
of ROR1 BiTE or PBS. Mice treated with ROR1 BITE had significantly enhanced survival compared to 
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4.3.8 hF(1x1) mediates cytotoxicity in a BiTE format but not as a bispecific 
antibody.  
 
BiTEs are small 55kDa proteins, freely filtered by the kidneys and therefore 
have a short half-life necessitating continuous infusions. Bispecific antibodies aim to 
harness the dual targeting properties of BITEs but in a conventional antibody 
format with an Fc stalk. These do however, rely on the correct pairing of heavy and 
light chain arms to ensure preserved and specific antigen binding, which can be a 
limiting feature of manufacture and purification. 
A number of full bispecific antibodies in this format are being tested in 
clinical trials including Catumaxomab, which binds EpCAM and CD3 (Strohlein and 
Heiss, 2010, Heiss et al., 2010) and Lymphomun, which binds CD20 and CD3 
(Schuster et al., 2015). These classify themselves as trifunctional antibodies as the 
Fc stalk allows recruitment of FcR bearing effector cells. Bispecific antibody 
manufacture has been made more commercially viable through the knobs-in-hole 
modification, which introduced mutations into each heavy chain CH3 domain to 
force hetero-dimerisation of the correct arms (Ridgway et al., 1996).  
A simpler construct is the scFv-Fc format, here the individual scFvs are 
continuous with heavy chain CH2 and CH3 domains. Dimerisation occurs through 
disulphide binds between the heavy chains as well as through use of knobs in hole 
modification of the CH3 domain (Figure 4.42).  The final scFv-Fc bispecific antibody 
has a molecular weight of 110kDa as opposed to 55kDa for the BiTE and 150kDa for 
a full antibody format.  
We assessed whether the humanised scFvs we had generated for ROR1 and 
CD3 would function as a scFv-Fc. This was produced, purified and characterised by 
Absolute Antibody Limited. Functional comparison between the BiTE and the 
bispecific scFv-Fc antibody demonstrated that although the BiTE mediated 
significant cytotoxicity of SKW6.4 and Kasumi2 cell lines as previously, the bispecific 
scFv-Fc showed no appreciable cytotoxicity at the same molar concentrations, 
despite both arms binding to their respective targets (Figure 4.42). We hypothesise 
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that the bispecific scFv-Fc format inhibits T cell and target cell interactions due to 
inappropriate inter-cellular distance or secondary to a lack of flexibility that allows 




FIGURE 4.42 ROR1 BITE PROVIDES ENHANCED CYTOTOXICITY COMPARED WITH A ROR1 BISPECIFIC 
ANTIBODY IN THE SCFV-FC FORMAT 
Structure of conventional ROR1 BiTE and the corresponding scFv-Fc bispecific antibody which utilises 
the same scFv sequences. Association of heterodimers occurs through disulphide bonds and knobs 
in hole modification of the CH3 domain. No off target cell killing was seen with ROR1 BiTE or 
bispecific antibody against SupT1 cells. ROR1 BiTE but not bispecific antibody mediated cytotoxicity 




4.3.9 Ibrutinib enhances ROR1 BiTE mediated cytotoxicity against primary CLL 
 
We next assessed the potential of our ROR1 BiTE to target primary CLL cells, 
which provides a more challenging target compared to cell lines. Initial assessment 
with allogeneic healthy donor T cells, co-cultured with CLL cells in the presence of 
1g/ml ROR1 BiTE resulted in decreased CLL viability at 24 hours, with normalised 
survival of 32.3% (Figure 4.43A).  
In comparison, when we used T cells isolated from CLL patients, we saw no 
cytotoxicity at 24 hours under identical conditions (Figure 4.43B). In these 
experiments, T cells were from patients with untreated CLL or from 
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relapsed/refractory patients with relatively high circulating lymphocyte counts, 
although we adjusted for this by using a constant effector to target ratio. 
We hypothesised that the lack of ROR1 BiTE mediated killing was due to 
inherent T cell dysfunction. In CLL, this is multifactorial in origin and includes 
abnormal T cell synapse formation, increased levels of inhibitory signalling 
molecules and an exhausted phenotype (Riches et al., 2013, Ramsay et al., 2008, 
Brusa et al., 2013). It also explains the higher risk of infections and secondary 
malignancies (Morrison, 2009, Tsimberidou et al., 2009).  
 
Ibrutinib, a first in class Bruton’s Tyrosine Kinase (BTK) inhibitor, 
demonstrates impressive efficacy in front line, relapsed/refractory and p53 deleted 
patients (Byrd et al., 2014, O'Brien et al., 2014, Burger et al., 2015a). In addition to 
the direct anti-leukemic effect mediated by BTK inhibition, it modulates the tumour 
micro-environment, skews T cells to a Th1 phenotype, reduces PD-1 expression and 
reverses pseudo-exhaustion (Podhorecka et al., 2017, Yin et al., 2017, Niemann et 
al., 2016, Natarajan et al., 2016a, Natarajan et al., 2016b, Long et al., 2017). This 
may be in part due to the off target effects of Ibrutinib on other kinases, as the 
above T cell modulation is less apparent with the much more BTK specific 
Acalabrutinib (Long et al., 2017).  
We therefore isolated T cells from patients receiving Ibrutinib for at least 3 
months and cultured them with autologous CLL cells. This demonstrated 
significantly enhanced cytotoxicity compared to non-Ibrutinib treated patients 
(survival rate 43% vs 85% respectively, p=0.012) (Figure 2C). This cohort included 
patients who had failed multiple previous lines of therapy as those with 17p 
deletions. Ibrutinib treatment was associated with enhanced secretion of a range of 
pro-inflammatory T cell mediators including TNF, IFN, Granzyme A and perforin 
(Figure 2D). 
 
To ensure this effect was not secondary to enhanced CLL sensitivity, we 
analysed matched samples from the same patient pre and post Ibrutinib treatment.  
Post Ibrutinib T cells were able to kill leukaemic cells irrespective of whether the 
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CLL cells had been exposed to Ibrutinib, confirming improved T cell function was 
driving force of improved BiTE function (Figure 4.41E). 




FIGURE 4.43 IBRUTINIB PRE-TREATMENT ENHANCES ROR1-BITE MEDIATED CYTOTOXICITY AND CYTOKINE SECRETION AGAINST PRIMARY CLL CELLS 
A. Co-culture of primary CLL cells (n=4) with allogeneic healthy donor T-cells (3:1 effector to target ratio) and ROR1-BiTE at 1g/ml results in marked cytotoxicity (p<0.0001 
One sample t-test). Data representative of 3 independent experiments. B. T cells isolated from non-Ibrutinib treated patients showed minimal cytotoxicity when co-
cultured with ROR1-BITE and autologous CLL cells (n=9) whilst T-cells isolated from patients on Ibrutinib and co-cultured with autologous CLL cells and ROR1 BiTE showed 
markedly improved cytotoxicity (n=6, p=0.012) and perforin, granzyme A, IFNand TNF secretion. C. Matched pre and post Ibrutinib T-cells from the same patient were 
co-cultured with CLL cell isolated at the same time point. Ibrutinib treatment significantly improves ROR1 BiTE mediated cytotoxicity irrespective of the CLL cells exposure 
to Ibrutinib.  
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The above experiments were undertaken with high effector to target ratio 
of 3:1 which was fixed to allow for comparison between patients. This is certainly 
higher than would be encountered in patients and to better define if our ROR1 BiTE 
retained function with a more physiological T cell and target cell numbers we 
isolated PBMCs from a patient with CLL but did not undertake T cell and CLL 
separation. Despite the patient being on Ibrutinib for over 6 months 47.4% of 
PBMCs were CD19+CD5+ leukaemic cells and expressed weak levels of ROR1. CD3+ 
T cells accounted for 26.58% of the total. Addition of ROR1 BiTE to cultures without 
further manipulation demonstrated dose dependent cytotoxicity at 24 hours. 
Although preliminary, this has to be further corroborated with a larger cohort of 




FIGURE 4.44 ROR1-BITE RETAINS FUNCTION AT PHYSIOLOGICAL A EFFECTOR TO TARGET RATIOS 
PBMCs from a patient with CLL who had been on Ibrutinib for greater than 6 months were isolated 
and characterised and demonstrated 47.4% residual CLL at this time point (CD19+CD5+ cells), which 
were weakly ROR1 positive. CD3+ T cells accounted for 25% of the total PBMC population with 
17.1% CD4+ and 9.5% CD8+. Addition of ROR1 BiTE from 1000ng/ml to 0.0001ng/ml demonstrated 
effective cytotoxicity at a T cell to CLL  
 
Given the immunosuppressive nature of the CLL, especially in untreated 
patients or those with high burden relapsed disease, the use of Ibrutinib to de-bulk 
disease and reset T cell function allows a rationale context to maximise efficacy 
with BiTE therapy. In addition, although we had planned to undertake a comparison 
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of Blinatumomab against our humanised ROR1 BITE but due to limited access have 
been unable to undertake this yet.  
 
4.3.10 Immunohistochemistry (IHC) using clone F antibody 
 
 
Targeting of ROR1 with an affinity matured antibody has been proven safe in 
patients with CLL and ROR1 CAR T cells incorporating the R12 scFv showed no 
toxicity in non-human primates. The R12 scFv has been transitioned to a clinical 
trial targeting a range of malignancies, including CLL.  
Given the unique nature of our scFv in terms of the epitope it binds, it is 
essential we exclude non-specific binding. We therefore undertook 
immunohistochemistry in collaboration with Dr Claudio Sorio at the University of 
Verona, who has provided the images for this section of the thesis.  
A full conventional antibody with the same variable regions as in the 
humanised hF(1x1) scFv, as used in both the CAR and BiTE, was generated by 
Absolute Antibody Limited with a murine IgG1 Fc stalk. IHC against a panel of 
normal tissues as well as pancreatic cancer was undertaken with this but was 
limited by quality of the tissue microarrays. We nevertheless demonstrated strong 
staining in pancreatic cancer samples, which was not seen in normal pancreas, with 
the exception of pancreatic islet cells, as previously reported (Balakrishnan et al., 
2017). Extended staining against normal human tissues comprising brain, kidney, 
heart, liver and lung showed no staining but some staining was seen in stomach 
tissue, which is again in keeping with Balakrishnan et al. 
In order to progress this we are in discussion with Propath limited to 
undertake a tissue cross reactivity study with our ROR1 antibody, comprising 












FIGURE 4.45 IMMUNOHISTOCHEMISTRY STAINING OF HUMAN TISSUES. 
Tissue microarrays were stained with anti-human ROR1 antibody with the same specificity and 
antigen binding arms as the BiTE. (A) and (B) Normal pancreas, with pancreatic islet cells highlighted 
(arrow); (C) and (D) pancreatic cancer from two independent patients; (E) normal brain; (F) normal 
kidney; (G) normal heart; (H) normal liver; (I) normal lung, and (J) normal stomach. Scale bars: 100 
μm. 
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4.3.11 BiTE Section Discussion  
 
4.3.11.1 ROR1 BiTE generation and assessment 
 
Within this section of work we have detailed how we have generated a 
ROR1 BiTE for the treatment of solid and haematological malignancies. It functions 
both at a low concentrations and at a low effector to target ratio, leading to 
cytotoxicity and resultant pro-inflammatory cytokine release in vitro and in mouse 
models. We developed a simple FPLC protocol using an imidazole gradient resulting 
in reproducible purification process with the final product not demonstrating 
significant levels of aggregation by size exclusion HPLC, a pre-requisite for clinical 
translation.   
As per CAR T cells, the distance between target and effector cell, as 
mediated by the BiTE, is critical for optimal effector function. A BiTE targeting the 
frizzled domain demonstrated superior cytotoxicity than those targeting the more 
membrane distal immunoglobulin domain. The rat immunisation programme did 
not unfortunately generate any antibodies specific for the kringle domain, although 
it would have been of interest to assess the function of a BiTE targeting this most 
membrane proximal domain.  
Other strategies to enhance BiTE function include modification of the linker 
between each scFv arms. We utilised the GGGGS linker but we have seen improved 
function with other BiTE constructs with longer linkers, such as (GGGGS)3 (data not 
shown) and deserves consideration.  
We substituted the parental rat scFv with the humanised binders generated 
earlier and demonstrated the hF(1x1) provided comparable cytotoxicity, even at 
low concentrations. This was therefore selected as the humanised scFv for the 
ROR1 arm of the BiTE and it is likely that the distance we generated between 
effector and target cell was key to efficacy.  
 To fully humanise the BiTE, we tested a panel of 25 humanised CD3 scFv 
sequences based on OKT3, of which 12 bound. Head to head assessment led to a 
lead candidate, CD3(3x5), which showed comparable cytotoxicity but enhanced 
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cytokine secretion. This fully humanised BiTE retained in vivo function in mice, but 
one limitation of this statement, was the lack of comparison between the fully 
humanised BiTE and the BiTE containing the murine OKT3 scFv. Biacore SPR 
assessment of these different CD3 scFvs would also add valuable information as to 
whether the humanisation process had modified the affinity and accounted for the 
higher cytokine secretion seen.  
We utilised the OKT3 scFv based on the availability of the sequence, the lack 
of intellectual property restriction associated with its use and the ability to activate 
T cells. It is likely that the final Blinatumomab construct does not utilise the OKT3 
sequence, but one which balances affinity with T cell activation. An early report 
with a CD19 BiTE, which may not be representative of Blinatumomab demonstrated 
a relatively low affinity for CD3 and a higher affinity for CD19 (2.6 × 10−7 M and 1.49 
× 10−9 M respectively as assessed by flow cytometry Scratchard analysis rather than 
SPR (Dreier et al., 2002). It is thought that the lower affinity of the CD3 arm allows T 
cells to receive serial triggering of CD3, thus leading to activation. It may also 
explain how a single T cell can engage multiple target cells with BiTEs (Hoffmann et 
al., 2005).  
Our humanised scFv has an affinity of 7nM, which is comparable to the 
affinity of the anti-CD19 fmc63 scFv of around 5nM (Sommermeyer et al., 2017), 
although both of these are much lower than that reported for Blinatumomab. To 
assess whether increasing the affinity of hF(1x1) would allow enhanced function we 
require a panel of antibodies that target the same epitope, maintain specificity and 
have a higher affinity. This can be achieved by screening phage display libraries 
against the known epitope of clone F or undertaking error prone PCR or alanine 
substitution to generate a high affinity variant although the latter two options have 
no guarantee of success and have to be screened to ensure no loss of specificity. 
A further iteration would be the identification of a panel of novel CD3 scFvs 
through phage display, which are able to activate T cells and have differing affinities 
to assess the optimal configuration of ROR1 and CD3 scFv with in vitro and in vivo 
function and specificity. Getting these correct is important, as a bispecific antibody 
targeting C-type lectin-like molecule-1 and CD3 demonstrated higher levels of in 
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vitro cytotoxicity with a very high affinity CD3 binder, but significant spontaneous 
T cell activation and resultant toxicity in non-human primates (Leong et al., 2017). 
Our BiTE demonstrated no autonomous activation and cytokine secretion of 
T cells in in vitro in cultures. Importantly we saw no toxicity associated with human 
T cell and ROR1 BiTE administration in mice, despite high doses of both being used 
and the ability of clone F to cross react with murine ROR1 based on the target 
epitope being shared between humans and mice.   
 
4.3.11.2 Other Bispecific ROR1 Formats 
 
One of the limitations of BiTEs is their relatively short half-life, necessitating 
continuous infusions. This however, introduces an inherent safety advantage in that 
ceasing infusion limits adverse events due to rapid clearance of circulating BiTE. 
Modification of the BiTE through pegylation or addition of albumin binding moieties 
are strategies to increase the half-life (Kontermann, 2009). Another strategy is the 
use of bispecific antibodies, which incorporate an Fc stalk and also bring into play 
FcR receptor bearing immune cells such as NK cells.  
We assessed whether our humanised hF(1x1) and CD3(3x5) scFvs function in 
a more antibody like configuration as a scFv-Fc. Although binding to each target 
antigen was retained, the scFv-Fc format did not show demonstrable cytotoxicity 
against cell lines. There are a number of potential causes for this, including the 
distance introduced on the scFv-Fc format creates a suboptimal distance between 
target and effector cell, or alternatively the presence of the Fc domain inhibits 
interactions between the cells. Substitution of the Frizzled binding clone F with one 
of the Immunoglobulin binding constructs, may have led to enhanced function in 
this format but was not tested due to the complexity of manufacture of these 
antibodies.  
 
A range of other antibody constructs have been designed to bring T cells and 
target cells in close proximity and include dual affinity retargeting antibodies 
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(DARTs) (Johnson et al., 2010). DARTs are similar to BiTEs but differ in that the 
variable domains of heavy and light chains of the 2 antigen binding arms are on 2 
separate polypeptide chains which interact covalently, with further stabilisation 
through a C terminal disulphide bridge (Figure 4.46) (Rader, 2011).  
A CD19 DART has demonstrated superiority over a corresponding CD19 BiTE 
in vitro (Moore et al., 2011) but this has not been transitioned to clinical trials. A 
CD123 DART, has demonstrated in vivo eradication of AML blasts in mice, 
eradication of CD123+ cells in non-human primates (Chichili et al., 2015) and has 
been safety administered in a Phase I clinical trial (NCT02152956). The DART format 
was created to overcome limitations of commercialising BiTEs due to patents filed 
by Micromet, which was subsequently acquired by Amgen.  
 
 
FIGURE 4.46 SCHEMATIC OF DART VS BITE 
A. Schematic of a CD19 DART, in which two separate proteins interact through covalent hetero-
dimerisation to generate a bispecific binding protein in comparison with B. A CD19 BiTE which is 
composed of a single protein chain. From (Moore et al., 2011). 
 
A ROR1 DART, combining an ROR1 scFv with a CD3 scFv along with a Fc 
domain to extend half-life has been generated by Macrogenics and demonstrates in 
vitro and in vivo efficacy across a range of tumour subtypes including against the 
PC3 cell line we used in our solid malignancy panel (Barat et al., 2016). Direct 
comparison of our BiTE and the DART is difficult, due to differences in the scFvs, 
additional Fc domain and the cell lines used. However, as BiTEs and DARTs are 
similar in size and structure, combined with our finding that targeting frizzled give 
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superior cytotoxicity a comparison of the R12 DART and hF(1x1) DART would make 
an interesting comparison.  
 
4.3.11.3 ROR1 BiTE mediates cytotoxicity against CLL in Ibrutinib treated patients  
 
Assessment of primary CLL cells is difficult due to inherent cell death ex vivo, 
especially in the absence of feeder cells and exogenous cytokines that provide a 
favourable microenvironment (Collins et al., 1989, Burger et al., 2000). 
An initial CD19 BiTE and subsequently clinical grade Blinatumomab have 
both been tested against primary CLL (Wong et al., 2013, Loffler et al., 2003). 
Within these assays BiTE was added to peripheral blood mononuclear cells 
containing both CLL and effector cells, at effector to target ratios comparable to 
peripheral blood. Functional cytotoxicity readouts were undertaken 5-10 days later, 
thus representing prolonged co-cultures. We assume earlier time points were not 
reported because evidence of cell death would have been limited. This would have 
been because of a disadvantageous effector to target ratio combined with impaired 
T cell function. Therefore, although these studies demonstrated cytotoxicity, these 
results have to be taken in relation to the high rates of spontaneous cell death at 
this time point, especially as the mechanism of BiTE activation and resultant 
cytotoxicity is rapid (Dreier et al., 2002).  
We chose to assess purified T cells and CLL cells in a fixed ratio to overcome 
variability introduced by differing effector to target rations, although we note that 
the purification process may have affected T cell function. We demonstrated 
healthy donor T cells were able to mediate cytotoxicity against CLL cells but T cells 
from patients were not. Although these patients had CLL, the majority were Binet 
stage A patients and in otherwise good general health implying a direct role of the 
immunosuppressive nature of CLL in limiting ROR1 BiTE mediated function (Riches 
et al., 2013, Ramsay et al., 2008, Brusa et al., 2013). We next demonstrated that 
Ibrutinib treatment normalises T cell function in terms of BiTE mediated cytotoxicity 
and cytokine secretion, with this effect being T cell dependent. We initially using a 
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higher effector to target ratio of 3:1 to make this assessment comparable with the 
non-Ibrutinib samples but we have also demonstrated retained effector function at 
physiological levels of CLL and T cells in a patient pre-treated with Ibrutinib. This is 
being expanded upon in a wider cohort of Ibrutinib treated patients to ensure 
reproducibility.  
Although Ibrutinib monotherapy has resulted in improved outcomes for 
relapsed/refractory and newly diagnosed patients, with prolonged responses for a 
number of years, it rarely leads to disease eradication in the form of MRD 
negativity. This is not associated with a poor responses, as disease burden can 
improve slowly with time (Barr et al., 2016). 
This provides insight into the optimal sequencing of BiTE therapy for CLL. 
Based on the above ROR1 BITE administration in untreated patients or those with 
high disease burden with suboptimal T cell function will lead to inadequate 
responses, whilst treatment following Ibrutinib would be the ideal context to utilise 
improved T cell function to eradicate residual disease and aim for a MRD negative 
status. In addition, regulatory T cell numbers correlate with function of 
Blinatumomab in ALL, with a cut off of 8.525% FoxP3+ T cells discriminating 
responders from non-responders (Duell et al., 2017) and Ibrutinib decreases the 
ratio of Treg cells in CLL patients (Long et al., 2017). A study investigating combined 
use of Ibrutinib and Blinatumomab in relapsed/refractory ALL is ongoing 
(NCT02997761).  
Ibrutinib is not the only pharmacological agent that can reverse T cell 
dysfunction in CLL, with lenalidomide also demonstrating repair of the 
immunological synapse and ability to mount immune responses (Ramsay et al., 
2008, Lapalombella et al., 2010) Investigation of T cell function with ROR1 BiTE in 
this patient cohort is also of interest, although high rates of toxicity with its use in 
CLL patients may preclude future combination therapy with BiTEs (Chanan-Khan et 
al., 2017)  
Beyond CLL, Ibrutinib is being investigated in solid malignancies as it inhibits 
mast cells, decreases fibrosis and alters the stroma in pancreatic cancer with 
beneficial effect in mouse models (Masso-Valles et al., 2015). A trial of Ibrutinib in 
Page | 173 
 
combination with chemotherapy for pancreatic cancer is recruiting patients 
currently (NCT02562898) and could be combined with ROR1-BITE therapy in the 
future.  
Overall, the use of ROR1 (or CD19) BiTE post Ibrutinib represents the clinical 
context best suited to test their efficacy within CLL and other haematological 
malignancies.  
 
4.3.11.4 ROR1 BiTE for solid malignancy 
 
We have demonstrated that our ROR1 BiTE can mediate cytotoxicity of a range 
of solid tumour cell lines including pancreatic cancer, breast cancer and ovarian 
cancer. We demonstrate in vivo ability to reduce disease burden and limit tumour 
growth but at a fixed and relatively high BiTE dose. These models could be further 
refined with the use of lower concentrations to delineate dose response 
assessment.  
Nevertheless, the combined data provides proof of concept of this approach 
and is in keeping with other BiTEs that target solid tumour antigens including 
EpCAM (English et al., 2015, Cioffi et al., 2012, Salnikov et al., 2009), CEA (Osada et 
al., 2010) and PSMA (Friedrich et al., 2012).  
Despite this, efficacy of BiTEs in solid malignancies has been lacking even when 
safely administered and tolerated, such as with the CEA BiTE (Pishvaian et al., 
2016). Interestingly, with regards to EpCAM, Catumaxomab a trifunctional, full 
bispecific antibody has been licensed for the treatment of malignant ascites (Berek 
et al., 2014), whilst Solitomab, the EpCAM BiTE equivalent, has had development 
paused. It is the context of ascites and intra-peritoneal treatment that is of interest 
as detectable responses against solid lesions have not been seen. BiTEs also have a 
theoretical advantage of better tumour penetration given their smaller size 
compared to antibodies, although this has not been conclusively demonstrated.  
As with CAR T cells, BiTE function can be enhanced with checkpoint inhibitors, 
as demonstrated with a CEA targeting BiTE (Osada et al., 2015). In addition PDL-1 
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upregulation has been seen as an escape mechanism following Blinatumomab 
(Köhnke et al., 2015), with non-responders having higher levels of PD-1 (Duell et al., 
2017). A number of clinical trials with checkpoint inhibition with Blinatumomab are 
underway (NCT03160079 & NCT03160079). 
A potential method to circumvent current limitations is through the synergistic 
use of ionising radiation, to induce immune cell infiltration, reprogramme the 
tumour micro-environment and allow enhanced function with 
immunotherapeutics, including BiTEs and CAR T cells (Weichselbaum et al., 2017). 
Other methods to enhance BiTEs include the transduction of T cells to deliver 
BiTE to tumour targets, with the rationale of the BiTE simulating both the 
transduced T cell and bystander T cells, whilst also driving enhanced mRNA 
expression of the BITE following activation (Velasquez et al., 2016, Iwahori et al., 
2015). Oncolytic viruses can also be modified to deliver BiTEs to combine viral 
induced cell damage with local production of BITE (Freedman et al., 2017). 
Taken together, our ROR1 BiTE represents a novel therapeutic for a range of 
solid tumour subtypes, but to ensure successful clinical translation, the context in 
which they are used is equally important. The FDA approval of Catumaxomab for 
malignant ascites, provides an interesting therapeutic indication in which to 
possibly test our ROR1 BiTE. More widely for solid tumours in general, combination 
with other modalities and agents will likely be needed to realise their potential but 
in the interim a phase I trial to assess safety and feasibility is the next step for 
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5 Overall Discussion & Future Work 
 
ROR1 is an attractive therapeutic target due to its expression haematological 
and solid malignancies, making it a rationale choice for CAR T cell and BiTE therapy. 
More importantly ROR1 expression in solid tumours correlates with aggressive 
disease and an invasive phenotype and thus self-selects for high risk patients, who 
have limited therapeutic options. Expression on a cancer stem cell like cells, in 
ovarian cancer and glioblastoma, add to its appeal and is in keeping with its 
embryonic nature.  
From an initial hybridoma library we have undertaken extensive pre-clinical 
evaluation of a novel humanised ROR1 CAR T cell and BiTE constructs to generate 
lead versions for each format. Within the CAR domain, this competes with the R12 
CAR which is already being assessed in clinical trials, but ours has the advantage of 
being humanised as well as demonstrating enhanced cytotoxicity and cytokine 
secretion against a panel of cell lines. The different ROR1 domain hF(1x1) binds to 
along with the above functional differences warrant assessment in clinical trials to 
assess for safety and efficacy.  
In addition our BiTE is the first published bispecific against ROR1 that functions 
as low effector to target ratios and low concentrations and similarly deserves 
assessment in clinical trials (Gohil et al., 2017).  
These also compete with Cirmtuzumab, which is being investigated in CLL, with 
planned expansion in trials with Ibrutinib and paclitaxel combination therapy. The 
low antigen density on CLL, however precludes utility of using cytotoxic antibodies 
for CLL. As part of our screening process we assessed the ability our 13 ROR1 
antibodies to mediate ADCC, CDC, direct cytotoxicity or internalisation but saw no 
evidence of this, thus highlighting a limitation of their use in an unarmed format 
(data not shown).  
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 BiTE vs CAR T Cells 
 
Although both CAR T cells and BiTEs utilise the potential of endogenous T cells, 
direct comparison between them is fraught with difficulty because of the different 
mechanisms by which they function. Despite this, a study using the same scFv in a 
BiTE and CAR format, demonstrated CAR T cells, specifically CD8+ subtype, have a 
greater sensitivity to low antigen targets compared with the corresponding BiTE 
(Stone et al., 2012). However this study had a number of limitations: firstly the 
affinity of both scFvs was not defined and both CAR and BiTE construct were not 
optimised in terms of extracellular spacer and affinity. In keeping with this a BiTE 
targeting the intracellular oncoprotein WT1, with a TCR mimic antibody converted 
into a scFv format, is able to recognise ultra-low copies of the antigen on target 
cells due to enhanced affinity for the target (Dao et al., 2015). 
 
Proof of concept with both CAR T cells and BiTEs has been undertaken by 
targeting CD19 in haematological malignancies, with significant success leading to 
FDA approval of both. CAR T cells have seen major commercial interest with the 
formation of a large number of pharmaceutical companies keen to maximise on 
their potential. The eventual aim being incorporation of CAR T cell therapy as a 
standard of care, which is likely given current response rates and progress within 
the field. In relation to BiTEs, a number of companies and academic groups are 
developing differing bispecific T cell engaging antibodies, such as DARTs, to 
challenge the patent portfolio of Amgen, which can only expand their clinical use 
and offer wider therapy options.  
 
Despite the potential and success of CAR T cells there are significant logistical 
considerations associated with their wider use. T cell engineering requires large 
quantities of validated viral vectors, with associated production and qualification 
costs, especially for those based on a lentiviral platform as a stable producer cell 
line is not a viable option. In addition, the need to undertake leukapheresis can only 
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be undertaken at specialist units and manufacturing at central sites has associated 
shipping and processing requirements and costs. Novartis, in conjunction with the 
University of Pennsylvania have gone some way in demonstrating the feasibility of 
this approach with the ELIANA trial, which included central manufacturing unit, 
with worldwide shipping not seeming to affect response rates (Buechner et al., 
2017). The cost of their CAR T cell product, known as Tisagenlecleucel (CTL019) is 
approximately $475,000 per infusion, whilst Yescarta, the CD19 CAR generated by 
Kite Pharma costs $373,000. This compares with $178,000/year for Blinatumomab 
when initially launched.  
 Apart from lower costs, BITEs are suitable for large scale batch production 
allowing generation of an off the shelf product which is not patient specific. There is 
no need for associated T cell isolation, vector production and manipulation, 
therefore reduces costs and expands potential therapy.  
CAR T cells raise the possibility of achieving long term disease control 
following a single infusion of T cells, due to persistence of the CAR T cell population. 
Although BiTEs can induce remission and MRD negativity, CAR T cells appear to 
provide a more durable response.  
One common feature of both is the risk of CRS, which can be fatal and 
requires close clinical monitoring and early intervention with steroids, tocilizumab 
and multi-organ support. One benefit of BiTEs in this regard is their short half-life, 
with cessation of the infusion leading to rapid decrease in circulating BiTEs. Steroids 
are routinely used with BiTE administration to prevent CRS, with minimal loss of 
effector function but are not typically used with CAR T cells due to limiting effects 
on efficacy and persistence of the transduced population. 
One current limitation of both CAR T cell and BiTEs is the disappointing 
responses seen with solid malignancies. Targeting ROR1 would allow for critical 
analysis of targeting the same antigen in haematological and solid malignancies to 
better define tumour and T cell factors that mediate response or resistance and 
initial assessment in phase 1 clinical trials to assess safety can be then built upon 
using additional synergistic therapies.  
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 Further Preclinical Assessment 
 
5.2.1 Immunohistochemistry  
 
Although the expression of ROR1 has been documented, we need to ensure 
tissue binding with our scFv is as expected, which is especially true given our 
experience with clone A. To better address this we are in discussion with Propath 
Limited, to undertake a GLP qualified and FDA and EMEA compliant tissue cross 
reactivity study with both humanised hF(1x1) and CD3(3x5) as full antibodies. This 
comprises two phases, an initial optimisation phase to ensure reproducible staining 
and detection with the antibody followed by staining of good quality tissue sections 
and independent histopathology review to determine specificity.  
For the EMEA the following tissues are required: Tonsil, thymus, lymph 
node, Bone marrow, blood cells, Lung, liver, kidney, bladder, spleen, stomach 
including underlying smooth muscle, intestine, pancreas, parotid, thyroid, 
parathyroid, adrenal, pituitary; brain, peripheral nerve, heart, striated muscle, 
ovary, testis,  Skin and blood vessels (EMA/CHMP/BWP/532517/2008) and FDA 
panel which includes all target organs/tissues, bone, bone marrow, liver, spleen, 
adrenal, kidney, lung, heart, urinary bladder, gallbladder, thyroid, brain, gonads, 
gastrointestinal tract and adjacent organs of interest (FDA, 1997).  
In addition to the above we are in collaboration with the Royal Marsden 
NHS Trust and St Jude Children’s Hospital to undertake IHC on a range of 
haematological and solid malignancies respectively to add to the body of evidence 
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5.2.2 Murine and Non-Human Primate Studies 
 
5.2.2.1 Patient Derived Xenografts 
 
Our in vivo experiments were undertaken with cell lines, which may not 
necessarily represent the complexities of patient samples. This can be overcome in 
part by utilising primary human tumour samples which can be engrafted directly 
into animals which may better represent the original tumours (Siolas and Hannon, 
2013). These do have their own inherent complexities and limitations (Stewart et 
al., 2017) but in vivo assessment with patient derived xenograft models would 
provide more robust evidence of the potential of ROR1 therapeutics both CAR T 
cells and BITES. We have investigated the use of these via the Jackson Laboratory 
PDX depository, EurOPDX and through ongoing collaborations.  
 
5.2.2.2 Toxicology Assessment  
 
The expression of ROR1 within the parathyroid, pancreatic islet cells and areas 
of the gastrointestinal tract is of concern and requires careful consideration and 
detailed assessment to demonstrate safety before translation to clinical trials. 
 
Although ROR1 in developing mouse embryos has been assessed, its 
expression in adult mice is unknown. We plan to undertaken RT-PCR and western 
blotting from adult murine tissue to qualify murine ROR1 expression. If confirmed, 
we would substitute the CD3 scFv with an anti-murine CD3 capable of activating 
murine T cells and infuse this murine ROR1 BiTE into immunocompetent mice to 
assess toxicity. This would take advantage of the ability of clone F to bind to murine 
ROR1 as the target epitope is conserved between mice and humans.  
The preclinical assessment of Blinatumomab utilised a similar approach with 
a murine specific CD3. The exact sequence of the anti-murine CD3 Amgen utilised is 
unknown, but was reported to have a similar affinity to that found in 
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Blinatumomab. Despite thus, administration of our BITE with high doses of human T 
cells demonstrated no toxicity in terms of behaviour, weight loss, skin changes or 
distress. An alternative to this, provided we demonstrate murine ROR1 expression, 
is the repopulation of Nod-SCID IL2 mice with a human haematopoietic system, 
in which we would simply infuse ROR1 BiTE to assess potential toxicity (Ishikawa et 
al., 2005).  
Cirmtuzumab and R12 CAR T cells have been tested in non-human primates 
and the lack of toxicity in these studies is at odds with expression data and in vitro 
toxicity against adipocytes. This may be because Cirmtuzumab primarily functions 
by inhibition of signalling as opposed to mediating cytotoxicity, which therefore 
does not provide proof of safety with CAR or BiTE therapies. Furthermore CAR T cell 
administration in primates may drive only low level activation due to limited 
expression and therefore insufficient to generate a sufficiently pro-inflammatory 
state to drive expansion and subsequent toxicity, that may be encountered in 
patients with significant disease burden. The ROR1 CAR T cell clinical trial already 
recruiting patients will provide further safety information in this regard. 
For the ROR1 BiTE, there is the added complication that the OKT3 CD3 scFv 
does not react with all non-human primate species, specifically Rhesus macaque, 
therefore limiting utility of testing in this group of animals. One potential non-
human primate model to use is the Chimpanzee, in which OKT3 shows T cell 
activation, as was undertaken with Blinatumomab, but restrictions on testing in 
chimpanzees, along with the limited information that may be gleaned, negates the 




5.3.1 CAR T Cells 
 
CAR T cells require viral vector production incorporating the transgene of 
interest which can be undertaken with academic partners (for example the viral 
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vector facility at King’s College London), or through a range of commercial 
suppliers. In addition to the cost, it is the time scale required for production and 
qualification. Following this, any potential trial requires a manufacturing facility that 
is able to generate CAR T cells from the starting leukapheresis product and requires 
careful process development and qualification of standard operating protocols 
including for T cell activation, transduction, cell splitting, freezing and quality 
release criteria. In this regard a number of scale up runs would need to have been 
undertaken to test the processes and screen for any deficiencies. This production 
process may also be disease specific, as in CLL, large number of contaminating 
leukaemic cells may require alteration in methodologies which have to be properly 
accounted for. To start this process, we have successfully applied for and obtained 
NHS ethical approval to undertake leukapheresis from CLL patients to develop and 
validate a robust production process for CAR T cells pending confirmation of the 
final retroviral construct.  
 
5.3.2 ROR1 BiTE 
 
Once we are satisfied that we have the optimum scFv configuration based 
on affinity of the ROR1 and CD3 arm we can proceed to manufacture of the BiTE. 
Blinatumomab is produced in CHO cells before purification and lyophilisation, the 
latter to ensure stability and limit aggregation as per the EMEA assessment report 
(EMEA/H/C/003731/0000). Although we have included a hexa-histidine tag in our 
BiTE, there is no mention of this for Blinatumomab in the EMEA filing. We have 
explored a range of manufacturing options for the ROR1 BiTE from transient 
transfection to generation of a stable producer cell line in conjunction with NHS 
Blood and Transplant. We are currently developing a GMP compliant purification 
process utilising the His tag followed by downstream processing to place the BiTE 
into an optimised buffer followed by assessment of stability and aggregation over 
time. This will be undertaken in line with the EMA guidance 
(EMA/CHMP/BWP/532517/2008), which covers production, specification and 
characterisation of monoclonal antibodies.  
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 Concluding Remarks 
 
We have described how from an initial rat immunisation we have developed 
ROR1 CAR T cells and ROR1 BiTEs, both of which demonstrate efficacy in proof of 
principle assessments. CAR T cells and BiTEs gave unique advantages and limitations 
and it is likely that they will both need to be combined with other agents, such as 
checkpoint inhibitors to maximise their clinical efficacy, especially for solid tumours, 
as well as selecting the right patient group and providing treatment within the 
correct context.  
Despite their appeal, careful consideration has to be made of normal ROR1 
expression on healthy tissue to mitigate against on target off tumour toxicity. In this 
regards initial assessment with BiTEs to demonstrate safety of targeting ROR1 with 
our scFv, in a system which is cheaper and easier to translate to clinical trials, 
combined with the ability to start at exceedingly low concentrations is appealing. 
Additionally, this makes use of the inherent short half-life of BiTEs to minimise 
toxicity and allow gradual dose escalation to assess for safety.  
Following on from this and provided there are no limiting toxicities, we would 
be much more confident of the ability to safely administer ROR1 CAR T cells, with 
the aim of generating long lived immune responses.  
 
Overall the ROR1 BiTEs and CAR T cells we have generated warrant 
assessment in high risk patients with unmet therapeutic need and strategies to 
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